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Abstract
Acanthamoeba castellanii is an amoeboid protozoan which causes
opportunistic infections, including granulomatous encephalitis in immune-
compromised patients. Haematogenous dissemination follows initial infection
and the pathogen exhibits an ability to cross the blood-brain barrier (BBB).
In the bloodstream and at the site of BBB penetration in the brain
microvasculature A. castellanii is exposed to host humoral immunity. Here, we
have provided insights into A. castellanii pathogenesis and the identity of
amoeba antigens participating in immune control. We have investigated the
role circulating immunoglobulin plays in preventing penetration of the BBB,
and whether trophozoites can alter the efficacy of the immune response.
Furthermore we have extended previously published data, demonstrating that
amoeba proteases can degrade all antibody classes including physiologically-
derived antibody. Nonspecific binding of polyclonal antibody was also
observed, and attributed to Fc-binding activity by trophozoites. Additionally,
we have examined the binding dynamics of A. castellanii under physiological
conditions. BBB disruption was shown to be not directly linked to binding,
instead it is reliant on secreted proteases.
This study provides insights into mechanisms by which A. castellanii evades
host immunity and crosses the BBB. This has the potential to enhance
therapeutic strategies aimed at restoring essential disease prevention processes.
In addition we have identified a number of amoeba antigens that are targets for
the immune system and which may therefore be exploited through vaccination
or immunotherapy.
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11. Introduction
21.1. Life Cycle
Acanthamoeba castellanii is a free-living amoeboid protozoan of soil and
water environments. Isolation from a number of man-made environments
including bottled water, ventilation, cooling and water systems has also
been made (De Jonckheere, 1991). Trophozoites are typically 15-30µm in
length and distinguishing morphological features include cytoplasm
containing numerous large vacuoles and thin tapering pseudopodia termed
acanthopodia (Figure 1.1). The free-living trophozoites divide by binary
fission and are vegetative, predating a variety of bacterial species as well as
smaller eukaryotes (Weekers et al., 1993, Gomez-Couso et al., 2007).
Figure 1.1 An Acanthamoeba trophozoite.
×4000 magnification. V = vacuole, A = acanthopodia, N = nucleus. Adapted from
Culbertson et al., 1959.
Trophozoites can also encyst in response to hostile environmental
conditions and cysts are highly resistant to lack of food, extremes in pH and
temperatures, desiccation, and many available antimicrobials (Aksozek et
al., 2002, Coulon et al., 2010). Morphologically the cyst is also highly
V
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3distinctive, having a double wall of which the inner part is smooth and
rounded whilst the outer wall appears wrinkled (Pussard and Pons, 1977).
1.2. Classification
Acanthamoeba was first officially described by Castellani in 1930 and was
subsequently placed into the genus Hartmanella (Culbertson et al., 1965a,
Culbertson et al., 1965b). This group was revised soon afterward, and
Acanthamoeba species were placed into their own genus. Classification
thereafter followed the pattern suggested by Pussard and Pons who used
cyst and other morphological characteristics to define relationships between
species using a three group classification scheme (Pussard and Pons, 1977,
Kong, 2009). Subsequently a robust genetic classification system, using
18S and 16S ribosomal RNA (rRNA) was developed (Daggett et al., 1985,
Stothard et al., 1998, Schroeder et al., 2001, Kong, 2009). This yielded the
current generally accepted scheme of fifteen genotypes (T1-T15) exhibiting
at least 5% sequence divergence, with some basis for an additional genotype
(T16) recently suggested (Goldschmidt et al., 2009, Corsaro and Venditti,
2010).
As well as the advantages of clarity and reliability, rRNA genotyping has
illuminated genetic similarities between samples otherwise classed as
separate species, particularly amongst clinical isolates. For the most part
pathogenicity is confined to a small subset of genotypes, with T1 and T4 the
dominant groups for both keratitis and granulomatous encephalitis (section
41.4 and 1.5) (Khan et al., 2002, Alsam et al., 2005b, Sissons et al., 2006a, Di
Cave et al., 2009).
1.3. Emerging clinical importance
The first observations of Acanthamoeba pathogenicity were made by
Culbertson, who identified the amoeba as a contaminant of mammalian
tissue culture and subsequently demonstrated pathogenicity both in vitro and
in vivo (Culbertson et al., 1958, Culbertson et al., 1959). Numerous case
reports emerged in subsequent years (Jones et al., 1975, Martínez et al.,
1977, Visvesvara et al., 1983, Blackman et al., 1984, Gardner et al., 1991)
and Acanthamoeba species are now well-recognised to produce two distinct
disease states, Acanthamoeba keratitis (AK) and Acanthamoeba
granulomatous encephalitis (AGE). Whilst both diseases are rare,
Acanthamoeba infections are being detected by clinicians with increasing
frequency, especially as opportunistic infections of immunocompromised
patients (Slater et al., 1994, Feingold et al., 1998, Steinberg et al., 2002,
Tilak et al., 2008). This at-risk population is expanding as a result of
increasing use of immune-suppressing therapies for cancer treatment and the
worldwide HIV/AIDS pandemic (Friedland et al., 1992, Schwarzwald et al.,
2003, Nachega et al., 2005).
1.4. Acanthamoeba Keratitis (AK)
AK is an infection of the cornea causing severe inflammation, intense pain
and impaired vision and which is blinding if left untreated (Jones et al.,
51975, Awwad et al., 2007). Infection is initiated by trophozoite adhesion to
corneal epithelium following which the infection develops as a ring
infiltrate. In the latter stages of the disease amoebae invade the stromal
layer, with the resulting opacity leading to loss of visual acuity and
eventually blindness. Existing corneal damage is known to predispose to the
condition and in addition more than 80% of AK infections are correlated
with the use of contact lenses (Moore et al., 1985, Alizadeh et al., 2005,
Gagnon and Walter, 2006). These risk factors are incorporated into
experimental models of the disease, for example in work by van Klink et al.
who used corneal abrasion and parasite-laden lenses to investigate AK in
Chinese hamsters (van Klink et al., 1993). Nevertheless, a small subset of
infections does not correlate with either risk factor (Barbeau, 2007,
Ertabaklar et al., 2007).
Poor lens hygiene and inappropriate disinfection regimes are thought to
contribute to infection risk by promoting the growth of bacteria on lenses
onto which amoebae in turn adhere and proliferate. Trophozoites may also
be accidentally inoculated directly onto lenses by exposure to contaminated
water during swimming, washing with tap water or as a result of poor
personal hygiene (Kaji et al., 2005, Bower et al., 2006, Niyadurupola and
Illingworth, 2006). In epidemiological terms the infection is comparatively
rare (Table 1.1), however the proportion of the population at increased risk
of developing AK may rise as contact lenses continue to gain popularity for
ophthalmic and recreational purposes (Moore et al., 1987, Lee et al., 2007).
6Incidence rate
(per 10,000
population)
Study Area Reference
0.33 Hong Kong (Stehr-Green et al., 1989)
0.05 Holland (Stehr-Green et al., 1989)
0.01 USA (Stehr-Green et al., 1989)
0.19 England (Radford et al., 2002)
1.49 Scotland (Lam et al., 2002)
Table 1.1 Incidence rates for Acanthamoeba keratitis
Per 10,000 head of population, various sources.
Diagnosis is typically reached by isolating amoebae from corneal biopsies
and/or contact lens cases. PCR-based assays have been developed for rapid
diagnosis however their use in clinical settings is limited by logistical and
economic considerations. The high sensitivity and specificity of these assays
however means that they are likely to see greater use in the future (Mathers
et al., 2000, Yera et al., 2007). In vivo confocal microscopy may also be
used but requires specialised equipment and appropriately trained staff and
so is unlikely to enter routine use (Winchester et al., 1995). Standard
treatment regimens are complex and prolonged, with a high intensity
polyhexamethylene biguanide and propamidine isethionate therapy
producing the most favourable outcomes without resorting to corneal
transplant (Tien and Sheu, 1999, Gooi et al., 2008). Nevertheless
complications such as bacterial and fungal co-infections and increased
amoeba proliferation due to steroid anti-inflammatory treatments frequently
prove detrimental to successful treatment (Rumelt et al., 2001, Rama et al.,
72003, Lorenzo-Morales et al., 2007). An additional difficulty is the
parasite’s ability to encyst, often prompted by initiation of treatment. This
can cause an easing of symptoms only for the infection to re-emerge at a
later date (Peterson et al., 1990). This is particularly apparent where
keratoplasty has been attempted as the donor cornea may be re-infected by
excysting amoebae. It is often the case that several transplants are necessary
before the infection is finally eliminated (Peterson et al., 1990,
Camposampiero et al., 2009).
1.5. Amoebic Granulomatous Encephalitis (AGE)
Whilst AK is a debilitating disease it is not the most severe manifestation of
an Acanthamoeba infection. Amoebic granulomatous encephalitis (AGE) is
an opportunistic infection mostly of immunocompromised patients, wherein
amoebae enter neural tissue causing necrosis and severe encephalitis
(Martínez et al., 1977, Di Gregorio et al., 1992). Evidence suggests that
invasion occurs by one of two routes: either Acanthamoeba enter directly
via the olfactory bulb and neuroepithelium, or the amoeba spreads
haematogenously to brain microcapillaries (Martinez et al., 1975, Martínez
et al., 1977). The initial route of entry for the latter has been suggested to be
via cutaneous or pulmonary lesions with the latter probably resulting from
the germination of inhaled cysts (May et al., 1992, Helton et al., 1993,
Duarte et al., 2006, Walia et al., 2007). Trophozoites then disrupt the blood-
brain barrier and enter the CNS (Culbertson et al., 1959, Kidney and Kim,
1998, Khan and Siddiqui, 2009)
8Once amoebae reach the brain tissue the disease has a slow progression with
neuronal damage inducing pro-inflammatory immune responses that lead to
the formation of granulomas and haemorrhagic necrotic lesions (Martínez et
al., 1977, Martínez et al., 1980). Symptoms include headache, fever,
behavioural changes, aphasia, ataxia, vomiting, and seizures. These are
common to a wide variety of unrelated neurological conditions however,
frequently leading to slow or mis-diagnosis (Khan, 2007, Pemán et al.,
2008, Bloch and Schuster, 2005).
Confirmation of AGE is achieved by isolation and in vitro culture of the
parasite from cerebrospinal fluid (CSF), a method which may prove time
consuming or inconclusive (Petry et al., 2006, Abd et al., 2009, da Rocha-
Azevedo et al., 2009). There is evidence from AK infections that detection
by PCR may improve diagnostic outcomes, however this method has yet to
enter routine use for AGE (Yera et al., 2007, Thompson et al., 2008, Reddy
et al., 2009). There is no recommended treatment, although early application
of one or a combination of multiple drugs may improve prognosis e.g.
ketoconazole, fluconazole, voriconazole, sulfadiazine, miltelfosine,
amphotericin B, maxifloxacin, linezolid, meropenem azithromycin, or
rifampin (Ofori-Kwakye et al., 1986, Seijo Martinez et al., 2000, Aichelburg
et al., 2008, Sheng et al., 2009, Lackner et al., 2010) .
AGE is largely confined to patients with underlying immune suppression,
due to co-infection (particularly HIV), chemotherapy treatment, primary
immune deficiency or other underlying conditions which compromise
immunity (Gardner et al., 1991, Uschuplich et al., 2004, MacLean et al.,
2007). The immune-compromised condition of the patient, combined with
9difficulties in diagnosis and therapy results in an alarmingly high mortality
rate of around 90% (Bloch and Schuster, 2005, Khan, 2005). Fortunately the
infection is very rare with case numbers in the low hundreds – in their 1997
review Martinez and Visvesvara give a figure of approximately 150
reported cases (Martinez and Visvesvara, 1997).
The scale of the problem may be underestimated by current measures
however as a result of the aforementioned difficulties with diagnostics. This
is especially the case in countries with poor access to primary healthcare and
without thorough post-mortem procedures. Such countries often have large
populations of HIV+ individuals and this increases the likelihood of AGE
cases remaining undiagnosed and untreated. The global at-risk population is
also expanding due to the HIV/AIDS pandemic. In their 2011 global AIDS
summary the World Health Organisation reported a population of 34 million
people infected with HIV, increasing from 29.5 million in 2002 (WHO,
2011). Infection rates for AGE in areas with highest HIV incidence are
unknown; however it seems likely that of the 1.7 million AIDS-associated
deaths which occurred in 2011 a proportion are attributable to
Acanthamoeba species
1.6. Immunity
The role played by the immune system in controlling A. castellanii
infections is yet to be fully explored and is complicated by the existence of
two distinct clinical syndromes occurring in settings of different immune
competency. AGE is primarily a disease of immunocompromised patients
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and disseminates haematogenously from an initial cutaneous, pulmonary or
intranasal infection to primarily affect the brain. AK is confined solely to
the eye, but does not require impaired immunity in order to initiate an
infection. The immune environments that A. castellanii encounters in each
disease therefore exhibit substantial differences; however it is worthwhile to
explore the two diseases in parallel in order to gain an insight into potential
protective immune mechanisms.
1.7. Innate immunity
1.7.1. Barriers to infection
Upon initial inoculation a combination of antimicrobial and physical
defences prevent trophozoites from adhering to host cells. In the eye the
greater proportion of corneal immunity is mediated by secretions from the
tear glands and eyelids, distributed across the eye’s surface by a pumping
action created by the blink reflex (Niederkorn, 2002, Sack et al., 2001). Tear
secretions are a complex mixture of peptides both nonspecific (lysozyme,
lactoferrin, prostaglandins) and specific (secretory IgA) which combine with
physical sweeping by the eyelids to form a strong barrier to infection
(Alsam et al., 2008). In AK the use of contact lenses adds to infection risk
as extended use induces hypoxia and a stress-related impairment of ocular
immunity (Alizadeh et al., 2005, He et al., 1992). Additionally, infected
contact lenses permit close contact to be maintained between trophozoites
and corneal epithelial cells. This thins the tear film and protects amoebae
from physical removal by eyelid sweeps.
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The role played by antimicrobial peptides (AMP) in AGE is less clear due to
the fact that both cutaneous and pulmonary infection routes have been
reported in the literature (Steinberg et al., 2002, Duarte et al., 2006).
Supporting evidence for the importance of AMP in mucosal defence against
amoeba is also seen in a recent study which demonstrated that β-defensin-2
is produced by colonic epithelial cells in response to Entamoeba histolytica
infection (Ayala-Sumuano et al., 2013). Specifically in A. castellanii, a
study by Otri et al. using immortalised corneal epithelial cells showed
upregulated expression of several genes involved in production of AMP
upon infection. Elevated levels of mRNA coding for β-defensin-2, hepcidin,
and RNase-7 were all seen (Otri et al., 2010). It is likely that similar AMP
expression profiles are seen at all mucosal surfaces including the nasal,
cutaneous and pulmonary epithelium. However this has yet to be
empirically shown and the interaction between AMP and A. castellanii
remains to be determined.
1.7.2. Complement
The complement cascade is one of the most important pathogen recognition
and effector mechanisms of the innate immune system. Complement
subunits present in the tear film and blood self-assemble on pathogen
surfaces into complexes that prompt recognition and phagocytosis by
phagocytes or else lyse pathogens directly by permeabilising the plasma
membrane. Activation follows one of three pathways: the classical pathway,
where complement is fixed in the presence of pathogen-specific antibody;
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the alternative pathway, where complement subunits bind to pathogen
surfaces directly; and the lectin pathway where pathogen surface
glycoproteins activate the cascade.
A. culbertsoni, unspeciated T4 genotype, and unspeciated T6 genotype
strains have been shown to activate serum complement via the alternative
pathway (Ferrante and Rowan-Kelly, 1983, Pumidonming et al., 2011).
Pumidonming et al. (2011) showed that binding of the C3 subunit which
initiates the alternative pathway and C9 which is the final subunit to bind
prior to formation of the membrane attack complex occurs when
trophozoites were incubated with human serum. However there is
conflicting evidence as to whether complement fixation leads to lysis of
trophozoites in all cases. Some studies show that several strains are all lysed
by human complement (Ferrante and Rowan-Kelly, 1983, Pumidonming et
al., 2011) but differential susceptibility to complement lysis has been
demonstrated by others (Toney and Marciano-Cabral, 1998). Complement
resistance in this latter case correlated with strain virulence and is supported
by evidence from the pathogenic amoebae Naegleria fowleri that virulent
strains have greater resistance to lysis (Whiteman and Marciano-Cabral,
1987, Whiteman and Marciano-Cabral, 1989).
1.7.3. Pro-inflammatory cytokines
Pro-inflammatory cytokines govern and regulate many aspects of the
immune response including proliferation and recruitment of lymphocytes
and macrophage/neutrophil activation and trafficking. Both AK and AGE
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are characterised by a vigorous inflammatory reaction, which is thought to
be partly responsible for the observed pathology i.e. the characteristic eye
reddening in AK and tissue oedema and encephalitis in AGE. Whilst this
process is essential to clearing an infection, where inflammation is not
resolved or correctly regulated the resulting tissue damage can make a major
contribution to disease pathology (Mattana et al., 2002, Shin et al., 2001).
Studies characterising cytokine signalling in response to A. castellanii are
sparse however data from corneal epithelial cells and stromal fibroblasts
suggests TLR4 may play a role in pathogen detection leading to an increase
in levels of IL-8, TNFα, and IFNβ (Ren et al., 2010, Ren and Wu, 2011).
Additionally TNFα, IL-1α and IL-1β, whilst having no direct anti-amoebic
activity in isolation are capable of enhancing killing of amoeba by brain-
resident macrophages (microglia), and promoting further pro-inflammatory
cytokine release (Benedetto et al., 2003, Benedetto and Auriault, 2002).
This process is likely to be phagocytosis-dependent as comparable anti-A.
castellanii effects are not seen from macrophage-conditioned media (Hurt et
al., 2003c). In addition, secretion of TNFα, IL-1α and IL-1β as well as IL-6
by macrophages increases when they are presented with trophozoites
(Benedetto et al., 2003). This inflammatory mechanism is therefore self-
reinforcing, and probably at least partially responsible for the excessive
inflammation seen in disease.
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1.7.4. Macrophages and Neutrophils
Macrophages and neutrophils are important effector arms of the innate
immune system, and respond rapidly during A. polyphaga infections (Larkin
and Easty, 1991). The most potent effects of these cells are seen when they
have been primed with pro-inflammatory cytokines or ligands such as LPS
(Benedetto et al., 2003). Naïve macrophages and especially neutrophils
exhibit only low lytic activity. However, this effect is greatly enhanced by
prior inoculation of experimental animals with amoeba antigens and greatest
in the presence of active serum. This suggests that plasma components such
as complement, cytokines and antibody interact with leukocytes to promote
killing (Stewart et al., 1992, Marciano-Cabral and Toney, 1998).
This effect can also been seen in other free-living amoeba infections and
there is a particular similarity to the macrophage and neutrophil response to
Naegleria fowleri. In both cases neutrophils play a major role as
demonstrated by studies in which specific neutrophil and macrophage
depletion exacerbates infections (van Klink et al., 1996, Hurt et al., 2001,
Hurt et al., 2003c). Activation of endogenous macrophages (specifically by
IFNγ) results in significant lowering of AK incidence, and even nonspecific
boosting of macrophage infiltration by latex beads has a protective effect
(Clarke et al., 2006). Interestingly Acanthamoeba species demonstrate an
ability to kill in vitro macrophage and microglia cultures (Marciano-Cabral
and Toney, 1998, Harrison et al., 2010) and this suggests that
amoeba/macrophage interactions are not unidirectional.
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1.8. Acquired immunity
Acquired immunity is a crucial property of the mammalian immune system
which combats pathogens and preserves immunological memory of past
infections, so that a response can be initiated more rapidly and with greater
magnitude during a subsequent infection by the same organism. It consists
of two distinct but complementary mechanisms: cell-mediated responses
governed and co-ordinated by T-lymphocytes; and humoral responses
governed by antibody produced by B-lymphocytes and their specialised
secretory derivatives plasma cells.
1.8.1. B cells and antibody
B-cells are one of two classes of lymphocytes which permit acquired
immunity to infection. B-cells express a highly variable receptor which is
structurally similar to antibody, and which is highly antigen-specific as a
result of variable regions generated by somatic recombination. If a
circulating B-cell encounters an antigen for which its receptor is specific it
will proliferate in a process known as clonal expansion. This also requires a
signal from CD4+ T-helper (Th) cells specific to the same antigen and
results in eventual differentiation into specialised antibody-secreting plasma
cells. Antibody production dynamics are then modified in lymph structures
called germinal centres to generate higher affinity molecules (affinity
maturation) or to alter antibody class for specialised functions (class
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switching). Differentiation into memory B-cells also occurs at this stage,
permitting a more rapid and specific response to be raised in any future
infection. Other than these general processes however, relatively little is
known about the specifics of the B-cell response for either AK or AGE. The
majority of previous studies have focused instead on the protective effect of
antibody itself, or else used it as a marker of infection and the immune
response.
A high proportion of healthy subjects have been shown to test positive for
serum antibodies against Acanthamoeba species (Chappell et al., 2001,
Brindley et al., 2009, Kiderlen et al., 2009). This is consistent with common
exposure resulting from the organism’s wide environmental distribution and
also reflects the importance of antibody function in disease control, as
patients from these studies were free from clinical disease.
Serum IgG levels are elevated in AK with no apparent effect on the outcome
of infection and there appears to be limited translation of immunity between
the systemic and mucosal response. This is shown by studies where corneal
infection fails to stimulate humoral or cell-mediated immunity (Van Klink
et al., 1997) and where systemic immunisation fails to protect against
subsequent ocular challenge (Alizadeh et al., 1995). Mucosal immunisation
produces better outcomes however; monoclonal IgA is shown to protect
hamsters by passive transfer (Leher et al., 1999) and oral immunisation also
demonstrates an IgA-mediated protective effect in pigs (Leher et al., 1998b).
Interestingly, secretory (sIgA) levels in the cornea are lower in patients with
keratitis (Alizadeh et al., 2001). However it is not clear at this stage
whether lower sIgA levels occur as a result of parasite activity or whether an
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underlying sIgA deficiency permits infections to establish. SIgA has been
shown to prevent trophozoites from adhering to corneal epithelial cells,
leading to immobilisation and destruction by leukocytes resident in the
conjunctiva (Leher et al., 1998a, Campos-Rodríguez et al., 2004). However
antibody cleavage has been demonstrated by A. castellanii isolates and so
the efficacy of sIgA may not entirely depend on host factors (Na et al.,
2002b).
The role of systemic antibody circulating in the blood is less well
established. Anti-Acanthamoeba IgG and IgM antibody is found in surveys
of healthy populations (Chappell et al., 2001, Kiderlen et al., 2009).
However, anti-Acanthamoeba antibody has also been detected in serum
from infected patients (Schuster et al., 2006), although in this particular
study no isotype was given for the detected antibody. It is therefore unlikely
that the presence of antibody alone is sufficient to grant total protection and
this is supported by the inability of elevated serum IgG to affect the
outcome of AK, as noted above (Alizadeh et al., 2001).
Where detected, serum antibody is of either the IgG or IgM class (Cursons
et al., 1980, Alizadeh et al., 2001, Schuster et al., 2006). The IgG response
has the greatest specificity and longest duration of all antibody responses
and so its presence in serum of patients is further indication that antibody
plays an important role in on-going control of the parasite. Since epitopes
associated with previous infections are preserved in the bone marrow via
long-lived memory B-cells this may also be an indication of repeated
exposure to Acanthamoeba species generating a vigorous humoral response
in response to subsequent pathogen challenge. The presence of IgM in
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serum surveys supports this view (Cursons et al., 1980). This class is
relatively less specific but is produced rapidly in response to an infection.
Levels of serum IgM wane rapidly post-infection however and so the
presence of IgM in serum generally represents a recent or on-going
exposure. This reinforces the conception that individuals either undergo
frequent short-lived A. castellanii infections or are constantly exposed to A.
castellanii antigens, perhaps as a result of colonisation by cysts.
Previous investigators have attempted to take advantage of the antibody
response to generate specific monoclonal antibody for therapeutic and
diagnostic purposes. However many of the antibodies raised in these studies
reacted mainly with the cyst stage, which is only weakly immunogenic
(Turner et al., 2005). This reinforces the view that the on-going IgG
responses detected in serum surveys may represent an immune response
against cysts, and that the lower levels of antigen expression permit cysts to
persist in host tissues. In support of this view the presence of cysts in the
cornea is frequently asymptomatic (Camposampiero et al., 2009).
Where reactivity to trophozoites was shown, the precise role and targets of
specific antibody and therefore relevance to known methods of pathogenesis
was not consistently demonstrated (Fiori et al., 2006, Turner et al., 2005,
Kennett et al., 1999). The presence of IgM in serum from both healthy and
diseased patients indicates frequent infection and so this class is likely to
have a major role to play in the response to trophozoites.
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1.8.2. T-cells
T-lymphocytes are another important participant in the acquired immune
response, and can be classified by expression of one of two cell surface
molecules. CD8+ T-cells are cytotoxic effector cells which target mostly
intracellular pathogens by inducing apoptosis of infected cells. CD4+ T-cells
are described as ‘helper’ cells and perform two major functions: secretion of
cytokines which influence inflammation and activate other immune cells;
and aiding B-cell recognition of target antigens. T-cell antigen recognition is
mediated by the T-cell receptor, which like B-cell receptors contains both
conserved and variable regions. T-cells will not recognise free antigen
however but instead respond only to antigen presented in consort with major
histocompatibility complex (MHC) molecules of antigen-presenting cells.
This ensures T-cell responses are sufficiently regulated and appropriate to
the nature of the microbial threat. T-cell responses to infection by
Acanthamoeba species have not been elucidated in great detail. Nevertheless
because of the extracellular infection route it is likely that the T-cell
response involves primarily CD4+ cells. Understanding of T-cell responses
to A. castellanii is still at an early stage however, and so the relative
contributions of Th1, Th2 or Th17 pathways are yet to be definitively
deduced. Evidence from a study by Tanaka et al. (1995) points towards Th1,
as T-cells responsive to clinical Acanthamoeba isolates were of a
CD4+/CD8- phenotype with elevated IFNγ levels but low IL-4 production.
This promotes a potent macrophage-activating phenotype, and macrophages
have been shown to be important effector cells for destruction of
trophozoites (see section 1.7.4).
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Of significance to AGE, T-cells are amongst the cell types most depleted by
artificial immune suppression and HIV infection. AIDS patients are at
particular risk of acquiring AGE, so it is likely that T-cells have a critical
role to play in preventing the disease. As CD4+ T-cells have little
antimicrobial activity of their own however, their significance lies in
activation of effector mechanisms such as macrophages, neutrophils, and B-
cell differentiation into plasma cells.
T-cells proliferate in response to amoebic antigens (Tanaka et al., 1994),
and interestingly this response was greater to antigens derived from cysts
rather than trophozoites (McClellan et al., 2002). This may indicate that
cell-mediated immunity is preferentially activated in order to mount a
response against cysts, however McClellan et al. also report that
immunisation with trophozoites impairs subsequent cell-mediated responses
to cysts. An additional layer of complexity is added by reports from
Massilamany et al. which describe expression of mimicry epitopes in A.
castellanii that generate cross-reactive T-cell responses (Massilamany et al.,
2010, Massilamany et al., 2011). These responses were shown to generate
autoimmunity in the CNS. It is not clear whether this mechanism
contributes to the inflammation seen in AGE however these results
demonstrate that there are likely to be underlying complexities to T-cell
responses which are not yet appreciated.
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1.9. Pathogenesis
1.9.1. Non-secreted factors
The importance of binding in the initiation of Acanthamoeba infections has
been demonstrated in a variety of model systems, showing that when
adhesion is blocked (primarily by exogenous mannose) the parasite’s ability
to kill corneal or endothelial host cells is reduced (Hurt et al., 2003b, Garate
et al., 2006a, Morton et al., 1991). The involvement of mannose residues in
binding was first tangentially demonstrated by Brown and colleagues who
showed that carbohydrates were involved in phagocytosis by amoeba, a
process in which binding is crucial (Brown et al., 1975). The specific
involvement of the carbohydrates mannose and methyl-α-D-
mannopyranoside was demonstrated by Morton et al. (1991) who showed
that addition of these to culture media reduced trophozoite binding to
corneal epithelial cells. Further investigation identified a specific mannose-
binding protein (MBP) expressed on the cell surface which has subsequently
been well characterised in several studies (Yang et al., 1997, Cao et al.,
1998, Garate et al., 2004).
Addition of mannose or its derivatives prevents the occurrence of disease in
several models, and taken with the widespread presence of mannose
residues on a variety of cell types including corneal epithelium and brain
endothelium this protein evidently has a major role to play in pathogenesis
(Alsam et al., 2003, Hurt et al., 2003b, Garate et al., 2006a, Garate et al.,
2006b). Some findings however suggest that adhesion to non-cellular
structures such as extracellular matrix and inert surfaces is also MBP-
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mediated and that this binding mechanism may therefore be non-specific
(Gordon et al., 1993, Imbert-Bouyer et al., 2004). Nevertheless, some
functional roles for MBP in pathogenesis have been partially elucidated and
point to a direct role in cytotoxicity.
It is known that A. castellanii is capable of inducing apoptosis in a variety of
cell types (Alizadeh et al., 1994, Shin et al., 2000, Zheng et al., 2004), a
property it shares with major protozoan pathogens such as T. brucei and P.
falciparum (Stiles et al., 2001, Stiles et al., 2004, Pino et al., 2005, Wilson et
al., 2008). Hurt and colleagues observed secretion of a 133kDa protein
(MIP-133) by trophozoites in response to addition of mannose or its
derivatives (Hurt et al., 2003a, Hurt et al., 2003b). MIP-133 induced
caspase-3 mediated apoptosis in both human and hamster corneal epithelium
and also showed collagenase activity. Other apoptotic responses are also
seen in response to A. castellanii; including alterations in cytosolic calcium,
upregulation of genes involved in cell cycle arrest, and activation of
phosphatidylinositol-3-kinase (Sissons et al., 2005, Taylor et al., 1995,
Alizadeh et al., 1994, Mattana et al., 2001). However the relative
contribution of each to cell death remains uncertain. The precise role of
MBP in initiating these cellular events also remains undefined although the
fact that addition of exogenous mannose can mitigate disease shows that
some form of direct induction by MBP binding is likely.
Nevertheless MBP alone may not be sufficient to explain the entirety of
contact-dependent interactions between host and pathogen, as low levels of
binding are maintained even where amoebae have been treated with
exogenous sugars (Imbert-Bouyer et al., 2004, Rocha-Azevedo et al.,
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2009a). Supporting evidence for the involvement of additional binding
factors in pathogenesis has been shown in work by Kennett et al. (1999).
They describe a membrane-bound glycoprotein which when inhibited by
binding of specific antibody caused reductions in the ability of amoebae to
adhere to corneal epithelial cells. No competitive binding was observed
between this antibody and mannan and so the authors concluded that this
represents a protein distinct from MBP (Kennett et al., 1999). Any direct
role for this molecule in pathogenesis was not characterised however and so
it is possible that this represents a non-pathogenic adhesion mechanism.
Alternatively host cell attachment may be mediated by more than one
surface protein, and the fact that the adhesin described by Kennett et al. is a
glycoprotein suggests that host carbohydrate-binding proteins could
contribute to trophozoite adherence. There may also be many other
molecules and molecular mechanisms involved in A. castellanii cytotoxicity
which are yet to be described.
1.9.2. Secreted factors
Binding is evidently an important and possibly the limiting step in A.
castellanii infections however taken alone it does not fully explain disease
pathogenesis. Protease activity makes important contributions to
pathogenesis in other protozoan pathogens such as Entamoeba histolytica,
Leishmania major, Trichomonas vaginalis and Trypanosoma cruzi (Doyle et
al., 2007, Kumar et al., 2012, Mahmoudzadeh-Niknam and McKerrow,
2004, Sommer et al., 2005) . Secreted proteases of E. histolytica in
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particular make significant pathogenic contributions, having been shown to
promote invasion by mucin cleavage (Moncada et al., 2003); and pathology
by direct cellular damage (Lourenssen et al., 2010, Kumar et al., 2012).
Acanthamoeba species secrete proteolytic enzymes both in vitro and in vivo
(Serrano-Luna et al., 2006, Sissons et al., 2006a). Interestingly this trait is
not restricted to pathogenic isolates but is common to many Acanthamoeba
species. Levels of expression vary across species/genotypes however with
the highest levels observed in pathogenic isolates (Hadas and Mazur, 1993,
Khan et al., 2000b). Acanthamoeba secreted proteases are of several classes
including serine, cysteine and metalloproteases (Alfieri et al., 2000, Alsam
et al., 2005b). Of these, serine proteases appear to be the most intimately
associated with disease as use of PMSF (a serine protease inhibitor) reduces
pathogenicity in vitro (Alizadeh et al., 2008, Kim et al., 2006, Sissons et al.,
2006a).
Broadly speaking, categories of activity demonstrated by Acanthamoeba
secreted proteases include degradation of extracellular matrix (ECM), tight
junctions, and immune system components (Na et al., 2002a). Serine and
metalloproteases have been shown to break down components of the ECM,
particularly collagen type I, type IV and fibronectin; and elastase activity
has been similarly demonstrated (Ferrante and Bates, 1988, He et al., 1990,
Mitro et al., 1994, Kong et al., 2000, Sissons et al., 2006a, Ferreira et al.,
2009). It is likely that this enhances infectivity by facilitating invasion, both
in the cornea and brain microvasculature, with a causal link between
proteases in cell-free conditioned medium and concordant tissue damage
having been established (He et al., 1990, Na et al., 2001). With particular
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reference to AGE, serine proteases have been shown to target tight junctions
leading to increased permeability of the blood-brain barrier and cell
monolayer disruption (Sissons et al., 2006a, Alsam et al., 2003, Cho et al.,
2000). Again there is a potential link with infectivity since, as previously
discussed, crossing of the BBB is a prerequisite in establishment of AGE
(Alsam et al., 2005b, Sissons et al., 2006a, Khan and Siddiqui, 2009).
1.10. The blood-brain barrier
Any discussion of pathogenesis during AGE is fundamentally incomplete
without an appreciation of the structure and composition of the blood-brain
barrier (BBB). In mammals the barrier is composed of three cell types:
pericytes, astrocytes and endothelial cells, supported on a laminin basement
membrane. Its primary purpose is to control the interaction between the
brain and vasculature, restricting entry into the delicate neural tissues and
preserving a dedicated neural microenvironment. Brain microvascular
endothelial cells (BMEC) have historically received most research attention
however astrocytes and pericytes are increasingly being recognised as
having vital roles to play in the maintenance of barrier function. Many
researchers are seeking to incorporate important contributions from these
cell types into the working understanding of BBB function, and in vitro
modelling.
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Figure 1.2 Cross-sectional diagram of the BBB
Reproduced from Khan (2007).
1.10.1. Cells of the BBB
BMECs may be considered to be the primary component of the BBB,
forming the structure and lining of the blood vessels themselves and as such
they are the main obstacle that any microorganism attempting to enter the
CNS from the blood must first traverse. BMECs are highly specialised
endothelial cells, expressing high levels of tight junction proteins such as
occludin, claudin, and accessory proteins such as zonula occludens (ZO)
(Watson et al., 1991, Hirase et al., 1997, Tsukita, 1998, Morita et al., 1999).
As a result a highly impermeable barrier is formed and even small
molecules are unable to diffuse across the BBB without active uptake or
transport. This enables regulation of which cells and molecules move from
the blood into the CNS and vice versa. BMEC monolayers in particular are
impermeable even in comparison with other cell types which express tight
junctions, such as epithelial cells (Milton and Knutson, 1990). BMECs have
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also been shown to exhibit particularly high Trans-Endothelial Electrical
Resistance (TEER), a common measure for the efficacy of barrier function.
Typical TEER values in vitro vary according to culture technique. Static
mono- and co-culture models fall in the range of 20-200Ω/cm2 (Booth and
Kim, 2012, Griep et al., 2012) however introduction of other parameters
such as fluid flow can produce TEER in excess of 600Ω/cm2 (Santaguida et
al., 2006).
The barrier function of endothelial cells is further enhanced by the presence
of other cell types which ensheath BMECs on the basal CNS surface,
namely astrocytes and pericytes. Either the end-feet (astrocytes) or whole
cell surface (pericytes) are in close proximity with the basement membrane
on which BMECs sit, and there is a solid body of evidence suggesting that
they are responsible for further regulating and enhancing barrier function
(Hayashi et al., 1997, Armulik et al., 2010, Cantrill et al., 2012). Astrocytes
in particular may have a dual effect in this regard, as both direct cellular
contact and conditioned media from in vitro astrocyte cultures enhance
BMEC TEER (Janzer and Raff, 1987, Siddharthan et al., 2007).
1.10.2. BBB in vitro models
BMECs, being the primary BBB component and site of the tight junctions
which grant enhanced barrier function have been the main candidate for
construction of in vitro models of the BBB. Primary human BMECs grow
well in standard tissue culture environments, and to facilitate measurement
of TEER or barrier-crossing assays transwell inserts are often used (Stins et
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al., 1997, Alsam et al., 2005a, Grab et al., 2004). As the components of the
BBB have become increasingly well understood so the models available to
researchers have become more sophisticated. Co-culture models of
astrocytes and BMECs have risen to prominence particularly in neurological
research. These may be either simple mixed models or more elaborate
methodologies which attempt to mimic structural aspects of
astrocyte/BMEC interactions (Cucullo et al., 2002). It has been shown by
Santaguida et al. and Siddarthan et al. for instance that the action of shear
stress and blood flow rate has an impact on the integrity of the BBB
(Santaguida et al., 2006, Siddharthan et al., 2007). In light of this the latest
generation of BBB models now incorporate co-cultures under dynamic fluid
flow (Booth and Kim, 2012, Griep et al., 2012, Prabhakarpandian et al.,
2013). This is likely to lead researchers to the closest in vitro representation
yet of BBB function.
1.10.3. The BBB in parasitic disease
The close binding of endothelial cells to one another is a highly effective
physical barrier precluding access to the CNS, however a number of
parasites are able to circumvent this barrier and produce neural infections.
This may occur either by a transcellular pathway, where pathogens infect
BMECs and emerge at the basal surface without disrupting cell-cell
interaction; or a paracellular pathway, where disruption of cellular junctions
permit parasites to traverse spaces between cells. Paracellular traversal is
obligatory for large extracellular parasites due to physical size constraints.
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A. castellanii for example is 15-30µm in size, not much smaller than a
typical endothelial cell. As a result of this BBB traversal in these organisms
is mediated by degradation of tight junction proteins by secreted proteases
and direct cytotoxicity (Alsam et al., 2003, Kiderlen et al., 2006, Siddiqui et
al., 2007, Khan and Siddiqui, 2009). Smaller pathogens such as T. brucei
and T. gondii are not so restricted by size however and can exploit
alternative mechanisms.
For example T. gondii disseminates through the host organism primarily by
infection of phagocytes. This includes trafficking into the brain which has
been demonstrated to depend on motility of infected leukocytes, namely
monocytes and dendritic cells. These cells, infected with T. gondii are able
to cross the blood-brain barrier and allow tachyzoites to infect neural cells
(Courret et al., 2006). However the molecular mechanisms which underpin
this process and any resemblance they bear to beneficial BBB traversal by
uninfected phagocytes have not been fully elucidated. Conversely however,
T. gondii is not intracellular at all stages of its lifecycle and this links with
data which shows that free tachyzoites cluster around cellular borders and
display tropism for tight junctions (Barragan and Sibley, 2002, Barragan et
al., 2005). Transmigration assays performed in these studies demonstrated
that traversal of epithelial monolayers occurred without disruption of barrier
integrity or host cell lysis and this may imply that T. gondii can also cross
the BBB by a paracellular route; however this process has yet to be
observed in endothelial cell cultures. Transcellular crossing of the BBB is
another possibility as tachyzoites are also capable of infecting endothelial
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cells themselves, a process in which cell adhesion molecules such as
ICAM1 may play a part (Lachenmaier et al., 2011).
T. brucei BBB traversal is a similarly complex process. Unlike T. gondii, T.
brucei is extracellular at all stages of its lifecycle and thus the paracellular
route is the most likely means of BBB traversal. This process has been
shown to occur early in infection, prior to the mounting of an extensive
inflammatory response and with little impairment of BBB function
(Nikolskaia et al., 2006b, Frevert et al., 2012). Mulenga et al. (2001)
showed that in a rat model of disease tight junctions were preserved during
trypanosome crossing, with no reduction in immunostaining for occludin or
ZO-1 (Mulenga et al., 2001). Grab et al. (2004) additionally showed that
overall barrier function of BMEC was maintained as procyclic
trypanosomes (non-infectious in mammals) were unable to traverse BMEC
monolayers even in the presence of infectious trypomastigotes. The authors
suggest that this indicates large-scale perturbations of the BBB do not occur.
Nevertheless they also reported a reduction in TEER, indicating that BBB
integrity was somewhat reduced. As with T. gondii, trypanosomes could
also be visualised at cell junctions, further suggesting the importance of
paracellular migration (Grab et al., 2004). Paracellular traversal is also
enhanced by the ability of the parasite to induce apoptosis in BMEC,
mediated through intracellular calcium alterations and Protease Activated
Receptor (PAR) signalling (Nikolskaia et al., 2006a, Grab et al., 2009).
Interestingly, exploiting paracellular traversal may not entirely explain BBB
crossing as results from other experiments conducted by the same group
show evidence for trypanosome entry into BMEC (Nikolskaia et al., 2006b).
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Whether this represents transcellular crossing of the BBB however, or
merely a dead-end entry event such as endocytosis to a lysosome has yet to
be determined.
Perhaps the best studied interaction between a parasite and the BBB is in
cerebral malaria. In contrast to T. gondii and T. brucei, breach of the BBB
by P. falciparum is highly destructive, involving host cell death, tight
junction loss and host inflammatory processes. Sequestration of parasitized
erythrocytes in the brain microvasculature leads to occlusion of blood
vessels and BBB dysfunction due to a combination of altered blood flow,
tissue hypoxia, and cellular signalling responses. This latter process is
mediated by host cellular adhesion molecules such as ICAM (also an
important mediator of T. gondii and T. brucei BBB traversal) (Barragan et
al., 2005, Girard et al., 2005). ICAM1 interacts with parasite proteins
expressed by infected erythrocytes, for example PfEMP1 (Adams et al.,
2000, Claessens et al., 2012). The result of this interaction is to activate the
endothelium, leading to increased expression of adhesion molecules which
in turn exacerbates further sequestration of infected RBC (Gray et al., 2003,
Tripathi et al., 2006) .
The effects that this has on the BBB itself have been the subject of several
independent studies, and are contributed to at least in part by the host
immune response. For example increased pro-inflammatory cytokine
expression, specifically TNFα and IL-1β, has been seen in tissue from
cerebral malaria patients and was especially high in samples from the
cerebellum (Brown et al., 1999b). Additionally, binding of infected
erythrocytes has been shown to result in upregulation of apoptosis-related
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genes including Bad and Bax, and activation of caspases (Pino et al., 2003).
Loss or redistribution of tight junction markers occludin and ZO-1 have also
been observed in brain sections from cerebral malaria patients (Brown et al.,
1999a), alongside decreases in TEER induced by parasitized RBC (Tripathi
et al., 2007).
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1.11. Project Rationale and Aims
Pathophysiology of Acanthamoeba disease is mediated by multiple immune
and pathogenic factors. However as a result of their low prevalence diseases
caused by A. castellanii are not well understood despite their debilitating
and life threatening consequences. Some pathogenic mechanisms have been
partially characterised, however in many cases a full description is yet to be
achieved. In particular haematogenous spread in AGE is an area which
requires further study; both of BBB breakdown and pathology, and the role
played by the immune system. Serum studies have illustrated common
exposure across several populations and organisms from the Acanthamoeba
genus are thought to be amongst the most numerous of free-living amoebae.
It is thus an interesting question as to why and how infections with such
devastating consequences arise from these otherwise adequately controlled
microbes.
The ability of certain Acanthamoeba genotypes to sequester in the CNS
following breach of the blood-brain barrier is of particular interest as an
uncommon trait for many pathogens, but one which is shared with a number
of parasites of considerable veterinary and medical importance; P.
falciparum, T. gondii, and T. brucei. Within this context study of A.
castellanii may also provide insights into broader mechanisms by which
parasites cross the BBB, and the resultant consequences for infected
patients.
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Thus our aim is to investigate the haematogenous stage of AGE, and we
have approached the question of how trophozoites survive during
dissemination and breach the blood-brain barrier from two perspectives:
Firstly we focussed on the humoral immune response and the ways in which
amoebae may evade antibody-mediated responses.
Secondly we investigated mechanisms of pathogenesis in an infection model
of human brain microvasculature.
To facilitate this we immunised experimental animals and retrieved
polyclonal antibody from hybridomas by in vitro fusion and culture
techniques. Specific antibody was used to interrogate amoeba lysates to
identify immune recognition targets, and tested for functional effects on
adherence and cytotoxicity. Evasion mechanisms including cleavage of
serum antibody and antibody inactivation via Fc-binding proteins were also
investigated.
Additionally we addressed the issue of BBB breach using a dynamic flow
system to improve modelling of the brain microvasculature in vitro. Current
in vitro models of the BBB may not closely mimic the situation in vivo as
measures of binding, cytotoxicity, and monolayer disruption are generally
obtained from static 24-well plate cultures. This new model allowed us to
investigate the relative importance of A. castellanii secreted and non-
secreted virulence factors to BBB pathology in a physiologically relevant
system.
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2. Materials and Methods
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2.1. Culture techniques
2.1.1. Acanthamoeba castellanii
A clinical isolate of A. castellanii belonging to the T4 genotype was
obtained from the American Type Culture Collection (ATCC #50492).
Amoebae were grown in 175cm2 tissue culture flasks (Sarstedt, UK)1 in
autoclaved axenic peptone-yeast-glucose (PYG) medium comprising 0.75%
w/v proteose peptone (Oxoid™, Thermo-Fisher Scientific, UK)2, 0.75% w/v
yeast extract2, and 1.5% w/v glucose2 in distilled water. Flasks were
maintained in a humidified standard air incubator at 30°C. Every 3-5 days
the growth medium was removed from culture flasks and replaced with
fresh PYG. Under these conditions more than 90% of A. castellanii
remained bound to the flask as trophozoites.
2.1.2. Human Brain Microvascular Endothelial Cells (HBMEC)
Primary Human Brain Microvascular Endothelial Cells (HBMEC) were
obtained from Dr N.A. Khan and originated from individuals who had
undergone neurosurgery at Johns Hopkins University School of Medicine
(USA), as described by Khan and Siddiqui (2009). Isolation followed
methods detailed by Alsam et al. (2003) and Stins et al. (1997). Purified
cultures were obtained by fluorescence-activated cell sorting (FACS) and
1 Sarstedt Ltd., Leicester, UK
2 Thermo Fisher Scientific Ltd., Basingstoke, UK
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tested positive for endothelial markers Factor-VIII, carbonic anhydrase IV
and uptake of acetylated low density lipoprotein (Stins et al., 1997, Alsam et
al., 2003, Khan and Siddiqui, 2009). HBMEC were maintained in 75cm2
tissue culture flasks1 in RPMI 1640 (Sigma-Aldrich, UK)2 media
supplemented with 100U/ml penicillin (Gibco®, Life Technologies, UK)3,
100µg/ml streptomycin3, 2mM L-glutamine3, 1× minimum essential, 1mM
sodium pyruvate3, and 20% FBS2, and were grown at 37°C with 5% CO2.
Under these conditions HBMEC have been shown to retain trans-endothelial
electrical resistance (TEER) of >200mΩ and exhibit barrier function against 
bovine serum albumin (BSA) (Alsam et al., 2005a). Cells were used
between passages 11-20 and retained normal growth characteristics until
around the 20th passage. HBMEC were harvested by incubation with 5ml
10× Trypsin/EDTA3 solution until cell monolayer detachment was observed
at which point the Trypsin was inactivated by addition of 5ml complete
culture medium and cells were collected by centrifugation at 1,000×g for 5
minutes.
2.1.3. Sp2/0 mouse myelomas
Sp2/0 murine myeloma cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)3 plus 10% FBS, 2mM L-glutamine, 100U/ml penicillin,
1 Sarstedt Ltd., Leicester, UK
2 Sigma-Aldrich Ltd., Gillingham, UK
3 Life Technologies Ltd., Paisley, UK
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100µg/ml streptomycin, and 1× 8-azaguanine (QED Bioscience, USA)1 in
75cm2 tissue culture flasks at 37°C with 5% CO2. Cells were collected by
agitation and centrifugation at 1,000×g for 10 minutes and split 1 in 4 every
3-4 days in order to maintain log-phase growth.
2.1.4. Polyclonal hybridomas
Polyclonal hybridoma cells were maintained in DMEM supplemented with
10% FBS, 100U/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine,
and 5% Briclone2 in 175cm2 Nunc triple layer tissue culture flasks (Nalge
Nunc, USA)3 at 37°C with 5% CO2 overlay. Cells were collected by
agitation and centrifugation at 1,000×g for 5 minutes.
2.2. Antigen preparation
2.2.1. A. castellanii lysate
108 A. castellanii trophozoites were collected from flasks by incubation on
ice for 30 minutes followed by centrifugation at 1,000×g for 5 minutes.
PYG growth medium was aspirated and the cell pellet was washed in sterile
phosphate-buffered saline (PBS)4 by resuspension and centrifugation, with
the process repeated three times. Cells were again resuspended in 15ml of
1 QED Bioscience Inc. San Diego, CA, USA
2 QED Bioscience Inc. San Diego, CA, USA
3 Nalge Nunc International, Rochester, NY, USA
4 Life Technologies Ltd., Paisley, UK
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PBS and subjected to three freeze-thaw cycles (-80°C to 37°C). The
suspension was sonicated on ice for 5 minutes as 20s bursts with 20s
intervening rest periods. Remaining whole cells and large debris were
removed by centrifugation at 2000×g and the supernatant was inspected
microscopically to confirm the absence of surviving whole cells. The
protein content of the lysate was estimated by measuring the ratio of 280nm
versus 260nm absorbance measurements (Warburg-Christian method) using
a Nanodrop 8000 instrument1 (see also section 2.5.1). Samples were stored
at -80°C as 1ml aliquots.
2.2.2. A. castellanii-conditioned medium (ACM)
Flasks of trophozoites were prepared as described in section 2.1.1 so that at
least 90% of cells were adherent. PYG was then removed from flasks which
were then washed with RPMI twice to remove trace media and non-adherent
cells. 50ml of RPMI was then added to the flasks, and they were returned to
the incubator for three days to accumulate excretory-secretory (ES)
products. Supernatant from several flasks was then collected and cysts/non-
adherent trophozoites removed by passage through 0.22µm sterile vacuum
filters2. Samples were stored at -20°C (short term) or -80°C (long term) as
50ml aliquots.
1 Thermo Fisher Scientific Ltd., Basingstoke, UK
2 Sarstedt Ltd., Leicester, UK
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2.3. In vivo antibody generation
All animal experiments were carried out at the UoN Medical School animal
facility with ethical approval from University of Nottingham (project
number RP10/07). Animal handling was carried out by Professor Richard J.
Pleass, personal license number PPL 40/3287.
2.3.1. A. castellanii preparation for in vivo experiments
2×107 A. castellanii trophozoites were collected as described in section 2.2.1
and washed in 10ml of sterile Dulbecco’s phosphate-buffered saline
(DPBS)1 three times to remove trace PYG. The pellet was suspended in
200µl of DPBS and 200µl Imject Alum (Pierce™, Thermo Fisher Scientific,
UK)2 was added, with immunogen subsequently left on a roller to mix
thoroughly.
2.3.2. Immunisation protocol
Six BALB/c mice (4♀, 2♂) all aged between 6-8 weeks were immunised
with four receiving antigen preparation (3♀, 1♂) and two controls with
DPBS + Alum alone (1♀, 1♂). An immunisation schedule of three bi-
weekly injections was set, with each animal receiving 200µl of DPBS + 107
1 Life Technologies Ltd., Paisley, UK
2 Thermo Fisher Scientific Ltd., Basingstoke, UK
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amoebae + Alum or DPBS + Alum intraperitoneally. Mice were sacrificed
three days after the final injection by CO2 asphyxiation and exsanguination.
2.3.3. Serum testing
Terminal blood was collected from mice and deposited in lithium heparin-
coated vaccutainers (BD Bioscience, UK)1 to limit clotting. Blood samples
were then centrifuged at 10,000×g for 10 minutes to separate plasma which
was then collected and stored at -20°C. Serum samples were tested for the
presence of A. castellanii-specific antibody by enzyme-linked
immunosorbant assay (ELISA) and Western blot assay (see sections 2.8.1-
2.8.3 & 2.8.5).
2.3.4. Splenocyte extraction
Spleens from experimental mice were dissected out aseptically within the
animal facility and deposited in DMEM supplemented with 4mM L-
glutamine, 100U/ml penicillin, and 100µg/ml streptomycin for transport
back to the lab (Complete Medium No Serum, CMNS). Splenocytes were
extracted by crushing two spleens in 10ml of warmed CMNS with the
plunger from a sterile 5ml syringe (Terumo Medical, USA)2. Spleen extracts
were collected into sterile 50ml tubes and any large debris was allowed to
1 BD Bioscience Ltd., Oxford, UK
2 Terumo Medical Corporation, Somerset, NJ, USA
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settle out by gravity. Supernatant containing extracted splenocytes was then
carefully collected by pipette into a fresh 50ml tube. Splenocytes were
pelleted by centrifugation at 1,000×g for 10 minutes and subjected to four
further wash steps under identical conditions.
2.3.5. Fusion
Fusion was carried out using a Fuse-It® hybridoma development kit1 which
incorporates a short-duration polyethylene glycol (PEG) based fusion
technique with a dedicated post-fusion cloning factor (Briclone) obviating
the need for feeder layers. Sp2/0 myelomas were collected as described in
section 2.1.3 and adjusted to a concentration of 1×106 cells/ml. Two
splenocyte extracts were counted on a haemocytometer (Weber Scientific,
USA)2, yielding 5x106 and 7x106 cells respectively, which were likewise
suspended in CMNS. Splenocytes and myelomas were then combined in a
5:1 splenocyte to myeloma ratio (Table 2.1). The cell suspension was
thoroughly mixed and then centrifuged at 1,000×g for 10 minutes.
Supernatant was then aspirated with a 10ml pipette to leave the pellet as dry
as possible.
1 QED Bioscience Inc. San Diego, CA, USA
2 Weber Scientific Corporation, Hamilton, NJ, USA
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Splenocytes Myelomas Total Cells
100×106
(5×106/ml in 20ml)
20×106
(1×106/ml in 20ml)
120×106
(3×106/ml in 40 ml)
140×106
(7×106/ml in 20ml)
28×106
(1×106/ml in 28ml)
168×106
(3.5×106/ml in 48ml)
Table 2.1 Combination ratios for splenocytes and myelomas during fusion.
The PEG fusion reagent was prepared by melting 2g of PEG1 in a water
bath at 56°C and adding 2ml of CMNS to create a 50% solution as
prescribed by the kit instructions. 1ml of this solution was then added to the
cell pellet dropwise over a 30-second period with gentle agitation to disrupt
the pellet. Over a further 30 seconds, 1ml of CMNS was added dropwise to
gradually dilute out the PEG and then over the course of three minutes an
additional 10ml of CMNS was added in small increments. Gentle agitation
by hand was continued throughout the fusion process.
The fusion mixture was then centrifuged at 1,000×g for 10 minutes to
completely remove PEG traces. Cells were resuspended to 3×106/ml in
DMEM plus 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin, 4mM
L-glutamine, 10% BriClone1 and 1× hypoxanthine-aminopterin-thymidine
(HAT)1 (Hybridoma Cloning Medium, HCM) and aliquoted into 96-well
plates with 3×105 cells/well in a final volume of 100µl. Plates were then
placed in a 37°C incubator at 5% CO2 and left to grow for 7 days prior to
1 QED Bioscience Inc. San Diego, CA, USA
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microscopic inspection to check for colony formation. At this inspection
stage 50µl of fresh HCM was added regardless of whether growth was
detected and cultures were then returned to the incubator for a further three
days.
2.3.6. Post-fusion screening
After 10 days of culture 50µl of supernatant was removed from wells and
used neat as the primary antibody stage in ELISA assays as described in
sections 2.8.1 to 2.8.3. Culture supernatants were screened for production of
IgG, IgM and IgA antibodies.
2.4. In vitro infections
2.4.1. 24 and 48-well plates
HBMEC were collected by trypsin treatment as outlined in section 2.1.2 and
a 2.5×105/ml cell suspension was made by addition of fresh complete media.
One millilitre of this suspension was seeded into tissue culture grade 24-
well plates1 (300µl in 48-well plates1) and cell monolayers were then
allowed to grow to confluence over 18-24 hours. Once monolayers had fully
formed culture media was removed and cell layers were gently washed by
three rounds of addition and removal of 1ml RPMI 1640. Monolayers were
1 Sarstedt Ltd., Leicester, UK
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then treated with either a suspension of A. castellanii trophozoites in RPMI
or ACM according to the demands of specific assays.
2.4.2. Flow chambers
HBMEC were collected by trypsin treatment as outlined in section 2.1.2 and
a 5×106/ml cell suspension was made by addition of fresh complete media.
Fifty microliters of this suspension was pipetted into the anterior chamber of
0.2µm chamber microslides (Ibidi, Germany)1 that had been allowed to
equilibrate for gas and temperature for 10 minutes prior to use. The cell
suspension was then allowed to draw through by capillary action. Both
anterior and posterior chambers were then filled with 60µl of fresh HBMEC
growth medium and the slide was returned to incubation at 37°C, 5% CO2.
Media in microslide chambers was replaced daily by allowing slides to flush
by capillary action and under these conditions cells reached confluence after
18-24 hours. 60 minutes before commencement of experiments slides were
inspected for monolayer quality and if necessary were flushed with fresh
medium once again to maintain monolayer integrity.
Immediately prior to experiments anterior and posterior chambers were
brim-filled with fresh media to prevent the entry of air bubbles and attached
via elbow Luer connectors2 to 0.8mm silicone piping3 which had also been
1 Ibidi GmbH, Martinsried, Germany
2 Ibidi GmbH, Martinsried, Germany
3 Thermo Fisher Scientific Ltd., Basingstoke, UK
pre-filled with media.
peristaltic pump
piping were sterilised before each experiment.
experiment microslides
remove waste growth media.
primed with a suspension of trophozoites or ACM and once
initiated experimental solutions were
to avoid it running dry and exposing the cells to air bubbles. Th
maintained at 37°C
Figure 2.1 Schematic diagram of
Including illustration of use to circulate a suspension of
Tubing was passed through a Thermo FH10
2 to provide constant circulating flow. Connectors and
Prior to initiation of
were flushed with RPMI 1640
For the experimental runs the system was first
re-circulated through the initial stock
by use of a heat block.
in vitro flow system.
A. castellanii cells.
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for 5 minutes to
flow was
e system was
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2.5. Cell binding assay
2.5.1. Static
A 2×105/ml suspension of A. castellanii trophozoites was prepared as
described in section 2.2.1 with the exception that all washes and the final
suspension stage were carried out in warm RPMI 1640. One millilitre, or
300µl of cell suspension was then added to prepared HBMEC plates (see
section 2.4.1) and returned to the cell culture incubator. After a period of
three hours the plate was gently agitated to suspend non-adherent
trophozoites and the number of unbound cells was counted using a
haemocytometer. During counting A. castellanii cells were distinguished
from non-adherent HBMEC based on morphological criteria: irregular cell
shape, presence of acanthopodia and presence of vacuoles. Cells of
ambiguous identity were excluded from counts.
2.5.2. Flow
2×105/ml trophozoites in RPMI 1640 were prepared as before (section
2.2.1) with the exception of an increased final volume of 20ml. The cell
suspension was held in a stock tube so that constant circulation could be
maintained as described in section 2.4.2, whilst the temperature of the
system during the experimental period was maintained by a heat block set to
37°C. After priming the system with cell suspension a constant flow rate
was set and maintained for a period of three hours. At the end of this period
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the number of unbound amoeba was counted by sampling from the stock
suspension as described in section 2.5.1.
2.6. Monolayer disruption assay
2.6.1. Microscopy
At the conclusion of the experimental period tissue culture plates or flow
chamber slides were examined under the 10× objective lens of a Leica
DMIL instrument with DFC490 camera (Leica Microsystems, UK)1. Three
representative fields of view from each sample were selected and
standardised by applying in-built auto-exposure and white balancing, and
were then photographed under phase contrast. These settings provided
optimal contrast between cell and background during downstream semi-
quantification of monolayer disruption.
2.6.2. Quantifying monolayer disruption
TIFF image files were processed using open-source ImageJ analysis
software (available from http://rsbweb.nih.gov/ij/) (Schneider et al., 2012)
with monolayer disruption measured using a semi-quantitative method
based on grid scoring. A grid of 1600 pixels per square to give a total of
5000 squares was superimposed over the image and five representative
1 Leica Microsystems Ltd., Milton Keynes, UK
blocks of 196 squares per block (14
square in a block
scores for the five representative
of the total 980 squares counted.
Figure 2.2 Schematic illustration of semi
Semi-quantitative measurements of monolayer
number of squares scored as disrupted as a percentage of the total number examined.
2.6.3. Haematoxylin staining
Supernatant was carefully removed from plates that had been treated with
either a suspension of trophozoite
adherent trophozoites was fixed in 1ml or 300µl (24 or 48
×14) were then selected
was scored as disrupted if cell coverage was
blocks were then expressed as a percentage
-quantitation method for micrographs.
disruption are obtained by expressing the
s or ACM and the cell layer with/without
-
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. Each individual
≤50%. Total
well plates) of an
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ice-cold mix of equal parts glacial acetone to ethanol for 15 minutes. The
supernatant was carefully removed and discarded and 1ml/300µl of Harris
haematoxylin (VWR International, UK)1 was added to cell layers which
were then left to stain for 15 minutes. Haematoxylin was then carefully
removed and wells were washed three times by pipetting with 1ml/300µl
PBS to remove unincorporated stain and non-adherent cells. Stained
monolayers were then photographed using an ImageQuant 300 instrument
(GE Healthcare, UK)2 and qualitatively scored based on the gross level of
disruption.
2.6.4. Lactate dehydrogenase (LDH) release assay
Supernatants from either ACM or trophozoite-treated cultures were
collected after 3 and/or 24 hours and centrifuged at 1000×g for 5 minutes to
pellet cells and cell debris. Positive control supernatants were obtained by
adding an equal volume of lysis buffer (Roche, UK)2 to untreated HBMEC
and incubating for 15 minutes. Thereafter supernatants from lysed cells
were treated identically to those from inoculated wells. Fifty microliters of
supernatant was removed and placed in a 96-well microtitre plate to be
analysed for LDH release using a cytotoxicity detection kit3. Briefly the
catalyst and enzyme components of the kit were thawed on ice and a
detection mix was prepared with 125µl of reconstituted lyophilized catalyst
1 VWR International Ltd., Lutterworth, Leicestershire, UK
2 GE Healthcare Ltd., Buckinghamshire, UK
3 Roche Ltd., Burgess Hill, UK
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and 5.625ml of dye solution. This was then kept on ice until use. Equal
volumes (50µl) of sample and detection mix were pipetted into a 96-well
microtitre plate and incubated for 10 minutes protected from light.
Absorbance was then measured at 490nm using a LT-4000 plate reader
(Labtech, UK)1 and the percentage cell death calculated using the equation
below.
% cell death=
sample− negative control
100% cell death control − negative control
× 100
A background reading of supernatant alone was made prior to addition of
the reaction mix and this was subtracted from the final readings before cell
death was calculated to correct for optical interference by RPMI.
2.6.5. Antibody treatment
A full list of antibodies used in all experiments with supplier and specificity
is given in Table 2.2.
In experiments to determine the effect of specific and nonspecific antibody
and antibody fragments, HBMEC static plates were set up as described in
section 2.4.1. Cell suspensions of 2×105/ml trophozoites were then prepared
in RPMI with antibody variants added to a final concentration of 200µg/ml.
Where necessary antibody solutions were concentrated and dialysed to
remove sodium azide prior to use (see sections 2.7.2 and 2.7.4). With the
1 Labtech Ltd., Uckfield, UK
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exception of polyclonal antibody generated as part of the project antibodies
were purchased from external suppliers as follows: mouse IgM isotype
control MCA692 (AbD Serotec, UK)1, mouse IgG isotype control I8765
(Sigma-Aldrich, UK)2, human purified IgG Fc fragment (Alpha Diagnostic,
UK)3. Prior to infection, antibody was added to the A. castellanii cell
suspension and treated samples were then moved to an APT Line rotary
incubator (Biometra, Germany)4 set at 37°C for 3 hours to maximise
binding and/or aggregation effects.
1 AbD Serotec, Ltd., Kidlington, UK
2 Sigma-Aldrich Ltd., Gillingham, UK
3 Alpha Diagnostic International Inc., San Antonio, TX, USA
4 Biometra GmbH, Goettingen, Germany
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Text reference
number
Antibody Supplier Catalogue
number
Specificity
1 Mouse IgM negative control AbD Serotec MCA692 Negative control
2 Mouse IgG (from serum) Sigma-Aldrich I8765 Negative control (from serum)
3 Mouse IgA isotype control Alpha Diagnostic Intl. 20102-100 Negative control
4 Mouse IgE isotype control Alpha Diagnostic Intl. 20102-106 Negative control (anti-dimethylaminonaphtalene-1-sulfonyl)
5 Human IgG Fc fragment Alpha Diagnostic Intl. 20007-1-Fc Negative control (from serum)
6 Goat anti-mouse IgM – HRP AbD Serotec STAR86P IgM mu heavy chain specific
7 Goat anti-mouse IgG – AP Sigma-Aldrich A3673 Gamma chain specific
8 Goat anti-mouse IgG - HRP Sigma-Aldrich A9917 IgG Fab
9 Goat anti-mouse IgA – AP Sigma-Aldrich A4937 Alpha chain specific
10 Mouse anti-human IgG Fc - FITC Sigma-Aldrich F5016 Monoclonal (clone HP-6017), Fc-specific
11 Goat anti-mouse IgM - FITC AbD Serotec OBT1713F IgM (Heavy and Light chain)
12 Goat anti-mouse IgG - Texas Red AbD Serotec 103007 IgG1, 2a, 2b, 3 Heavy chain
Table 2.2 List of antibodies used in all experiments.
Detailing supplier, catalogue number, and specificity. When referenced in chapter texts antibodies are referred to by list number (first column)
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2.6.6. Aggregation assay
Samples that had been incubated with specific and nonspecific antibody as
described in section 2.6.5 were removed from the rotary incubator and 1ml of
suspension was deposited in 24-well tissue culture plates. Wells were then
photographed immediately using a Leica DMIL microscope and DFC490
camera1 instrument and after a further 24 hour incubation at 37°C, 5% CO2.
The degree of trophozoite aggregation visible in each image was the scored
qualitatively using the following criteria:
+++ = ≥20 trophozoites per aggregate and/or high aggregate number.
++: 10-20 trophozoites per aggregate and/or medium aggregate number.
+: 5-10 trophozoites per aggregate and/or low aggregate number.
+/-: <5 trophozoites per aggregate and/or very low aggregate number.
-: No visible aggregation.
2.6.7. Protease Activated Receptor (PAR) antagonist treatment
HBMEC cultures were set up as described in section 2.4.1 and grown to
confluence overnight. HBMEC monolayers were washed three times in 1ml
RPMI to remove trace growth media and were then treated with either:
1 Leica Microsystems Ltd., Milton Keynes, UK
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100nM N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-
f]quinazoline-1,3-diamine dihydrochloride (SCH 79797) - a PAR1 antagonist
(Tocris Bioscience, UK)1;
Or,
100nM Trans-Cinnamoyl-Tyr-Pro-Gly-Lys-Phe-NH2 (tcY-NH2)1 - a PAR4
antagonist.
Both PAR antagonists were dissolved in RPMI. Concentrations were based on
previous reports and datasheet values. Where IC50 values were stated a higher
concentration was used to achieve maximal inhibition (Ahn et al., 2000,
Hollenberg et al., 2004, Lidington et al., 2005).
PAR antagonists were diluted to working concentration from 10mM and 1mM
stock solutions respectively and so an equal volume of stock solution solvent
was included in matched controls for each antagonist (DMSO or ddH2O). After
30 minutes of stimulation, PAR solutions were removed and replaced with 1ml
ACM or 1ml of a suspension of 2×105/ml trophozoites, containing either PAR1
antagonist, PAR4 antagonist, matched controls (antagonist solvent), no PAR
antagonist (positive control) or 1ml of RPMI only (negative control). Plates
were then returned to incubation at 37°C, 5% CO2 and cell layers were
photographed at 3 and 24 hour time points using a Leica DMIL microscope
and DFC490 camera2 (see section 2.6). Micrographs from these time points
1 Tocris Bioscience Ltd., Bristol, UK
2 Leica Microsystems Ltd., Milton Keynes, UK
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were analysed for monolayer disruption using the methods outlined in sections
2.6.2 and 2.6.3.
2.6.8. TdT-mediated dUTP Nick-End Labelling (TUNEL) assay
HBMEC cultures were set up as described in section 2.4.1 and infected with
trophozoites/ACM plus PAR inhibitors as described in section 2.6.7. Since the
assay was to be used to detect apoptotic cells, positive control wells were
included on the plates and were treated with 50µM cisplatin1 in RPMI at the
time of infection. Post-treatment, culture plates were returned to incubation at
37°C, 5% CO2 for 18 hours. Monolayers were photographed at 3 and 18 hours
using a Leica DMIL microscope and DFC490 camera2 and disruption
quantified as described in section 2.6.2. After 18 hours had elapsed, cells were
collected by vigorous pipetting in the case of infected wells, or trypsin
treatment (as per section 2.1.2) followed by pipetting in the case of negative
and positive control wells, where HBMEC remained adherent. Cells were
pelleted at 2000rpm for 5 minutes and then fixed in 4% formaldehyde for 15
minutes. Cells were then washed twice in PBS by centrifugation and
resuspended to a final concentration of 1×106/ml. 200µl of cell suspension was
affixed to microscope slides using a Shaydon cytospin, set to 500rpm for 5
minutes.
1 Sigma-Aldrich Ltd., Gillingham, UK
2 Leica Microsystems Ltd., Milton Keynes, UK
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After cytospinning, cells were stained for nuclear fragmentation using
DeadEnd™ fluorometric TUNEL system (Promega, USA)1 and following the
accompanying protocol. Briefly, cells were permeabilised with 0.2% w/v
Triton X-100 in PBS for 5 minutes, and then rinsed by immersion in PBS for
2× 5 minutes. Excess PBS was tapped onto tissue paper and then cells were
covered with 100µl of equilibration buffer for 10 minutes. A reaction mix was
then made up with 45µl equilibration buffer, 5µl nucleotide mix, and 1µl of
rTdT enzyme per reaction. The mix was kept on ice until use and protected
from light. Slides were again tapped on tissue paper to remove equilibration
buffer before adding 50µl of reaction mix per slide and covering with film
coverslips. Slides were then placed in a humidified chamber protected from
light and incubated at 37°C for 60 minutes. Samples were continually
protected from light during all subsequent steps.
After the incubation period reactions were terminated by immersion of slides
for 15 minutes in 2× Saline Sodium Citrate (SSC) diluted from 20× stock with
ultrapure water. Slides were then washed 3× in PBS to remove unincorporated
fluorescein-12-dUTP and finally mounted with Vectashield mounting medium
containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs, UK)2 to
counterstain nuclei. Cells were examined and photographed under a Leica
DM5000B fluorescent microscope with a DFC350FX camera (Leica
Microsystems, UK)xi. Fluorescent filters applied for visualisation of DAPI and
fluorescein isothiocyanate (FITC) used excitation wavelengths of 360nm and
1 Promega Corp., Madison, WI, USA
2 Vector Labs Ltd., Peterborough, UK
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480nm respectively. In addition to representative images, counts of TUNEL-
positive cells were also made per field-of-view under a magnification of 40×.
2.7. Antibody preparation
2.7.1. Protein quantification
Concentrations of proteins in solution were measured using a Nanodrop 8000
instrument1. The instrument was first blanked against 2µl of solvent without
protein, cleaned and then 2µl of protein solution was pipetted onto pedestals
and concentration measured by absorbance at 280nm.
2.7.2. Protein concentration
Protein solutions which were too dilute to be usefully used were concentrated
using Amicon regenerated cellulose 10kDa or 50kDa molecular weight cut-off
concentrator columns (Millipore, USA)2. 10kDa columns were used for ACM
to ensure that low Mw components were not lost whilst 50kDa columns were
used to concentrate large, polymeric, high Mw IgM. Sample was introduced
into the upper chamber of the column, which was then centrifuged at 4,000×g
for 20 minutes at a temperature of 5°C. Concentrate was retrieved from the
upper chamber and quantified by absorbance at 280nm by Nanodrop (see
1 Thermo-Fisher Scientific Ltd., Basingstoke, UK
2 Merck-Millipore, Billerica, MA, USA
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section 2.7.1). Approximately ten to twentyfold levels of concentration were
achieved by this method. Protein solutions were then stored at 4°C for short-
term use or frozen at 20°C as small aliquots to minimise damage from multiple
freeze-thaw cycles.
2.7.3. Immunoaffinity purification
Polyclonal IgM was purified from raw bulk culture supernatant by affinity
purification on a CaptureSelect® anti-mouse-IgM agarose matrix (BAC, The
Netherlands)1. 10ml of matrix slurry was placed in disposable plastic columns2
on top of a semi-permeable membrane disk and allowed to settle to yield a
final capillary bed volume of 5ml. The column was carefully filled with sterile
PBS so as not to disturb the settled slurry bed and a second disk was gently
pushed down to a distance of 1-2mm from the top of the slurry. The column
was then equilibrated with five washes of 5ml sterile PBS.
250ml of bulk culture supernatant (see section 2.1.4) was concentrated tenfold
using protein concentration columns (section 2.7.2) and was passed dropwise
through the equilibrated column five times. A small volume of pre-column
supernatant and the column run-off was collected at this stage to assess the
efficiency of protein recovery. The column was re-equilibrated with five
washes of 5ml sterile PBS and then protein was eluted in 5ml of 0.1M glycine
pH3 and washed through with a further 5ml of sterile PBS. Elute was collected
1 BAC B.V., Naarden, The Netherlands
2 Thermo-Fisher Scientific Ltd., Basingstoke, UK
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as fifteen 1ml fractions and 250µl of 1M Tris Base pH8.8 added to raise the pH
and neutralise the glycine elution buffer. Each fraction was then individually
quantified in duplicate by Nanodrop (section 2.7.1). Positive fractions were
pooled and dialysed against sterile PBS to remove glycine and return samples
to neutral pH. The column was then washed with 25ml of sterile PBS and
finally stored in 20% ethanol for future use. Throughout the procedure care
was taken to avoid air bubbles entering the column and lowering binding
efficiency and rate of flow.
2.7.4. Antibody dialysis
IgM elutes from affinity purification (section 2.7.3) in glycine buffer and
commercially purchased antibody, with sodium azide preservative not suitable
for direct use in vitro, were dialysed into PBS. Solutions were injected into
pre-wetted 3kDa Mw dialysis cassettes1 using a 5ml syringe and a 21 gauge
needle2. The cassette was clipped into a foam float and then placed in a large
beaker containing 3L of sterile PBS. A stirring bar was added and the beaker
was covered and left on a magnetic stirrer set to 50rpm. The apparatus was left
at room temperature for 1 hour and then transferred to a 5°C coldroom for 18
hours. After this period, solutions were recovered from the dialysis cassette
again using a 5ml syringe and 21ga needle, and kept at 4°C for frequent use or
-20°C as small aliquots for longer-term storage.
1 Thermo-Fisher Scientific Ltd., Basingstoke, UK
2 Terumo Medical Corporation, Somerset, NJ, USA
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2.8. Immunoassays
2.8.1. Enzyme-Linked Immunosorbent Assay (ELISA)
General ELISA protocols followed the method detailed below. Additional
details and assay-specific modifications are given in relevant chapters.
For ELISA, capture antibody or A. castellanii antigen coated plates were
prepared by overnight incubation in carbonate/bicarbonate buffer at 4°C. 96-
well microtitre plates were coated with 100µl/well of 10µg/ml A. castellanii
lysate (see section 2.2.1) or isotype control antibody. Plates were washed three
times in PBS plus 0.05% Tween-20 (PBST) to remove coating buffer and then
blocked for one hour at room temperature or overnight at 4°C, using 5%
Bovine Serum Albumin (BSA) in PBST. Blocking solution was removed and
wells were washed three times in PBST before 50µl of sample was added at a
series of dilutions. Plates were then incubated for 90 minutes at room
temperature and washed five times in PBST prior to addition of secondary
antibody.
2.8.2. Alkaline Phosphatase (AP) chemistry
Alkaline Phosphatase conjugated antibody was used during the screening stage
of hybridoma production. Thereafter all ELISAs were performed using
horseradish peroxidase detection chemistry. 100µl of a 1:1000 dilution of AP
62
conjugated anti-mouse IgG (γ-chain specific)1 detecting antibody was added
and plates were once again incubated at room temperature for 90 minutes.
Subsequently wells were washed five times in PBST and 200µl of SigmaFAST
AP substrate1 was added and allowed to develop for 20 minutes at room
temperature and protected from light. Absorbance values at 405nm were read
using an LT-4000 plate reader2.
2.8.3. Horseradish peroxidase (HRP) chemistry
IgM and IgA ELISAs were conducted using Horseradish peroxidise-
conjugated secondary antibodies and HRP detection chemistry. 100µl of a
1:1000 dilution of HRP-conjugated goat anti-mouse IgM STAR86P3, or anti-
mouse IgA (α-chain specific) A49374 detecting antibody was added and plates
were incubated at room temperature for 90 minutes. Wells were washed five
times in PBST and then developed with 100µl of 3,3’,5,5’-
tetramethylbenzidine (TMB)2 substrate for 15 minutes at room temperature and
protected from light. Reactions were stopped by addition of 50µl 2M sulphuric
acid and absorbance values at 450nm were read using an LT-4000 plate reader.
1 Sigma-Aldrich Ltd., Gillingham, UK
2 Labtech Ltd., Uckfield, UK
3 AbD Serotec, LTD., Kidlington, UK
4 Sigma-Aldrich Ltd., Gillingham, UK
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2.8.4. Dot Blot
Whatman® Protran nitrocellulose membrane (GE Healthcare, UK)1 was cut
into 10×10cm squares, subdivided into a grid and blotted with 20µl of test
antigen (either raw hybridoma culture supernatant, 50µg/ml isotype control
mouse IgG2, 50µg/ml negative control mouse IgM1, 50µg/ml Acanthamoeba
PBS lysate or blank culture medium). The membrane was allowed to dry out
completely before transfer into blocking buffer (PBST plus 5% BSA) for 90
minutes at room temperature. Blots were washed in PBST for 3× 3 minutes
and then probed with 20µl of test antibody (either raw hybridoma culture
supernatant, 50µg/ml negative control mouse IgG, 50µg/ml negative control
mouse IgM, 1:1000 dilution of mouse hyperimmune serum or blank culture
medium). Blots were incubated for 90 minutes at room temperature and then
washed for 3× 3 minutes in PBST. Detecting antibody was either goat anti-
mouse IgG-HRP (Fab specific)2 or goat anti-mouse IgM-HRP3, diluted 1:1000
in PBST. 20µl of detecting antibody solution was pipetted onto target spots
and the blot was incubated for an hour at room temperature. After incubation,
blots were washed for 3× 3 minutes in PBST, and developed by adding 20µl of
TMB solution to each spot and photographing after 5 minutes.
1 GE Healthcare Ltd., Buckinghamshire, UK
2 Sigma-Aldrich Ltd., Gillingham, UK
3 AbD Serotec, LTD., Kidlington, UK
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2.8.5. Western Blotting
Prior to beginning the blotting procedure an SDS-PAGE gel was run with 90µg
per well of A. castellanii PBS lysate (see section 2.2.1), alongside 1µg of
negative control IgM and molecular weight ladder at 120V for 90 minutes (see
section 2.9.1 for full methodology). After the run, the gel was equilibrated in
cold 1× TGS blotting buffer (Expedeon, UK)1 for 15 minutes alongside
blotting paper and sponges. A sheet of polyvinylidine fluoride (PVDF)2 was
activated by washing in 100% methanol for one minute, then ultrapure water
for 2× 1 minute washes before equilibration in cold transfer buffer for 10
minutes. All components were assembled into a transfer sandwich and run at
110V for 90 minutes using an Owl VEP-24 blotting module.
After transfer, PVDF membrane was washed for 3× 5 minutes in ultrapure
water then blocked overnight with 5% BSA. The next day membrane was
washed for 3× 5 minutes in PBST, then cut into strips each of which was
incubated with either 25ml of 50ng/ml purified anti-A. castellanii polyclonal
antibody or negative control mouse IgM3, or 1:50 polyclonal bulk culture
supernatant or control culture medium. Strips and antibody/control solutions
were placed in 50ml centrifuge tubes on a roller and incubated at room
temperature for 60 minutes. Solutions were carefully discarded and strips
1 Expedeon Ltd., Harston, Cambridgeshire, UK
2 Thermo-Fisher Scientific Ltd., Basingstoke, UK
3 AbD Serotec Ltd., Kidlington, UK
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washed for 3× 5 minutes in 30ml PBST on a roller, before addition of 25ml
1:10,000 goat anti-mouse IgM-HRP1 in PBST. Samples were returned to the
roller for a further 60 minutes then washed again for 3× 5 minutes in 30ml
PBST.
Development of samples was carried out using Amersham ECL+
chemiluminescent substrate1 as per kit instructions. Briefly 3ml of room
temperature solutions A and B were mixed in a centrifuge tube and pipetted so
that the entire surface of the PVDF membranes was covered. Membrane strips
were incubated at room temperature for five minutes, excess ECL+ was drained
and then blots were sealed inside plastic film. CL-XPosure x-ray film2 was
then exposed to blots for 10 seconds in a darkroom exposure box and
developed with an SRX101A x-ray instrument (Konika Minolta, UK)3.
2.8.6. Immunofluorescence
Cell populations of HBMEC, Acanthamoeba and K562 (a chronic myeloid
leukaemia cell line) were prepared in PBS to a final concentration of 106/ml
following procedures outlined in sections 2.1.2 and 2.2.1. K562 were obtained
from the Health Protection Agency Culture Collection4 (catalogue number
89121407) from a line first isolated in 1979 (Lozzio and Lozzio, 1979, Lozzio
et al., 1981). Cells were first retrieved from liquid nitrogen storage and
1 GE Healthcare Ltd., Buckinghamshire, UK
2 Thermo-Fisher Scientific Ltd., Basingstoke, UK
3 Konika Minolta Ltd., Basildon, UK
4 Health Protection Agency Culture Collections, Salisbury, UK
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resuspended in 1ml RPMI + 10% FBS + 1× penicillin/streptomycin by
centrifugation at 1000×g to remove cryopreservative (DMSO).
200µl of the cell suspension (200,000 cells) was then affixed to microscope
slides using a Shaydon Cytospin 41 set to 450rpm for 5 minutes. Slides were
then fixed by immersion in 4% formaldehyde, and washed twice in PBS prior
to continuing with experiments.
Slides were firstly blocked with 600µl of 5% BSA in PBS for an hour at 37°C,
and then washed by immersion five times in PBST. Slides were dabbed dry to
remove excess liquid and then 300µl of primary antibody, antibody Fc
fragment, dilutions of mouse serum, or dilutions of culture supernatant were
added before returning to incubate at 37°C for 60 minutes. Slides were again
washed five times in PBST, dabbed dry and then incubated with appropriate
fluorochrome-conjugated secondary antibody again at 37°C for 60 minutes.
Finally slides were washed three times in PBST and twice in PBS without
Tween-20 before allowing to air-dry protected from light. Once slides were
almost dry they were mounted in Vectashield with DAPI mountant2 and
coverslips were sealed with nail polish. A Leica DM5000B fluorescent
microscope with DFC 350FX camera3 was then used to observe and
photograph fluorescing cells at excitation wavelengths of 360, 480 and/or
640nm respectively. Antibodies, dilutions and microscope settings for
individual assays are given in relevant experimental chapters.
1 Thermo-Fisher Scientific Ltd., Basingstoke, UK
2 Vector Labs Ltd., Peterborough, UK
3 Leica Microsystems Ltd., Milton Keynes, UK
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2.8.7. Fluorescence-Activated Cell Sorting (FACS)
5×106 HBMEC and A. castellanii cells were collected as outlined in sections
2.1.2 and 2.2.1 and washed 3× in RPMI by centrifugation at 1,000×g. Cells
were then fixed in 4% formaldehyde for 10 minutes and washed twice in PBS
by centrifugation at 2,000×g before blocking in 5% BSA for 30 minutes at
37°C. Cells were washed twice in PBS, then incubated with either 1:300
human IgG Fc fragment (Alpha Diagnostic International)1 in PBST+1% BSA,
or PBST/BSA alone at 37°C for 60 minutes. Cells were then washed again in
PBS + 1% BSA before incubation with 1:300 anti-human IgG (Fc-specific)-
FITC secondary antibody2 in PBST/BSA, or PBST/BSA alone at 37°C for 60
minutes. Finally, cells were washed 3× in PBS and stored at 4°C, protected
from light until use. A FACSCantoII instrument was used to analyse cells,
recording 50,000 events. FACS data was analysed using WEASEL version 3.0
software (The Walter and Eliza Hall Institute, Australia)3 as follows.
Unlabelled control cells were used to define populations for all samples based
on forward scatter (FSC) versus side scatter (SSC) dotplots. Dotplots of FITC
signal versus FSC were then drawn, gated against unlabelled cells. The
percentage of each cell population positive for FITC signal was automatically
calculated by the software based on this gating.
1 Alpha Diagnostic International Inc., San Antonio, TX, USA
2 Sigma-Aldrich Ltd., Gillingham, UK
3 The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
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2.9. Polyacrylamide Gel Electrophoresis (PAGE)
2.9.1. Sodium Dodecyl Sulphate PAGE (SDS-PAGE)
Precast polyacrylamide 12% and gradient 4-20% gels (Expedeon, UK)1 were
prepared by rinsing in distilled water prior to use so that wells were filled and
free of bubbles. The gel was locked into a Verti-gel Mini electrophoresis tank2
and 1L of 1× SDS running buffer2 was poured in to the fill line.
Per lane, 15µl of the sample to be run was mixed with 4µl of LDS loading
buffer2 and either 1µl of dithiothreitol (DTT)2 if reducing conditions were
required or ultrapure water for non-reducing conditions. Samples were
denatured by heating to 75°C for 5 minutes and then loaded onto the gel
alongside 10µl of ColorPlus prestained protein marker (New England BioLabs,
USA)3. A voltage of 120V was applied to the tank for 90 minutes, after which
the gel was retrieved from its cartridge and washed in ultrapure water for five
minutes.
2.9.2. Coomassie Blue staining
Samples to be visualised by coomassie blue staining were prepared using an
acetic acid/ethanol–based stain (see Appendix 1). Gels were immersed in stain,
1 Expedeon Ltd., Harston, Cambridgeshire, UK
2 Thermo-Fisher Scientific Ltd., Basingstoke, UK
3 New England BioLabs Inc., Ipswich, MA, USA
69
gently heated for 1 minute in a microwave oven and placed on a rocker for 60
minutes at room temperature. Gels were then washed for 3× 5 minutes in
ultrapure water to remove unincorporated stain. To resolve protein bands gels
were then placed in destaining buffer, again gently heated, and then placed on
a rocker for 30 minutes. Finally gels were washed for 3× 5 minutes in ultrapure
water prior to photography of visible bands.
2.9.3. Silver Nitrate staining
Where Coomassie staining was insufficiently sensitive to visualise low-
abundance bands, silver staining was used as an alternative. This was carried
out using a GE healthcare PlusOne kit1 following the instructions provided
(see Appendix 1 for solutions used). Briefly, gels were soaked for 30 minutes
in acetic acid/ethanol fixing solution then placed in sensitising solution for 30
minutes under shaking. Gels were washed for 3× 5 minutes in ultrapure water
before transfer to 0.1% w/v silver nitrate solution for 20 minutes under
shaking. The gels were then washed again for 2× 1 minute in ultrapure water
and developed for three minutes with developing solution. Once bands of
appropriate intensity were visible the reaction was terminated by immersing
gels in stopping solution for 10 minutes under shaking. Finally, gels were
washed for 3× 5 minutes in ultrapure water prior to photography of visible
bands.
1 GE Healthcare Ltd., Buckinghamshire, UK
70
2.9.4. Zymography
ACM collected from confluent Acanthamoeba cultures was concentrated using
a 10kDa column as described in section 2.7.2 yielding a final protein content
of 2.5mg/ml. Dilutions of ACM were made in ddH2O and 15µl of sample
mixed with 5µl of non-reducing sample buffer and heated to 75°C, alongside
0.1× Trypsin to act as a control. Samples were then run alongside ColorPlus
prestained protein marker1 using Bio-Rad precast 10% gelatin gels (Bio-Rad,
UK)2 at 110V for 60 minutes. After completion of the run gels were washed in
50mM Tris buffer pH7.5 with 2.5% w/v TritonX-100 for one hour to remove
SDS, then 18mΩ distilled water 3× 5 minute washes to remove remaining 
detergent. Proteins were refolded and the zymogram developed by incubation
in 50mM Tris buffer pH7.5 with 0.5M CaCl2 for 3 hours at 37°C after which
the gel was again washed for 3× 5 minutes in ultrapure water. Gels were then
stained in Coomassie Blue staining buffer for one hour, washed three times in
ultrapure water, and then destained for one hour. Finally, gels were washed
three times in ultrapure water and photographed using an ImageQuant 300
instrument3.
1 New England BioLabs Inc., Ipswich, MA, USA
2 Bio-Rad Laboratories Ltd., Hemel Hempstead, UK
3 GE Healthcare Ltd., Buckinghamshire, UK
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2.9.5. Antibody cleavage
Fifty millilitres of ACM was collected as described in section 2.2.2 and
concentrated using 10kDa Mw columns as per section 2.7.2 yielding a final
concentration of 1mg/ml as assessed by Nanodrop. Cleavage reactions were
then prepared with 1µg of either mouse IgA1, IgM2, IgG3 or IgE2 isotype
controls, or specific polyclonal IgM generated as described in sections 2.3 and
2.1.4. 3.6µg of concentrated ACM was then added to each reaction. For each
antibody class, serine (phenylmethylsulfonyl fluoride (PMSF))4, cysteine
(iodoacetamide)4 or metalloprotease ((2R,3S)-N4-Hydroxy-N1-[(1S)-2-
(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyul)-3-[(2-
thienylthio)methyl] butanediamide (Batimastat))4 inhibitors were added, to a
final concentration of 100µM. Ultrapure water was used to bring the total
volume of each reaction to 30µl. Reaction mixes were incubated at 37°C for 2
hours and then subjected to SDS-PAGE under reducing conditions, using 4-
20% gradient precast polyacrylamide gels (see section 2.9.1). Gels were
subsequently washed for 3× 5 minutes in ultrapure water and silver stained as
described in section 2.9.3.
Analysis of cleavage products was performed using ImageJ software
(Schneider et al., 2012) using an adapted method of Western blot band density
quantification. Briefly, lanes on gel images were delineated using the ‘Outline
1 Alpha Diagnostic International Inc., San Antonio, TX, USA
2 AbD Serotec Ltd., Kidlington, UK
3 Sigma-Aldrich Ltd., Gillingham, UK
4 Tocris Bioscience Ltd., Bristol, UK
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Lane’ tool and then expressed as density peaks using the Analyze>Gels>Plot
Lanes command sequence. Peaks of interest were then identified based on
molecular weight and closed off at either side using the ‘Straight Line’ tool.
The ‘Wand’ tool was then used to collect area measurements. Contributions to
peak area by ACM were corrected for by subtracting the area of any ACM
peaks at equivalent Mw and the remaining peak areas were expressed as a
proportion of the uncleaved control sample.
2.10. Peptide sequence identification by tandem mass
spectrometry
Due to the sensitivity of mass spectrometry analysis gel equipment and tanks
were washed thoroughly with ultrapure water prior to use. Running and
washing buffers were made fresh and used only once and trays used for
washing/staining had not previously been used for protein or immunological
procedures. Extra caution was used throughout the procedure to avoid keratin
contamination. Fresh A. castellanii PBS lysate was prepared as described in
section 2.2.1, with the addition of 1× P2714 protease inhibitor cocktail1 to limit
sample degradation. Thirteen microliters of 5mg/ml sample was then mixed
with 5µl of LDS loading buffer2 and 2µl of DTT2, denatured, and run on a
precast polyacrylamide gel (see section 2.9.1). After completion of the run the
gel was washed for 3× 5minutes in 18mΩ ultrapure water and then stained 
1 Sigma-Aldrich Ltd., Gillingham, UK
2 Expedeon Ltd., Harston, Cambridgeshire, UK
73
overnight at 4°C with SafeStain colloidal coomassie blue1. Bands were then
resolved by 3× 60 minute washes in ultrapure water to remove background
staining.
Tandem MS sequencing was performed by Dr S. Liddell at the Sutton
Bonington Proteomics Facility, University of Nottingham using standard in-
house procedures. Briefly, gel bands were excised with a clean scalpel and
diced into cubes (~1mm3), then placed into individual wells of a microtitre
plate. Gel cubes were then processed (destained, reduced, and alkylated) and
trypsin digested using standard procedures on the MassPREP station.
Digestion buffer was 25mM ammonium bicarbonate; trypsin gold was diluted
in this buffer at 10ng/µl and 30µl of the enzyme/buffer mixture was added to
each well. Trypsin was allowed to absorb into gel pieces at 4°C for 15 minutes,
then digestion proceeded at 40°C for 5 hours. The resulting peptides were
delivered via nanoLC to a Q-ToF2 instrument for tandem MS analysis.
An automated experiment (DDA = data dependent acquisition) was run where
selected peptides automatically enter MS/MS for fragmentation. The obtained
sequence data was then searched against the public databases using
MS/MSIONS search on the MASCOT web site using standard default settings.
Searches were made against the NCBInr and ESTs databases with the standard
variable modifications of 1) carbamidomethylation of Cysteine and 2)
oxidation of Methionine. Output was interpreted on the basis of E-values
1 Sigma-Aldrich Ltd., Gillingham, UK
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reported from MASCOT. The level for significance was set as E ≤0.05,
representing a less than 5% chance of false-positive identification.
2.11. Bioinformatics
Bionformatics analysis was carried out using a combination of the NCBI and
UNIPROT databases and NCBI’s Basic Local Alignment Search Tool
(BLAST). Sequences were obtained from the UNIPROT and NCBI protein
databases and compared with the A. castellanii genome assembly using
individual queries via the tBLASTn algorithm. Sequences from predicted or
observed extracellular domains were used where identified by annotation.
Where significant similarity was shown, matching A. castellanii transcriptomic
sequence was retrieved and translated into protein sequence using the most
appropriate reading frame (fewest interrupting STOP codons), identified with
SeaView version 4.4.1 software (Gouy et al., 2010). Reciprocal tBLASTn
queries were then run, comparing each peptide sequence to all others. Results
from reciprocal BLAST were then filtered for stringency. Sequences were
accepted as significantly similar if the length of the aligned region was ≥50aa
and the E-score for the alignment was ≤0.00001.
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2.12. Statistical analyses
Statistical analyses were performed using Prism version 5.04 software
(GraphPad Software Inc.)1. Types of analysis varied according to the nature of
each experiment and are detailed in individual chapters. These included 1-way
or 2-way Analysis of Variance (ANOVA), Regression and Mann-Witney tests.
Significance levels for individual groups were determined using Bonferroni or
Tukey post-tests for each treatment versus a control, or individual comparisons
of all treatments. The alpha level for significance was set at p ≤ 0.05 for all
tests.
1 GraphPad Software Inc., La Jolla, CA, USA
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3. Use of polyclonal antibody to investigate
pathogenesis of AGE, with focus on in vitro
functional assays and identifying antigenic targets
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3.1. Abstract
In the bloodstream and at the site of blood-brain barrier penetration in the brain
microvasculature A. castellanii is exposed to host humoral immunity. The host
responses and the amoebic antigens that form the target for this response have
yet to be fully identified and few studies have focussed on the effect specific
antibody has on pathogenesis in AGE. We generated a polyclonal antibody
(HE2) by hybridoma fusion and utilised it to investigate binding, monolayer
disruption and host cell death in an in vitro model of the BBB. HE2 reacted
strongly with trophozoite cell surface antigens by immunofluorescence, and
caused parasites to aggregate in vitro. Binding to endothelial cells was also
reduced, albeit to a similar extent as an isotype control; however this did not
result in a reduction of host cell death. Disruption of the cell layer was reduced
by high concentrations of antibody but this effect was seen in only one of the
two in vitro assay types employed. Identification of immunodominant antigens
using Western blotting and tandem MS sequencing techniques revealed
metabolic and protein synthesis enzymes as well as actin as targets of HE2.
These data provide insights into A. castellanii pathogenesis and the identity of
amoeba antigens that serve as targets for immunity.
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3.2. Introduction
Acanthamoeba granulomatous encephalitis (AGE) is a disease characterised by
the formation of large lesions in neural tissue, and the formation of granulomas
comprising of living and dead parasites and host material preceded by loss of
integrity in the blood-brain barrier (Martínez et al., 1980). In clinical disease
presentation the host response is insufficient to control infection, which as a
result is often fatal even with medical intervention (Sarica et al., 2009, Bloch
and Schuster, 2005, Carter et al., 1981). Granuloma formation and
accompanying neural inflammation depends to a large extent on macrophage
and neutrophil recruitment (Guarner et al., 2007, Hurt et al., 2003c, Stewart et
al., 1994) however beyond this relatively little is known about the immune
response to Acanthamoeba. In particular the haematogenous stage of infection,
during which trophozoites are exposed to many arms of the host immune
system is especially poorly understood. This includes the immune
microenvironment at the sites of BBB penetration in the brain
microvasculature, and as loss of BBB integrity is a key event in the
establishment of AGE it is important to increase our understanding of host and
parasite processes occurring in this zone.
One of the ways in which large extracellular pathogens are controlled by the
immune system is the secretion of specific antibodies. The role of antibody
within the host immune response includes: initiation of the complement
cascade resulting in pathogen lysis, recruitment and activation of other
immune cells at sites of infection, and limiting pathogen motility by
aggregation. Their high specificity for target antigens is the basis for
recognition of a wide variety of infectious agents. This results from
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hypervariability in the Fab (variable) region of the molecule, variants of which
are generated during somatic recombination in B-cells. Serum antibody is of
particular importance in haematogenous parasitic infections as the pathogen in
question may be too large to be ingested by phagocytes and must therefore be
targeted by the complement lysis cascade. Parasite material and fragments are
then phagocytised in order to promote antigen presentation to effector and
helper cells. Additionally antibody is of importance in inactivating pathogen
excretory/secretory (E/S) proteins, for example neutralisation of parasite
proteases and bacterial toxins (Smith et al., 1994, Adekar et al., 2008).
Acanthamoeba is known to express several classes of secreted protease
(Ferreira et al., 2009, Kim et al., 2003, Na et al., 2001) and so neutralisation by
antibody is likely to be of importance in AGE.
Due to their specificity antibodies are also very useful tools for molecular
dissection of parasite antigens. For example, antibody generated from in vivo
infections can assist in the identification of antigens important for immune
recognition of a pathogen. Additionally, specific immunoglobulin is a valuable
diagnostic marker for infection and can also be used for therapeutic purposes.
In the particular case of Acanthamoeba there have been attempts by several
groups to develop specific monoclonal antibodies using differing
methodological approaches. Khan et al. used phage display technology,
panning against amoeba antigens to identify molecules with novel specificities
(Khan et al., 2000a). By contrast Kennett et al. and Turner et al. adopted a
more classical approach based on polyethylene glycol (PEG) fusion (Turner et
al., 2005, Kennett et al., 1999). Both approaches yielded specific antibody
however they have yet to enter routine use due to low specificity and the
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difficulty of identifying clones that react well with both trophozoites and cysts
(Turner et al., 2005). Additionally, where reactivity to both life stages of the
parasite was shown, specific antigen targets were not determined and as such
relevance to known mechanisms of pathogenesis remains to be demonstrated.
In this study our aim was to understand the role played by the humoral immune
response in the interactions between trophozoites and the microvascular
endothelium and to examine relevance to pathogenesis. To accomplish this
polyclonal antibody was generated by classical hybridoma fusion from
immunised BALB/c mice. One strongly reacting clone was tested against a
range of parameters in an in vitro model of the blood-brain barrier. We then
used immunological methods to identify immunodominant antigens and
assigned sequence identities based on peptide fragments retrieved by tandem
MS sequencing. This study contributes to the understanding of important
antigens expressed by A. castellanii during infection, and also the role played
by specific antibody in controlling AGE at the endothelium.
3.3. Materials and Methods
3.3.1. Antibody generation
Polyclonal hybridomas were generated from splenocytes of BALB/c mice
immunised with 2×107 trophozoites in Alum using a protocol of three bi-
weekly injections as described in sections 2.3.1 and 2.3.2. Terminal blood
serum was collected (section 2.3.3) and used to assess IgG levels in immunised
mice by ELISA (section 2.6.1 and 2.6.1.1). Splenocytes were collected
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aseptically from mouse spleens and fused with Sp2/0 mouse myelomas using
PEG (sections 2.3.4 and 2.3.5) to produce hybridomas for downstream use.
3.3.2. Screening – ELISA
Microtitre plates were coated with A. castellanii PBS lysate then blocked and
incubated with either dilutions of mouse serum, cell culture supernatant or
purified polyclonal antibody as described in section 2.6.1. For initial IgG
screening of mouse hyperimmune serum, secondary reagents and detection
chemistry was based on alkaline phosphatase as described in section 2.6.1.1.
Thereafter ELISAs used were based on HRP detection chemistry (see section
2.6.1.2).
3.3.3. Screening – Dot Blot
50µg/ml Acanthamoeba PBS lysate (prepared as described in section 2.2.1)
was blotted onto subdivided nitrocellulose membrane, which was then dried
and blocked. Test samples (either culture supernatant, dilutions of
positive/negative serum or isotype control antibody) were then added to blots,
and binding detected by addition of anti-IgG and anti-IgM secondary
antibodies (Table 2.2 #6 and 8) as described in section 2.6.2.
3.3.4. Screening – Immunofluorescence
A. castellanii trophozoites were affixed to microscope slides by cytospin,
blocked and treated with neat culture supernatant, 1:500 serum dilutions,
82
2µg/ml purified polyclonal antibody or 2µg/ml isotype control antibody as
described in section 2.6.4. Primary antibody was detected using 1:500 goat
anti-mouse IgG – Texas Red conjugate (Table 2.2 #12) or 1:500 goat anti-
mouse IgM – FITC conjugate (Table 2.2 #11) and cells were counterstained
with DAPI. Photomicrographs were taken using exposures of 300ms (360nm
filter), and 500ms (480nm and 640nm filters). Gamma and gain settings were
both 1×.
3.3.5. Purification
Unpurified bulk culture supernatant was collected from polyclonal hybridoma
cultures (section 2.1.4) and concentrated using regenerated cellulose columns
as described in section 2.5.2. Concentrated antibody solutions were then
purified by elution from immunoaffinity column as described in section 2.5.3.
Purified antibody was then dialysed into PBS for use in vitro (see section
2.5.4), quantified (section 2.5.1) and if necessary re-concentrated to obtain
solutions of the required strength.
3.3.6. Functional assays
HBMEC were cultured as described in section 2.1.2 and grown in 24 or 48-
well plates (section 2.4.1). 2×105 A. castellanii trophozoites were incubated
with 200µg/ml of purified polyclonal antibody or isotype control in RPMI at
37°C under constant motion prior to use in vitro as described below.
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3.3.7. Binding inhibition
Binding of treated trophozoites was assessed by haemocytometer counts of
unbound amoeba from 24 or 48-well plates, as described in section 2.4.3.1.
3.3.8. Monolayer protection
Protection of HBMEC monolayers was assessed using both haematoxylin
staining of fixed monolayers and photomicrographs taken during the
experimental period (see section 2.4.4). Monolayer disruption visible in
photomicrographs was quantified using a grid counting method as described in
section 2.4.4.2.
3.3.9. Aggregation
Trophozoites were treated with specific and nonspecific antibody for 3 hours
as described above (section 3.3.6). Cell suspensions were then deposited in 24-
well plates, photographed and the degree of aggregation scored qualitatively
using the method outlined in section 2.4.7.
3.3.10. Cytotoxicity
Cytotoxicity in treated HBMEC was examined by detection of LDH release
into culture supernatants. Samples were collected after 24 hours and assessed
as described in section 2.4.5.
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3.3.11. Western Blotting
Following SDS-PAGE of amoeba lysate (see section 2.7.1), samples were
electrotransferred to PVDF membrane and probed with specific (HE2), or
nonspecific IgM antibody. Bands were then detected with anti-IgM secondary
reagent and ECL+ chemiluminescent substrate, and exposed to X-ray film. Full
details are given in section 2.6.3.
3.3.12. Tandem mass spectrometry (MS/MS) sequencing
A. castellanii lysate (see section 2.2.1) was resolved by SDS-PAGE under
ultra-clean conditions and bands of interest corresponding to those recognised
by specific polyclonal antibody on Western blot were excised and peptide
fragments sequenced using MS/MS methodology (see section 2.8). Sequence
data was searched against the NCBInr and ESTs public databases using
MS/MSIONS search on the MASCOT web site. Output was interpreted on the
basis of E-values reported from MASCOT. The level for significance was set
as E ≤0.05, representing a less than 5% chance of false-positive identification.
3.3.13. Statistical analysis
Analyses were performed using GraphPad Prism software version 5.04. Data
was analysed using 1-way ANOVA for multiple group comparisons. Analysis
of seroconversion data was conducted using the nonparametric Mann-Witney
test due to the presence of unequal sample numbers per group. The alpha level
for significance was set at p ≤ 0.05 for all tests (see section 2.10).
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3.4. Results
3.4.1. Mice seroconvert in response to immunisation with Acanthamoeba
Immunisation of mice with A. castellanii produced a strong response as
demonstrated by ELISA (Figure 3.1). Conversely, unimmunised mice showed
a weakly positive response at low dilutions, however this is consistent with
background serum reactivity seen in other studies (Cerva, 1989, Chappell et
al., 2001, Schuster et al., 2006, Kiderlen et al., 2009). Immunised mice
demonstrated significantly higher serum antibody titres compared with
unimmunised animals (Mann-Whitney test, p<0.05). It was possible to clearly
distinguish between positive and negative reactions at dilutions up to 1 in 500
using pooled sera from immunised versus unimmunised animals.
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Figure 3.1 Mice produced a positive immune response against Acanthamoeba by ELISA.
Serum was collected from mice immunised with 107 trophozoites in PBS + Alum and a control
group immunised with PBS + Alum alone. Plates were coated with 10µg/ml amoeba lysate,
blocked overnight and then incubated with a range of serum dilutions for 90 minutes. Plates
were washed several times and bound antibody detected with goat anti-mouse IgG conjugated
to alkaline phosphatase. Immunised mice showed higher antibody titres than unimmunised
mice (Mann-Whitney, p<0.05). Values are mean ± S.E.M. from four immunised mice (filled
points) and two negative control mice (open points).
3.4.2. Fused hybridoma colonies produced specific IgG and IgM
Given the positive immune response seen in experimental mice, splenocytes
were extracted and fused with Sp2/0 myelomas as detailed in section 2.3.4 and
2.3.5. Fused cultures were tested for IgG, IgM and IgA using class-specific
secondary antibodies. Wells were considered positive if they showed
absorbance equal to or higher than a 1:500 dilution of negative serum (abs =
0.1). Under these criteria IgG and IgM positive wells were identified from four
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plates tested. Six plates were tested for IgA but showed no response above
background levels. Wells demonstrating the highest absorbance readings were
picked from each plate and cell populations expanded by subculture in 25cm3
tissue culture flasks. After a week of growth cultures were examined visually
to determine which had survived transfer.
Non-proliferating clones were discarded and flasks with visible colonies were
screened by ELISA for the continued presence of antibody using IgG and IgM-
specific detecting reagents. 32 hybridoma pools tested positive for a
combination of one or both isotypes at this stage (Figure 3.2). All 32 clones
were subcultured to select for ability to sustain in vitro growth and hybridoma
populations which died at this stage were discarded.
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Figure 3.2 Hybridoma anti-Acanthamoeba antibody secretion.
32 of 40 hybridoma pools test positive for secretion of A. castellanii-specific IgG, IgM or both. ELISA plates were coated with 1µg/ml of sonicated PBS extract of amoeba.
Plates were washed and blocked with PBST + 5% milk protein and 50µl of supernatant from hybridomas cultures added and incubated for 90 minutes at room temperature.
Antibody was detected with goat anti-mouse IgG (γ-chain specific) and goat anti-mouse IgM conjugated to horseradish peroxidase, diluted 1:1000 in PBST (see section
2.2.3). Wells displaying absorbance of >0.1 (red line) were considered positive. *denotes hybridomas testing positive for both IgG and IgM.
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3.4.3. Immunofluorescence analysis of positive clones
Hybridoma pools displaying the strongest ELISA signal and most robust
growth characteristics were examined using immunofluorescence assays in
order to assess binding specificity and antibody target site. Binding of both
IgG and IgM isotypes was tested for each clone. In the IgG assay, hybridomas
DA1, DF11 and HE2 demonstrated higher levels of fluorescence than negative
control samples, however in all cases signal was weak relative to the positive
control. Staining was largely localised in the cytoplasm, although reactivity
with the membrane was seen with DF11 (Figure 3.3 D).
In the IgM assay, only hybridomas IA5 and HE2 produced fluorescence above
background levels. Signal for both clones was strong relative to the positive
control and showed specific localised staining. Fluorescence was observed in
both the cytoplasm and on the cell membrane for HE2 supernatants (Figure 3.4
F), but was tightly confined to the nucleus in IA5 (Figure 3.4 E). Acanthopodia
were also visibly stained by HE2 antibodies raising the possibility that antigens
for this hybridoma might be concentrated in these membrane structures.
Figure 3.3 Supernatants from hybridomas contain
Fixed A. castellanii
positive/negative control serum, or neat supernatants from hybridoma cultures. Texas Red
conjugated anti-mouse IgG secondary antibody was then used to detect binding and nuclei
were counterstained with DAPI. (A) Positive serum, (B) negative serum, (C) DA1 hybridoma,
(D) DF11 hybridoma, (E) IA5 hybridoma, (F) HE2 hybridoma, (G) CD9 hybridoma. Arrows
indicate sites of membrane staining. Bar = 50
Acanthamoeba-specific IgG.
trophozoites were blocked and incubated with 1:500 hyperimmune mouse
µm.
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Figure 3.4 Supernatants from hybridomas contain
Fixed A. castellanii
positive/negative control serum, or neat supernatants from hybridoma cultures. FI
conjugated anti-mouse IgM secondary antibody was then used to detect binding and nuclei
were counterstained with DAPI. (A) Positive serum, (B) negative serum, (C) DA1 hybridoma,
(D) DF11 hybridoma, (E) IA5 hybridoma, (F) HE2 hybridoma, (G) CD9 hybridoma
indicate staining of acanthopodia. Bar = 50
Acanthamoeba-specific IgM.
trophozoites were blocked and incubated with 1:500 hyperimmune mouse
µm.
92
TC-
. Arrows
93
3.4.4. Clone HE2 reacts with a PBS lysate of Acanthamoeba by dot blot
The hybridoma pool with the strongest responses from ELISA and IF assays
were screened by dot blot against a trophozoite lysate. IA5 supernatant showed
no reaction when screened for IgG (Figure 3.5 A) but was positive for the
presence of IgM, although at lower levels than was observed in positive
controls (Figure 3.5 B). By contrast HE2 supernatant reacted with a response
against amoeba lysate of equal magnitude to positive serum, using both anti-
IgG and anti-IgM secondary antibody (Figure 3.5 A and B). Levels of IgM in
particular were high in comparison to controls, and in accordance with the
strong absorbance and fluorescence readings seen in previous assays.
Figure 3.5 IA5 and HE2 supernatants react with
Amoeba lysate was spotted onto nitrocellulose membrane, blocked, and probed with
unpurified culture supernatants from cultures of IA5 and HE2 hybridomas. Binding was
detected with HRP
TMB substrate. (A) Anti
probed in duplicate.
A. castellanii lysate by dot blot.
-conjugated anti-IgG or anti-IgM secondary antibody and developed with
-IgG secondary, (B) anti-IgM secondary. Samples were loaded
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3.4.5. Unpurified hybridoma culture supernatants do not reduce amoeba
binding to HBMECs
Having established reactivity of hybridoma culture supernatants with both A.
castellanii lysate (ELISA, dot blot) and whole trophozoites (IF), we sought to
observe whether hybridoma supernatants produced any functional effects in the
context of parasite binding or host cell pathology. Trophozoite suspensions
were prepared in hybridoma supernatant as described in section 3.3.6.
Suspensions were then used to infect cultures of HBMEC in 24-well tissue
culture plates (see section 3.3.6.1 and 2.4.3.1) with binding assessed by
haemocytometer count (section 2.4.3.1). Data analysis showed no significant
difference between any treatment groups (p>0.05, 1-way ANOVA, Figure 3.6)
however binding did appear reduced in the HE2 treatment group.
96
P
er
ce
nt
ag
e
B
in
di
ng
Cu
ltu
re
me
diu
m
RP
MI HE
2 IA5 CD
9
DA
1
0
20
40
60
80
100
Figure 3.6 Hybridoma supernatants do not decrease binding of trophozoites to HBMEC
monolayers.
Trophozoites were treated with hybridoma supernatants and used to infect HBMEC
monolayers in 24-well plates. Numbers of unbound amoeba were counted in triplicate by
haemocytometer after 3 hours, and used to calculate percentage binding. No significant
differences were seen between treatment groups (p>0.05, 1-way ANOVA). Each treatment
was performed in triplicate and results are mean + S.E.M. from three independent experiments.
Additionally there was a slight effect in terms of monolayer protection as
assessed by post-infection staining of infected monolayers. Monolayers fixed
and stained with haematoxylin (see sections 2.4.4.3) showed marginally
reduced disruption of the cell layer in wells containing HE2-treated
trophozoites (Figure 3.7), compared with other hybridomas and controls.
Taken together with data from Figure 3.6 this implied that greater functional
effects on pathogenesis by HE2 might be detected using purified antibody at
higher concentrations. We therefore used purification procedures described in
section 2.5 to obtain
presented range of immune
Figure 3.7 Hybridoma supernatants provide partial protection from monolayer
destruction by trophozoites.
Trophozoites were treated with hybridoma supernatants and used to infect triplicate HBMEC
monolayers in 24-
hours. All hybridomas and hybridoma growth med
monolayer disruption, with HE2 supernatants having the greatest protective effect. Results are
representative of three independent experiments.
3.4.6. Purified HE2 polyclonal antibody maintains reactivity with
Acanthamoeba
On the basis of strong responses and membrane reactivity (see sections 3.4.2 to
3.4.4) the hybridoma HE2 was selected as a source of antibody for use in
subsequent assays. In order to obtain purified antibody solution with which to
work, HE2 supernatants were collected and then purified as described in
section 2.5. Purified solutions were then used in immunofluorescence assays
purified HE2 IgM and then repeated and extended the
- and functional assays.
well plates. Monolayers were fixed and stained with haematoxylin after 24
ium provided partial protection from
trophozoites
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(section 3.3.4) to ensure that the purification process had no adverse effects on
the strength or specificity of antib
Compared with positive control serum and a negative IgM isotype control
purified HE2 maintained a high level of binding to
Levels of fluorescence were consistent with those seen in assays conducted
with unpurified culture supernatant (see Figure 3.4) and as before, were in
excess of that seen in the positive control sample. Purified HE2 also retained
membrane binding specificity including localisation to acanthopodia (Figure
3.8 C, white arrows).
Figure 3.8 Purified HE2 supernatant retains membrane binding activity.
Fixed Acanthamoeba
mouse positive control serum, IgM isotype control, or purif
conjugated anti-mouse IgM secondary antibody was then used to detect binding and nuclei
were counterstained with DAPI. (A) Positive serum, (B) isotype control, (C) HE2. Arrows
indicate membrane staining and acanthopodia. Bar =
ody binding.
A. castellanii
trophozoites were blocked and incubated with 1:500 hyperimmune
ied HE2 antibody. 1:500 FITC
50µm.
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3.4.7. Unpurified and purified HE2 culture supernatants cause
aggregation of Acanthamoeba trophozoites
The antibody produced by the HE2 hybridoma displayed characteristics of
membrane reactivity and belonged to the IgM class. This class of antibody has
a pentameric structure constructed around a central conserved J-chain which
promotes agglutination of its target, immobilising recognised pathogens and
enhancing detection and destruction by the immune system. Because of these
characteristics we hypothesised that HE2 might have agglutination activity
against A. castellanii trophozoites, and that this might provide protection in
terms of parasite binding, or host cell death/monolayer disruption. Figure 3.9
and Table 3.1 show that aggregates of amoeba cells do indeed form in vitro
and that this effect is specific, as an isotype control IgM did not produce an
equivalent effect. However the ability of both unpurified and purified HE2 to
agglutinate trophozoites diminishes after 24 hours, potentially due to
degradation by the amoeba. This possibility is discussed further in Chapter 4.
Figure 3.9 Unpurified and purified HE2 supernatant causes trophozoites to aggregate in
vitro.
Suspensions of trophozoites were made
hybridoma medium; 200
and incubated under constant mixing for 3 hours. (A) RPMI negative control, (B) HE2
unpurified culture supernatant, (C) hybr
control IgM. Images are representative of results from three independent experiments. Arrows
indicate trophozoite aggregation. Bar = 200
in unpurified HE2 culture supernatant, control
µg/ml purified HE2, 200µg/ml isotype control IgM or RPMI alone
idoma growth medium, (D) purified HE2, (E) isotype
µm.
100
101
Unpurified HE2 Hybridoma Purified HE2 Isotype RPMI
A B C medium A B C control (-ve control)
3h + + ++ +/- + +++ +++ +/- -
+ +/- + - ++ +++ +++ +/- -
++ +/- + - + +++ +++ - -
24h + - + + + + + + +/-
+ +/- ++ +/- +/- ++ + +/- +/-
+ +/- + + +/- ++ +/- +/- +/-
Table 3.1 Trophozoite aggregation in unpurified and purified HE2 supernatant.
After incubation for 3 and 24 hours. (A, B, C) represent three different antibody batches.
Results are from three independent experiments.
3.4.8. Purified HE2 antibody reduces trophozoite binding, but to no
greater extent than an isotype control IgM
HE2 antibody had demonstrated an ability to bind to membrane antigens of A.
castellanii trophozoites and cause them to aggregate (sections 3.4.6 and 3.4.7).
We hypothesised that this may affect trophozoites’ ability to bind to HBMEC
in vitro and investigated this possibility by infecting monolayers with pre-
adsorbed amoeba and measuring percentage binding as described in sections
3.3.6.1 and 2.4.3.1. HE2-treated trophozoites behaved as predicted, showing a
significant decrease of approximately 20% (p<0.001 1-way ANOVA) in
comparison with an untreated positive control. However this was matched by
an equivalent inhibition of binding in samples treated with a nonspecific
isotype negative control IgM.
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Figure 3.10 Binding to HBMEC of trophozoites pre-adsorbed with specific/nonspecific
antibody.
Suspensions of 2×105/ml trophozoites treated with 200µg/ml HE2, isotype control IgM, or left
untreated were used to infect HBMEC monolayers. Binding was assessed by triplicate
haemocytometer counts after 3h. Each treatment was performed in triplicate and results are
mean + S.E.M. from three independent experiments. *** p< 0.001, * p< 0.05, 1-way ANOVA.
3.4.9. HE2 does not protect HBMEC monolayers from damage
Binding assays suggested that IgM antibody (both specific and nonspecific)
acted to reduce the percentage of amoeba binding to HBMEC monolayers in
vitro (section 3.4.8, Figure 3.10). We sought to determine whether this effect
was matched by a reduction in measures of pathology and cell death using
methods outlined in sections 3.3.6.2 and 3.3.6.4.
3.4.10. Haematoxylin staining
Monolayers fixed and stained with haemato
2.4.4.3 showed no substantial reduction in disruption of the cell layer in any
treated well (Figure 3.11), although very small patches of the monolayer were
preserved by the highest concentration (200µg/ml) of HE2 and to a
extent by isotype IgM.
Figure 3.11 HE2 and isotype control IgM do not protect HBMEC monolayers from
destruction by trophozoites
Trophozoites were treated with HE2 and isotype IgM at two concentrat
HBMEC monolayers in 24
after 24 hours. No treatment provided substantial protection against monolayer protection.
Results are representative of three independent exper
3.4.11. Monolayer counting
Prior to the fixation step for haematoxylin staining (see section 3.4.9.1), wells
were photographed and analysed for monolayer disruption using a grid
counting method as described in section 2.4.4.2. Results were similar to th
seen with haematoxylin staining, although the higher concentration of HE2 did
xylin as described in section
.
-well plates. Monolayers were fixed and stained with haematoxylin
iments.
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produce a small but significant protective effect when compared with a
positive control of untreated amoeba (p<0.05, 1-way ANOVA, Figure 3.12.).
The magnitude of this effect was small however (approximately 10%), in
accordance with data obtained from other assays (see Figures 3.7 and 3.10).
P
er
ce
nt
ag
e
m
on
ol
ay
er
di
sr
up
tio
n
g/m
l

+Ig
M
10
0
g/m
l

+H
E2
10
0
g/m
l

+Ig
M
20
0
g/m
l

+H
E2
20
0
No
Tro
ph
Tr
op
h
0
10
20
30
40
50
***
*
Figure 3.12 Treatment with antibody reduces percentage monolayer disruption only with
high concentrations of HE2.
Trophozoites were treated with HE2 and isotype IgM at two concentrations and used to infect
HBMEC monolayers in 24-well plates. Percentage monolayer disruption was estimated from
photomicrographs by a grid counting method. Significant reductions were seen in 200µg/ml
HE2 treatment (* p<0.05) and in controls without trophozoites (*** p<0.001, 1-way ANOVA).
Each treatment was performed in triplicate and results shown are mean + S.E.M from three
independent experiments.
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3.4.12. Cytotoxicity
Assays of monolayer disruption in sections 3.4.9.1 revealed that HE2 or
isotype IgM did not prevent monolayer disruption at the gross level, although
at the microscopic level there was some suggestion that high concentrations of
HE2 could increase monolayer protection (section 3.4.9.2, Figure 3.12). These
parameters do not necessarily correlate with cell death however, and so in
order to measure the necrotic response directly, supernatants from treated wells
were examined for release of LDH as a measure of cell death (see sections
3.3.6.4 and 2.4.5). Results showed that although a small reduction is apparent
by eye, in accordance with data from other assays there was no significant
difference between the percentage cell death in any of the treatment groups
(p>0.05, 1-way ANOVA, Figure 3.13), or relative to a positive control of
untreated amoeba.
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Figure 3.13 HE2 and isotype control IgM do not affect LDH release from HBMEC.
Trophozoites were treated with HE2 and isotype IgM at two concentrations and used to infect
HBMEC monolayers in 24-well plates. Culture supernatants were collected after 24 hours and
analysed for LDH release, relative to a 100% cell lysis control. Each treatment was performed
in triplicate. No treatment caused significant differences in percentage cell death (p>0.05 1-
way ANOVA). Results are mean + S.E.M from three independent experiments.
3.4.13. Western Blot
Assays investigating the properties of HE2 in respect of A. castellanii binding
and pathological responses of HBMEC had proved inconclusive using a range
of in vitro assays. Therefore in order to gain an insight into antigenic targets,
Western blots were prepared and probed with purified HE2 and isotype control
as described in sections 3.3.7 and 2.6.3. The polyclonal nature of the antibody,
and the fact that it was raised against a mixed antigen target meant a range of
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bands of different sizes was recognised in a range of 30 to >175kDa (Figure
3.14).
Blots that corresponded to high abundance bands seen on an SDS-PAGE gel of
the same amoeba lysate used for the blot were predicted to be of importance in
the immune response. Bands of particular interest were seen at just over
50kDa, 80kDa, and three between 120kDa and 140kDa (Figure 3.14, marked
as 5, 4, 2/3, and 1 respectively.) Bands identified at these molecular weights
were excised from the gel (Figure 3.14, panel C) and analysed by tandem MS
sequencing, in order to ascertain antigen identity.
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Figure 3.14 Western blot of A. castellanii lysate detected with purified HE2.
90µg of lysate (1) and 1µg of control IgM (2) were run on 12% polyacrylamide gels, blotted to
PVDF and then probed with 50ng/ml of (A) HE2 polyclonal antibody, or (B) isotype control
IgM. Binding was detected with goat anti-mouse IgM-HRP and 5s exposure to X-ray film. (C)
Bands with high intensity on both SDS-PAGE (left panel) and Western blot (right panel) were
identified and excised for peptide sequencing (C 1-5). Where multiple PAGE bands were
potentially responsible for a strong Western blot signal, all within the appropriate range of
molecular weights were excised and sequenced (C 1-3). Images are representative of two (C)
or three (A&B) experiments.
3.4.14. MS/MS sequencing
Mass spectrometry data was obtained using a Q-ToF2 instrument and analysed
according to standard parameters. Searches were performed against the
NCBInr database in the first instance and peptide matches to likely protein
identities were retrieved using MASCOT software version 2.4.01 (sections 2.9
and 3.3.8).
All peptides used to interrogate NCBInr sequence data returned matches from
A. castellanii and in the main peptides corresponded to sequences of enzymes
involved in metabolic pathways, such as malate dehydrogenase and
oxoglutarate dehydrogenase (Table 2.2). Additional hits to enzymes involved
in the translation machinery and protein synthesis were also seen (eukaryotic
translation elongation factor 2 and elongation factor 1γ) and there was a 
significant match to the cytoskeletal component actin.
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Further searches against “ESTs others” produced a limited number of
additional hits within the amoebazoa and in other organisms (Appendix 2).
Where sequence matched to known (i.e. non-hypothetical) proteins, the best
matches were found for the mitochondrial F1 complex ATP synthase in
Polysphondylium pallidum and Dictyostelium fasciculatum.
Table 3.2
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Band Identity (Best Match) Peptides Match Score Expectation Value
1 oxoglutarate dehydrogenase (succinyltransferring) K.AAINDVAIVR.V
R.ETGETYQPLR.H
R.VEQLAPFPFDR.V
48
22
72
2
8.1E+02
0.007
2/3† eukaryotic translation elongation factor 2 K.YGWDVTEAR.K
K.DLQDEFTGVELK.T
K.SGTITTSETAHNLR.V
42
31
53
9.4
1E+02
0.74
2/3† cobalamin independent methionine synthase K.HLTLGAGVVDAR.N
K.ANLLAQVDAGIER.I
R.YIVGGAQQAAPETK.A
41
31
39
14
1.1E+02
21
2/3† No data returned‡ N/D N/D N/D
4 NAD-dependent malic enzyme KHVDVIVVTDGSR.I
R.TLPVTLDVGTNNEK.L
R.AIVASGSPFDPVQYK.G
R.AIVASGSPFDPVQYK.G
R.AIVASGSPFDPVQYK.G
K.NVWVVDADGLIAQGR.S
38
29
7
66
38
33
24
1.8E+02
3.3E+04
0.042
26
67
5 elongation factor 1γ family protein R.VSLADIVVSMALYR.L
R.VSLADIVVSMALYR.L
R.VSLADIVVSMALYR.L
K.VPALETPEGPLFESNAIAR.Y
K.VPALETPEGPLFESNAIAR.Y
18
105
16
75
29
1.9E+03
3.2E-06
2.6E+03
0.003
1.2E+02
Table 3.2
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Band Identity (Best Match) Peptides Match Score Expectation Value
5 actin R.GYSFTTTAER.E
K.IWHHTFYNELR.V
K.SYELPDGQVITIGNER.F
37
36
99
25
25
1.1E-05
5 malate dehydrogenase R.QTVPEIDR.A
K.HQPVILQLLELEPAMK.A
K.YMAELEKPGAGPLSAVPPVR.V
50
29
96
1.4
1.1E+02
2.1E-05
5 4-hydroxyphenylpyruvate dioxygenase K.HGVAASAVGIEVEDAAEAYR.I
R.IAVENGAVSIAEPATLVNEATGAK.T
R.FISFSEGYDHPFLPGYETVTDQGPR.L
48
38
51
1.3
11
0.52
5 NADP-dependent isocitrate dehydrogenase R.LIDDMVAFAMK.D 57 0.25
Table 3.2 MS/MS analysis of A. castellanii peptide matches.
Searches of peptide fragments generated by mass spectrometry against the NCBInr database were analysed using MASCOT v2.4.01 software. Where several peptide
identifications were obtained from a single band excision from SDS-PAGE gel each is presented individually. Red text denotes samples with high match scores and low
expectation values, i.e. match score > 50, E-value <0.05 representing a less than 5% chance of a false-positive identification. † Bands 2 and 3 could not be fully separated by
dissection, so were analysed concurrently. ‡ No matches were returned for peptides obtained from this sample.
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3.5. Discussion
The use of specific antibodies as tools for molecular and immunological
dissection of host-parasite interactions is well established, originating with the
hybridoma fusion technique developed and first used by Kohler and Milstein
(1975). Additional techniques such as phage display technology and
improvements to in vitro methods mean that specific monoclonal antibody can
now be viably generated on a commercial basis. Nevertheless in many cases
the original in vitro technique remains in common use. This is especially true
where basic understanding of a particular pathogen and the host response to it
is still developing, such as in the particular case of A. castellanii. The
opportunity to make progress in this area has been recognised by previous
authors who generated specific antibody for numerous purposes including
diagnostics, therapeutics and as research tools (Turner et al., 2005, Khan et al.,
2000a, Kennett et al., 1999, Leher et al., 1999). Our goal was aligned with this
latter purpose, in order to discern molecular targets recognised by the immune
system and the immunological basis for control of the disease.
We based our protocol on the classical PEG fusion method modified with
specific experimental parameters published by Lane and Berry et al. (Berry et
al., 2003, Lane, 1985, Kohler and Milstein, 1975). Typical approaches of this
kind often incorporate feeder cell cultures to enhance post-fusion growth (de
StGroth and Scheidegger, 1980); however we favoured the use of a dedicated
cloning factor (BriClone) containing the cytokine Il-6, which has been shown
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to promote the growth of B-cell hybridomas (Bazin and Lemieux, 1989). This
dispensed with the need for any additional cell types.
The outcome of previous attempts to generate specific anti-Acanthamoeba
antibody has been mixed and despite successes in obtaining antibody specific
to some targets (Kennett et al., 1999) few, if any immunoglobulin reagents
have entered routine use. Khan et al. used a phage display library to generate
fragments which recognised a range of epitopes, and selected these for high
specificity and affinity via rounds of specific and nonspecific panning (Khan et
al., 2000a). The resulting antibodies were well suited for use in diagnostic
assays but having been generated and selected for entirely in vitro, did not
necessarily correspond to antigens and epitopes of in vivo relevance in either
immunity or pathogenesis. Similar drawbacks also affect the usefulness of
antibody produced by Flores et al. whose work focused on detection of the
organism in fixed brain sections (Flores et al., 1990).
Alternative approaches by Turner et al. and Kennett et al. generated
hybridomas using in vivo immunisations similar to those employed in our
study, and as such their work is more applicable in terms of which antigens or
epitopes are recognised by the immune system. In common with our data
(Figure 3.2), Turner et al. were able to generate a large number of hybridoma
clones in response to a similar immunisation protocol, many of which
produced antibody belonging to the IgM isotype (Turner et al., 2005). The
clone which produced the strongest reactivity against Acanthamoeba in a range
of our assays (HE2, see Figures 3.4 and 3.5) was also an IgM, and this could
point to a significant role for this antibody in controlling systemic A.
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castellanii. The multivalent structure of IgM allows it to play a role in
aggregation and immobilisation of pathogens, and specific HE2 IgM showed
an ability to aggregate trophozoites in vitro (Figure 3.9, Table 3.1). IgM may
also act to initiate lysis of pathogens by binding to complement proteins and
this may be relevant to immunological control of trophozoites. However the
precise role played by the complement cascade and whether amoebae are
resistant or susceptible by either the classical or alternative pathways is subject
to conflicting evidence (Pumidonming et al., 2011, Toney and Marciano-
Cabral, 1998, Ferrante and Rowan-Kelly, 1983). We did not examine whether
our HE2 antibody could enhance the efficacy of the complement cascade,
however this should prove an interesting topic for further investigation.
Another point of note is that IgM is typically produced early in the immune
response, as a precursor to the induction of other antibody classes. Its
preponderance in serum (Kiderlen et al., 2010, Walochnik et al., 2001, Cursons
et al., 1980) and in experimental infections (Turner et al., 2005, Flores et al.,
1990) could therefore be an indicator of repeated or recent infections. This is in
keeping with the wide environmental distribution of the parasite across the
globe for example in heated, fresh, and natural water systems (Gianinazzi et
al., 2009, Magliano et al., 2009, Rivera and Adao, 2008, De Jonckheere, 2007,
Lorenzo-Morales et al., 2006).
Our focus in this study was to understand the role played by antibody in
adhesion to and penetration of the blood-brain barrier. Kennett et al. and Leher
et al. demonstrated that specific antibody (monoclonal IgG and IgA
respectively) can act to prevent adhesion of trophozoites to layers of Chinese
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Hamster Corneal Epithelial Cells (CHCECs) both in vitro and in vivo (Kennett
et al., 1999, Leher et al., 1999). Building on these findings we used cell types
from within the brain microvasculature (HBMECs) as a model system to
investigate the effects of specific polyclonal HE2. Given the ability of HE2 to
aggregate trophozoites we hypothesised that this might have an effect on the
ability of treated trophozoites to adhere to or disrupt the cell layer.
Initial experiments with unpurified culture supernatants suggested that HE2
may reduce binding and monolayer disruption (Figures 3.6 and 3.7) but were
ultimately inconclusive, however experiments with quantified and purified
antibody proved easier to interpret. In terms of binding inhibition significant
reductions were seen in wells treated with HE2 (Figure 3.10), however the
magnitude of this effect was small (-20%) in comparison with the reduction in
binding seen by Leher (-60%) and Kennett (-80%). Notably, a similar
significant reduction was also seen with a nonspecific isotype control antibody.
This suggested the possibility that the antibody was acting to inhibit binding in
a nonspecific manner, perhaps by steric hindrance or due to capture by surface
factors on the parasite (discussed at greater length in Chapter 4).
As well as the effect of HE2 on binding we also examined the outcomes of in
vitro infections in terms of disruption of cell monolayers and host cell death.
Little protection was seen in terms of monolayer integrity at a gross level
(Figure 3.11) however a small reduction in monolayer disruption was seen
when using semi-quantified photomicrographs, which was statistically
significant at high antibody concentrations (Figure 3.12). This did not align
with measurements of cell death however, which demonstrated a small
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reduction in LDH release at higher antibody concentrations not reaching
statistical significance (Figure 3.13). Our use of LDH release assays is
beneficial in providing quantitative cell death data that could not be obtained
by analysis of monolayer disruption alone. One factor that should be
considered in interpreting this data however is the difficulty of separating LDH
release by dying HBMEC from LDH contributions made by trophozoites. No
substantial levels of A. castellanii death were observed in our assays. However
it is not certain that trophozoites did not release LDH in our experimental
system as a result of stress induced by the growth medium (RPMI) or antibody
treatment. We therefore suggest that future experiments take this into account
by including a trophozoite-only control to monitor LDH release by isolated A.
castellanii. Experiments to optimise conditions and designate appropriate
controls will also be of use for this widely utilised assay. There may also be
scope for a dedicated investigation into the use of A. castellanii LDH as a
stress marker for trophozoites.
The absence of a strong protective effect taken in the context of high levels of
reactivity to trophozoites shown in Figures 3.8 suggests that the antigens
recognised by HE2 are not of primary importance in host cell death and may
only be secondary factors in host cell binding. To investigate this further we
used tandem MS sequencing to elucidate the identity of A. castellanii proteins
recognised by HE2 polyclonal antibody.
As expected, due to the use of a complex whole parasite antigen and the
polyclonal nature of the antibody HE2 recognised a wide range of parasite
proteins (Figure 3.14). Those bands which gave the strongest signal and which
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corresponded to bands on a coomassie-stained SDS-PAGE gel were excised
and analysed by MS/MS. Interpretation of peptide identities was complicated
by the presence of multiple proteins within single SDS-PAGE bands,
representing several different proteins of equivalent molecular weight. For
example data from band 5 in Figure 3.14 C returned identities for five proteins
in the range of 45 to 46.5 kDa (Table 3.2). Three of these matched significantly
to annotated proteins in the A. castellanii genome. Similarly, difficulty was
encountered where Western blot bands had been insufficiently separated for
them to be individually resolved and matched to distinct SDS-PAGE bands
(Figure 3.14 C, bands 2/3). In this case bands were excised together and
analysed concurrently however not all peptides matched to database sequences.
It is not clear in this case whether non-matching peptides represent an inability
to obtain reliable data from this sample, or whether they instead correspond to
a unique A. castellanii sequence not previously reported. In the absence of
additional supporting data or further characterisation however it is difficult to
support this latter hypothesis.
Protein matches were nevertheless obtained for other bands recognised by HE2
supernatant. The majority of these corresponded either to metabolic enzymes
or key mediators of protein synthesis, and appeared highly immunogenic.
Uninhibited functioning of these molecules is likely to be critical to
trophozoite survival, and it is therefore straightforward to see why the host
mounts a strong immune response to them. It is pertinent however to sound a
note of caution that due to immunisation with a mixed antigen a strong
immunoassay response does not necessarily indicate that the most abundant
protein in any given sample is the most immunogenic. It is possible that the
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relative abundance of metabolic enzymes in our analysis masks detection of
less abundant, but more immunogenic proteins at the same molecular weight.
Finer separation of proteins or isolation of nuclear, mitochondrial, cytosolic,
and membrane fractions would assist in confirming our antigen identifications.
Nevertheless the protein identities that we were able to obtain from tandem MS
analysis open up interesting lines of inquiry regarding AGE pathogenesis and
the immune response to A. castellanii. Several of the proteins for which hits
were obtained have homologues in other pathogenic protozoa that have been
implicated in disease generation or control. Probst et al. generated and
characterised T-cell-stimulating antigens from Leishmania major and
identified malate dehydrogenase and elongation factor 2 amongst the resulting
targets (Probst et al., 2001). Another translation elongation factor (EF-1γ) has 
also been shown to be of importance in Trypanosoma cruzi infections where it
may play a role in resistance to clomipramine treatment, although this finding
was based on deliberate overexpression of the associated gene (Billaut-Mulot
et al., 1997). In addition, cobalamin-independent methionine synthase has been
suggested to be of use as an antifungal target (Suliman et al., 2007).
Perhaps most interestingly one enzyme in particular that emerged from our
analysis has been shown to have a direct role in virulence. The AP65 protein of
Trichomonas vaginalis is one of five which enable binding of the parasite to its
target cells (Alderete and Garza, 1988). Intriguingly AP65 also shares
considerable sequence homology with malic enzyme from a variety of
organisms (Engbring et al., 1996). There is evidence to suggest that it not only
associates with the cell surface (O'Brien et al., 1996) but may also be released
120
into the extracellular environment, having a role in T. vaginalis perforin-
mediated pathogenesis (Addis et al., 1997). A peptide match to A. castellanii
malic enzyme was seen in our analysis (Table 2.2, band 4). This does not
necessarily imply a similar pathogenic role for this enzyme in A. castellanii as
its usual function of catalysing oxidative decarboxylation of malate to pyruvate
is highly conserved. Nevertheless further examination of the localisation and
function of A. castellanii malic enzyme may be warranted in future studies.
Another target that may be of relevance is actin (Table 3.2, band 5). This key
component of the cytoskeleton has been well-studied in Acanthamoeba and has
been acknowledged to be of pathogenic importance (da Rocha-Azevedo and
Costa e Silva-Filho, 2007). For example, Alsam et al. demonstrated that
inhibition of actin polymerisation abolishes phagocytosis of bacteria.
Furthermore a protective effect on host cell death using the same treatment was
observed in a study by Taylor and colleagues, demonstrating the importance of
phagocytosis to disease (Taylor et al., 1995, Alsam et al., 2005a). Additionally
the cellular distribution of the actin cytoskeleton was investigated by
Gonzales-Robles et al. with actin bundles observed at the cell periphery. Actin
bundles also associate with membrane structures such as acanthopodia which
may mediate attachment to host cells (Gonzalez-Robles et al., 2008).
Furthermore actin also has a critical role to play in endo- and exocytosis,
processes of importance in disease due to the high levels of pathogenic
protease secretion (Alfieri et al., 2000).
One pertinent question arising from the results of tandem MS analysis is the
apparent localisation of fluorescent staining to the trophozoite cell membrane
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(Figures 3.4 and 3.8). The majority of peptide identities returned from tandem
MS analysis matched to either mitochondrial or cytosolic proteins so it is not
clear why such staining should be observed.
One possibility is that recognised antigens in the cytosol are associated with
the cell membrane or a membrane-bound organelle, either via a transmembrane
or other membrane-associated domain. This has been previously observed for
the T. vaginalis AP65 protein which possesses homology with malic enzyme
(O'Brien et al., 1996). Similarly EF-1γ is also known to associate with
membrane structures (Janssen and Moller, 1988) and actin too also associates
closely with the cell membrane (Gonzalez-Robles et al., 2008).
Secondly it might be the case that the antigens selected for MS/MS analysis
are not those which are recognised on the trophozoite cell surface at all. HE2
showed broad recognition of several antigen bands (Figure 3.14 C) from which
those giving the strongest signal were selected for further analysis. However
this does not exclude the possibility that antigens giving a lower signal might
localise on the cell membrane. This may be particularly true of antigens
involved in recognition of, or binding to host cells. For example A. castellanii
are known to possess a mannose-binding protein (MBP) which is involved in
adhesion and recognition of host cells (Cao et al., 1998, Hurt et al., 2003b,
Garate et al., 2006b). Characterisation of this molecule by Garate and
colleagues revealed the molecule to have a molecular weight of 400 kDa
(composed of 130kDa subunits), which if present in our trophozoite lysate
would give a band in the range considerably above the highest molecular
weight marker (Garate et al., 2004).
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A diffuse area of staining can be observed in the range corresponding to MBP
subunits, and also at a molecular weight corresponding to another >207kDa
adhesion molecule described by Kennett et al. (1999). Reliable isolation of
specific bands from these areas could not be made in our study due to
uncertainty over the precise molecular weights represented, and unreliable
correspondence with SDS-PAGE bands. It may prove enlightening to isolate
the protein recognised by this area of staining in the future. However if specific
antibody to MBP is desired in order to conduct blocking experiments an
approach based on immunisation with MBP alone, or an equivalent in vitro
method is more likely to yield success.
Since our analysis of the proteins recognised by HE2 did not reveal any
unambiguous membrane proteins a reduction in trophozoite binding such as
was seen in our assays (Figure 3.10) could be viewed as an unexpected result.
As discussed above such proteins may well be recognised. If this was the case
however a greater reduction in binding than the 20% observed in our assays
would be expected. In addition the role which A. castellanii adhesins have
already been shown to play in host cell death means a reduction in this
parameter might reasonably be predicted. However the lack of a protective
effect as demonstrated in our assays (Figure 3.13) implies that whatever
antigens are the target of HE2 they are not directly involved in host cell death
mechanisms. Instead the targeted antigens may represent proteins which are
sufficiently specific to the parasite to prompt rapid recognition, followed by
phagocytic clearance and/or complement fixation and lysis. We did not
perform experiments examining the interaction between HE2-treated
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trophozoites and either of these factors, so this would be a valuable next step to
determine the contribution of each pathway to elimination of trophozoites.
Alternatively it is possible that HE2 in particular and immunoglobulin in
general is effective at blocking certain aspects of pathogenesis, but that
amoebae are able to remove or degrade bound antibody. This point is raised by
Cursons et al. in their survey of humoral immunity to pathogenic free-living
amoebae, and indeed mechanisms for inactivation of antibody have been
shown in pathogenic amoebae (Garcia-Nieto et al., 2008, Na et al., 2002a,
Cursons et al., 1980). The potential for A. castellanii to evade the humoral
immune response is evaluated and discussed in Chapter 4.
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4. In vitro effects of specific polyclonal antibody and
evasion of host immunity mediated by parasite Fc-
receptor and antibody cleavage
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4.1. Abstract
During haematogenous spread, circulating A. castellanii trophozoites are open
to attack by the humoral immune system which is in most cases sufficient to
prevent development of the disease. However purified antibody has only a
limited protective effect in vitro, equivalent to that of a nonspecific control
antibody. It is therefore unclear what role circulating immunoglobulin plays in
preventing penetration of the blood-brain barrier, and whether trophozoites can
alter the efficacy of the immune response. Previously published data
demonstrated that amoeba proteases can degrade antibody. Here we extend
these findings to include all Ig classes including physiologically-derived
antibody. Degradation was found to be mediated by secreted serine- and
metallo-proteases. We also attributed nonspecific binding of polyclonal
antibody to Fc-binding activity by trophozoites as shown by
immunofluorescence and FACS analysis. Evidence from bioinformatics
analysis also demonstrated similarity between Fc-binding proteins in other
parasites and regions of the A. castellanii genome.
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4.2. Introduction
Characterisation of the mechanism by which Acanthamoeba trophozoites
circumvent or abolish the integrity of the BBB is further advanced than other
areas of understanding with respect to the pathogenesis of AGE. However the
immune response to systemic Acanthamoeba infections and in particular the
evasion of humoral immunity by the parasite has only been partially defined.
Experimental immunisations in rabbits, pigs, and hamsters produce strong
antibody titres with high specificity which confers protection in these most
commonly-used keratitis models (Leher et al., 1998b, Said et al., 2004, Garate
et al., 2006a). In vitro assays have also demonstrated that as a part of serum,
antibody can act effectively to limit trophozoite adhesion to host cells (Sissons
et al., 2006b).
Surveys of both vulnerable and healthy populations demonstrate widespread
positive titres indicating common exposure but also effective control as clinical
disease manifests in only rare cases (Alizadeh et al., 2001, Schuster et al.,
2006, Brindley et al., 2009, Kiderlen et al., 2010). Nevertheless purified
antibody was seen only to contribute non-specifically to a reduction in binding
to endothelial cells, and to have no effect on cytotoxicity or barrier integrity in
our experiments (see Chapter 3). Additionally, systemic immunisation does not
always produce favourable outcomes or translate to mucosal immunity that is
capable of combating the parasite (Van Klink et al., 1997). There is evidence
from some studies however that Acanthamoeba keratitis is responsive to
antibody-based intervention (Alizadeh et al., 1995, Leher et al., 1999). These
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confounding results would suggest that effective host antibody-mediated
responses and parasite evasion mechanisms both influence the outcome of
antibody-dependent immunity. In light of this we considered how A.
castellanii might evade host antibody.
Mechanisms for degradation of antibody are known to occur in a number of
parasites of medical importance including Schistosoma mansoni, Faciola
hepatica and Trypanosoma cruzi (Pleass et al., 2000, Berasain et al., 2003,
Smith et al., 1993). Antibody cleavage has additionally been observed in less
distantly related species such as Entamoeba histolytica which possesses both
IgG and IgA-degradation activity (Tran et al., 1998, Garcia-Nieto et al., 2008).
There is also evidence to suggest that secreted proteases of A. castellanii can
degrade immune components including antibody and inflammatory mediators
such as cytokines (Na et al., 2001, Na et al., 2002a). However substrate
specificity of the three main groups of Acanthamoeba proteases (serine,
cysteine, and metalloproteases) has not been fully determined. Uncertainties
also remain as regards action against immunoglobulin classes, and specific
antibody raised generated in vivo. In this study we sought to address these
questions with the application of electrophoretic techniques and image
analysis, examining the cleavage products of antibody-protease mixtures under
the action of various protease inhibitors.
A second mechanism by which parasites can avoid the action of antibodies,
and in turn inhibit forward stimulation of the cell-mediated response and other
effector mechanisms is by antibody capture. By either coating themselves with
ineffective Ig or recruiting it in incorrect orientation, parasites can inhibit the
usual activity of the molecule and interfere with downstream immune
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activation (Garcia et al., 1997, Holder et al., 1999). This is because the
conserved (Fc) portion of antibody is the basis for initiation of immune
effector functions.
Proteins with binding affinity for the Fc region (Fc receptors) are expressed on
phagocytes such as macrophages and neutrophils, and Fc/FcR recognition
prompts pathogens to be ingested and destroyed by phagocytes. IgG is the
most important antibody class in this response due to its high antigen affinity
and may be especially important in AGE due to its high expression level in the
bloodstream.
Additionally the Fc region plays an important role in activating the
complement cascade by binding to C1q, the first of the subunits which
eventually form the lytic Membrane Attack Complex (Sledge and Bing, 1973).
Whilst both IgG and IgM can fix complement IgM is the more efficient of the
two as a result of its pentameric structure. This means that only one IgM
molecule is required to bind to the C1 complement subunit and initiate the
cascade, whereas at least two IgG molecules in close proximity are required to
do the same.
Pathogens that are able to bind to the Fc region can thus dampen the
stimulatory signal to either phagocyte or complement effector mechanisms
may thereby protect themselves from the inflammatory response. In our
experiments (detailed in Chapter 3) the ability of both specific and nonspecific
IgM to inhibit trophozoite adhesion to endothelial monolayers raised the
possibility that A. castellanii might possess an immunoglobulin binding
mechanism, which could include a dedicated Fc binding protein. We sought to
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interrogate this possibility via the use of Fc-only Ig fragments, as well as the
possible structural effects (and steric binding inhibition) occurring as a result
of capturing different antibody classes. This was combined with a
bioinformatics approach, examining Fc binding residues characterised in
mammalian and parasitic organisms for sequences with similarity to the
recently-published A. castellanii genome (Clarke et al., 2013).
4.3. Materials and Methods
4.3.1. Polyclonal antibody generation
Polyclonal antibody was generated by hybridoma fusion from splenocytes of
BALB/c mice immunised with 2×107 trophozoites in Alum, as described in
Chapter 2 (section 2.3) and Chapter 3 (section 3.3.1).
4.3.2. Zymography
Dilutions of ACM were made in ddH2O and 15µl of sample was mixed with
5µl of non-reducing sample buffer and heated to 75°C (see section 2.7.2).
Samples were run on 10% gelatin gels at 110V for 60 minutes. After
completion of the run gels were washed in 50mM Tris buffer pH7.5 + 2.5%
w/v TritonX-100 for one hour, and then ddH2O for 3× 5 minutes. Proteins
were refolded by incubation in 50mM Tris buffer pH7.5 + 0.5M CaCl2 for 3
hours at 37°C. Gels were then stained with Coomassie Blue, destained and
photographed.
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4.3.3. Cleavage reaction
Fifty millilitres of ACM was collected and concentrated as described in section
2.2.2 and 2.5.2, yielding a final concentration of 1mg/ml. Cleavage mixes were
then set up with 1µg of either mouse IgA, IgM, IgG, IgE negative controls
(Table 2.2 #1-4), or specific polyclonal IgM generated as described in sections
2.3, 2.1.4 and 2.5. 3.6µg of concentrated ACM was added and for each
antibody class, protease inhibitors were added to a final concentration of
100µM (see section 2.7.3). Reaction mixes were then incubated at 37°C for 2
hours.
4.3.4. SDS-PAGE
15µl of cleavage mixture was mixed with 4µl of LDS loading buffer and
reduced by adding 1µl of DTT and heating to 75°C for 5 minutes. Samples
were loaded onto 4-20% polyacrylamide gels alongside 10µl of ColorPlus
prestained protein marker and run at 120V for 90 minutes (see section 2.7).
Gels were retrieved from their cartridges and washed in ultrapure water for
five minutes prior to visualisation of peptide bands by silver staining (see
section 2.7.1.2 for additional details).
4.3.5. Silver Nitrate staining
Silver staining was carried out using a GE healthcare PlusOne kit (see
Reagents and Buffers, Chapter 2, for solutions used). Gels were soaked for 30
minutes in acetic acid/ethanol fixing solution, then placed in sensitising
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solution for 30 minutes under shaking. Gels were washed for 3× 5 minutes in
ultrapure water before transfer to 0.1% w/v silver nitrate solution for 20
minutes under shaking. The gels were then washed again and developed for
three minutes. Reactions were terminated by immersing gels in stopping
solution for 10 minutes under shaking.
4.3.6. Gel analysis
Analysis of cleavage products was performed using ImageJ software
(Schneider et al., 2012) using an adapted method of Western blot band density
quantification. Lanes were plotted onto gel images and expressed as density
peaks as described in section 2.7.3. Peaks corresponding to heavy and light
chain were closed off at either side and the ‘wand’ tool was then used to collect
area measurements. Any contribution to peak areas from bands present in
ACM was discounted by subtracting peak areas of these bands from samples
containing ACM. Areas were then expressed as a proportion of measurements
from uncleaved control samples.
4.3.7. Functional assays
HBMEC were cultured as described in section 2.1.2 and grown in 24 or 48-
well plates (section 2.4.1). 2×105 A. castellanii trophozoites were incubated
with 200µg/ml of purified polyclonal antibody, negative isotype control IgM,
negative control IgG, or IgG Fc fragment (Table 2.2 #1, 2 and 5) in RPMI.
Treated trophozoites were incubated at 37°C under shaking prior to use in vitro
as described below.
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4.3.8. Functional assays: Binding Inhibition
Binding of treated trophozoites to HBMEC monolayers was assessed by
haemocytometer counts of unbound amoeba from 24 or 48-well plates, as
described in section 2.4.3.1.
4.3.9. Functional assays: Monolayer protection
Protection of HBMEC monolayers was assessed using both haematoxylin
staining of fixed monolayers and photomicrographs taken during the
experimental period (see section 2.4.4). Monolayer disruption visible in
photomicrographs was quantified using a grid counting method as described in
section 2.4.4.2.
4.3.10. Functional assays: Cytotoxicity
Cytotoxicity in treated HBMEC was examined by detection of LDH release
into culture supernatants. Samples were collected after 24 hours and assessed
as described in section 2.4.5.
4.3.11. Bioinformatics
Bionformatics analysis was carried out using a combination of the NCBI and
UNIPROT databases and NCBI’s Basic Local Alignment Search Tool
(BLAST) (see section 2.9). Sequences were obtained from the UNIPROT and
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NCBI protein databases and compared with the A. castellanii genome
assembly using individual queries via the tBLASTn algorithm. Sequences from
predicted or observed extracellular domains were used where identified by
annotation. Where significant similarity was shown, matching A. castellanii
transcriptomic sequence was retrieved and translated into protein sequence
using the “Props > view as proteins” menu sequence in SeaView version 4.4.1.
The most appropriate reading frame was selected based on fewest stop codons.
Reciprocal tBLASTn queries were then run, comparing each peptide sequence
to all others and filtered for stringency. Sequences were accepted as
significantly similar if the length of the aligned region was ≥50aa and the E-
score for the alignment was ≤0.00001 (Wallner et al., 2004).
4.3.12. Immunofluorescence (IF)
A. castellanii trophozoites and K562 cells were affixed to microscope slides by
cytospin, fixed, blocked and treated with 1:300 human IgG Fc fragment (Table
2.2, #5) as described in section 2.6.4. Primary antibody was detected using
1:1000 anti-human-Fc-fragment FITC conjugate (Table 2.2, #10) and cells
were counterstained with DAPI. Photomicrographs were taken using exposures
of 1s (360nm filter), and 3s (640nm filters). Gamma and gain settings were
both 1×.
4.3.13. Fluorescence-Activated Cell Sorting (FACS)
A. castellanii trophozoites and HBMECs were fixed in 4% paraformaldehyde
for 10 minutes, and then blocked in PBS + 5% BSA. Cells were then treated
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with 1:300 human IgG Fc fragment (Table 2.2, #5) as described in section
2.6.4. Primary antibody was detected using 1:1000 anti-human-Fc-fragment
FITC conjugate (Table 2.2, #10) and after 3 washes in PBS + 1% BSA cells
were run using a BD FACSCantoII instrument. Voltages were adjusted to
bring cell populations within range and 50,000 events were recorded and
analysed using Weasel software (see section 2.6.5).
4.3.14. Statistical analysis
Analyses were performed using GraphPad Prism software version 5.04. Data
was analysed using 1-way analysis of variance (ANOVA) and significance
levels for individual group comparisons were obtained using Bonferroni post-
tests (see section 2.10). The alpha level for significance was set at p ≤ 0.05 for
all tests except bioinformatics analysis for which a higher stringency threshold
was set (see section 4.3.11).
4.4. Results
4.4.1. Protease secretion
Previous studies have demonstrated the secretion of a variety of proteases by
A. castellanii. In order to confirm protease secretions for the strain and growth
conditions used in this study, cell-free supernatant (Acanthamoeba conditioned
medium, ACM) from A. castellanii cultures was collected and run on 10%
gelatin zymograms at a range of concentrations (see section 4.3.2).
Concentration-dependent cleavage of gelatin substrate by ACM was observed,
with bands visible in the range 30 to >175kDa. Cleavage bands were visible
between 80 and 175 kDa, and at >175kDa, with an additional diffuse band
visible between 30 and 58kDa at high concentrations (Figure 4.1). Bands
approximately corresponded to previously identified proteases of
130-150kDa as elucidated by
accurate size determination wa
molecular weight markers through substrate gels
2006, Sissons et al., 2006a
Figure 4.1 A. castellanii
ACM was serially diluted
10% gelatin gels at 110V for 60
then refolded in calcium chloride buffer and allowed to digest gelatine. Gels were then
with Coomassie Blue
substrate has occurred due to
experiments.
Kim et al., Hurt et al., and Sissons
s not possibly due to the impaired mobility of
(Hurt et al., 2003a
).
trophozoites secrete proteases in vitro.
1 in 2 with RPMI alone as a negative control.
minutes. Gels were washed to deplete SDS, and proteins were
, destained and imaged. Light bands indicate where
protease activity. Image is representative of three independent
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33, 85 and
et al. although
, Kim et al.,
Dilutions were run on
stained
digestion of gelatin
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4.4.2. Antibody cleavage
Secreted proteases of Acanthamoeba have activity against a number of
components of the immune system including cytokines and immunoglobulin
(Na et al., 2002a). We were able to confirm and expand upon this data,
demonstrating proteolytic activity across all subclasses of antibody, as well as
against polyclonal antibody that had been raised against trophozoites in vivo
(antibody HE2, as described in Chapter 3). Use of PMSF (a serine protease
inhibitor) and Batimastat (a metalloprotease inhibitor) resulted in limited
protection of Ig fragments from cleavage in the majority of cases (Figures 4.2
to 4.6, lanes 3 and 5). Banding patterns and peak traces corresponded closely
with Ig alone after subtracting bands present in ACM and clear peaks were
observed corresponding to antibody heavy and light chain fragments (Figures
4.2 to 4.6, panels B1 to B3). This effect was not observed with Iodoacetamide
(a cysteine protease inhibitor), which produced banding patterns and peak
traces indistinguishable from untreated controls.
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Figure 4.2 Murine IgG cleavage by ACM is reduced by addition of class-specific protease inhibitors.
Cleavage mixtures of ACM and antibody were prepared with or without protease inhibitor, incubated for 2 hours at 37°C and separated by SDS-PAGE (Panel A). Gels were
silver stained, photographed and peak density analysed using ImageJ software (Panel B). (L) Ladder, (1) Ig alone, (2) Ig + ACM, (3) Ig + ACM + Batimastat, (4) Ig + ACM +
Iodoacetamide, (5) Ig + ACM + PMSF, (6) ACM alone. Trace peaks correspond to protein bands on SDS-PAGE gel. Boxes denote Ig heavy (red) or light (green) chain.
Bands corresponding to IgG heavy and light chains showed greatest preservation in samples treated with serine and metalloprotease inhibitors indicating these classes of
protease to be primarily responsible for IgG degradation. Results are representative of two independent experiments.
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Figure 4.3 Murine IgE cleavage by ACM is reduced by addition of class-specific protease inhibitors.
Cleavage mixtures of ACM and antibody were prepared with or without protease inhibitor, incubated for 2 hours at 37°C and separated by SDS-PAGE (Panel A). Gels were
silver stained, photographed and peak density analysed using ImageJ software (Panel B). (L) Ladder, (1) Ig alone, (2) Ig + ACM, (3) Ig + ACM + Batimastat, (4) Ig + ACM +
Iodoacetamide, (5) Ig + ACM + PMSF, (6) ACM alone. Trace peaks correspond to protein bands on SDS-PAGE gel. Boxes denote Ig heavy (red) or light (green) chain.
Bands corresponding to IgE heavy and light chains showed greatest preservation in samples treated with serine protease inhibitors indicating this class of protease to be
primarily responsible for IgE degradation.Results are representative of two independent experiments.
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Figure 4.4 Murine IgA cleavage by ACM is reduced by addition of class-specific protease inhibitors.
Cleavage mixtures of ACM and antibody were prepared with or without protease inhibitor, incubated for 2 hours at 37°C and separated by SDS-PAGE (Panel A). Gels were
silver stained, photographed and peak density analysed using ImageJ software (Panel B). (L) Ladder, (1) Ig alone, (2) Ig + ACM, (3) Ig + ACM + Batimastat, (4) Ig + ACM +
Iodoacetamide, (5) Ig + ACM + PMSF, (6) ACM alone. Trace peaks correspond to protein bands on SDS-PAGE gel. Boxes denote Ig heavy (red) or light (green) chain.
Bands corresponding to IgA heavy and light chains showed greatest preservation in samples treated with serine and metalloprotease inhibitors indicating these classes of
protease to be primarily responsible for IgA degradation. Results are representative of two independent experiments.
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Figure 4.5 Murine IgM cleavage by ACM is reduced by addition of class-specific protease inhibitors.
Cleavage mixtures of ACM and antibody were prepared with or without protease inhibitor, incubated for 2 hours at 37°C and separated by SDS-PAGE (Panel A). Gels were
silver stained, photographed and peak density analysed using ImageJ software (Panel B). (L) Ladder, (1) Ig alone, (2) Ig + ACM, (3) Ig + ACM + Batimastat, (4) Ig + ACM +
Iodoacetamide, (5) Ig + ACM + PMSF, (6) ACM alone. Trace peaks correspond to protein bands on SDS-PAGE gel. Boxes denote Ig heavy (red) or light (green) chain.
Bands corresponding to IgM heavy and light chains showed greatest preservation in samples treated with serine and metalloprotease inhibitors indicating these classes of
protease to be primarily responsible for IgM degradation. Results are representative of two independent experiments.
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Figure 4.6 HE2 cleavage by ACM is reduced by addition of class-specific protease inhibitors.
Cleavage mixtures of ACM and antibody were prepared with or without protease inhibitor, incubated for 2 hours at 37°C and separated by SDS-PAGE (Panel A). Gels were
silver stained, photographed and peak density analysed using ImageJ software (Panel B). (L) Ladder, (1) Ig alone, (2) Ig + ACM, (3) Ig + ACM + Batimastat, (4) Ig + ACM +
Iodoacetamide, (5) Ig + ACM + PMSF, (6) ACM alone. Trace peaks correspond to protein bands on SDS-PAGE gel. Boxes denote Ig heavy (red) or light (green) chain.
Bands corresponding to HE2 heavy and light chains showed greatest preservation in samples treated with serine and metalloprotease inhibitors indicating these classes of
protease to be primarily responsible for HE2 degradation. Results are representative of two independent experiments.
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Peak traces were also semi-quantified using the measurement protocol
described in sections 4.3.6. Bands corresponding to heavy and light chains
from each antibody subclass were identified based on molecular weight and
peak area measured using digital tools included in the ImageJ analysis
software package. Peak area measurements were corrected for contributions
from ACM proteins and then expressed relative to control Ig. Analyses
confirmed findings from SDS-PAGE, with PMSF and Batimastat providing the
most consistent protection from cleavage (Figure 4.7). PMSF-mediated
protection was observed across all subclasses (Figure 4.7 panels A to E) and
also with HE2, an anti-A. castellanii polyclonal IgM antibody generated de
novo (Figure 4.7, panel E). Inhibition of cleavage by Batimastat was more
restricted, with the clearest levels of protection seen for IgG and IgA
subclasses (panels A and C), and either ambiguous or no protection for IgE,
and IgM (panels B, D, and E).
Additionally, variation in susceptibility to cleavage was observed between
heavy and light chains. The majority of classes, and treatments within classes
exhibited lower relative peak areas for light than for heavy chain. This was the
case even where protease inhibitor treatment prevented a substantial proportion
of degradation, for example in PMSF treatments (panels C and E).
148
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
ive
pe
ak
ar
ea
Co
ntr
ol
+B
at
+Io
do
+P
MS
F
0.0
0.2
0.4
0.6
0.8
1.0
A
B
C
D
E
Heavy Light
Figure 4.7 Peak area of Ig heavy and light chains in antibody plus ACM cleavage mixes.
Peak areas are higher in PMSF and Batimastat treatments relative to control Ig (value set to 1).
Peak density traces of silver-stained gels were analysed using ImageJ software. (A) IgG, (B)
IgE, (C) IgA, (D) IgM, (E) HE2. Bat = Batimastat, Iodo = Iodoacetamide, PMSF=
phenlymethylsulfonyl fluoride. Results are representative of two independent experiments.
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4.4.3. Structural effects: Binding
Previous experiments had shown that polyclonal antibody generated by
immunisation and in vitro hybridoma fusion did not protect HBMEC
monolayers from cell death or loss of monolayer integrity (Chapter 3, section
3.4.9). However a decrease in binding was observed, both with polyclonal and
negative control IgM (Chapter 3, section 3.4.8). To investigate whether this
effect was confined to IgM or also extended to antibodies of other subclasses,
binding experiments were set up as described in section 4.3.8. Examples of
multimeric (IgM), monomeric (IgG), and fragmented (Fc fragment) antibody
were included to determine which levels of structure produced a measurable
effect. In accordance with the response in previous assays, both polyclonal
HE2 and isotype control treatments produced a reduction in binding of
approximately 20% relative to untreated controls (Figure 4.8, p<0.001, 1-way
ANOVA). No effect on binding was observed in any other treatment group,
implying that the ability to reduce trophozoite binding in a nonspecific manner
is confined to multimeric Ig.
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Figure 4.8 Adherence of trophozoites to HBMEC is reduced by multimeric, but not
monomeric or fragmented immunoglobulin.
105 trophozoites were treated with 200µg/ml antibody/fragment for three hours and then used
to infect HBMEC monolayers. Binding was assessed by triplicate haemocytometer counts of
unbound trophozoites after three hours. Results are mean + S.E.M. from three independent
experiments (*** p<0.001, 1-way ANOVA).
4.4.4. Structural effects: Monolayer protection
Given the observed reduction in binding confined to multimeric Ig, we sought
to determine whether the same antibodies/fragments afforded protection to
HBMEC monolayers. Experiments detailed as part of Chapter 3 (section 3.4.9)
had not demonstrated a protective effect as assessed by a variety of measures,
and these were extended to include negative control IgG and Fc fragment.
4.4.5. Haematoxylin sta
HBMEC monolayers were infected with antibody or Fc fragment
trophozoites and incubated overnight as described in section 4.3.7. Wells were
then fixed and stained with haematoxylin to assess cell coverage, as described
in section 4.3.9. No pro
wells with levels of disruption being equivalent to those produced by untreated
trophozoites, representing almost total loss of the cell layer (Figure 4.9).
Figure 4.9 Disruption of HBMEC monolayers by trophozoites is not reduced by
multimeric, monomeric or fragmented immunoglobulin.
105 trophozoites were treated with 200
used to infect HBMEC
haematoxylin staining after 18
independent experiments.
ining
tection of the monolayer was observed in any treatment
µg/ml antibody/ Fc fragment for three hours and then
monolayers. Monolayer disruption was assessed in triplicate by
-24 hours incubation. Image is representative of three
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4.4.6. Monolayer disruption
Wells infected as described in sections 4.3.7 were photographed after 18-24
hours and percentage monolayer disruption estimated from photomicrographs
using the method outlined in section 4.3.9. No protection was observed for any
of the treatment groups versus the positive control (Figure 4.10) and a
significant difference in percentage monolayer disruption was only observed in
negative control samples (p<0.0001, 1-way ANOVA).
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Figure 4.10 Percentage monolayer disruption of HBMEC monolayers by trophozoites is
not reduced by multimeric, monomeric or fragmented immunoglobulin.
105 trophozoites were treated with 200µg/ml antibody/ Fc fragment for three hours and then
used to infect HBMEC monolayers. Monolayer disruption was assessed in triplicate from
photomicrographs by a grid counting method. No significant differences were observed
between columns other than the negative control (**** p<0.0001 1-way ANOVA). Results are
mean + S.E.M. from three independent experiments.
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4.4.7. Structural effects: Cytotoxicity
HBMEC monolayers were infected as described in sections 4.3.7, and cell free
supernatants collected after 18-24 hours. The supernatants were then tested for
LDH release as a necrotic marker, and percentage cell death calculated for
each treatment (see section 4.3.10). Significant differences were seen between
treatment groups (p<0.0001 1-way ANOVA) however this did not correlate
with protection as all groups produced cell death measurements in excess of
untreated controls (Figure 4.11). Enhancement of cell death was statistically
significant for both IgM treatments, and Fc fragment alone (Figure 4.11).
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Figure 4.11 Percentage cell death in trophozoite-infected HBMEC monolayers is not
reduced by multimeric, monomeric or fragmented immunoglobulin.
105 trophozoites were treated with 200µg/ml antibody/fragment for three hours and then used
to infect HBMEC monolayers for up to 24 hours. Supernatants from each treatment were then
assessed for LDH release in triplicate. Treatment values differed significantly from untreated
controls (p<0.0001 1-way ANOVA) and cell death was significantly enhanced by IgM and Fc
fragment treatments (** p<0.05, *** p<0.01). Results are mean + S.E.M. from three
independent experiments.
154
4.4.8. Fc receptor in A. castellanii
The reduction in binding by both polyclonal and negative control IgM that had
been observed in sections 4.4.3 and in Chapter 3 was potentially explicable as
capture of antibody by trophozoite surface factors. One such factor previously
demonstrated in other parasitic protozoa is the presence of an Fc-binding
protein. To investigate whether A. castellanii trophozoites demonstrated
dedicated Fc-binding-like activity a bioinformatics approach,
immunofluorescence assays and FACS analysis were performed.
4.4.9. Fc receptor in A. castellanii: Bioinformatics
No Fc-binding activity has previously been reported in A. castellanii and an
interrogation of A. castellanii information deposited in the NCBI database
(www.ncbi.nlm.nih.gov/) using the terms “Fc”, “Fc binding protein”, and “Fc
receptor” produced no hits. An alternative approach was therefore used
whereby sequences of proteins with known Fc-binding activity were retrieved
from NCBI and UNIPROT databases and individually compared with the A.
castellanii transcriptomic sequence using the tBLASTn algorithm (see section
4.3.11). The best five matches from queries producing significant hits were
recorded, with sequences from Schistosoma mansoni, Leishmania major,
Trypanosoma cruzi, Trypanosoma brucei, and Toxoplasma gondii
demonstrating significant E-values (Table 4.1, Figures 4.12 - 4.14).
Table 4.1155
Protein Accession Query length Match Length Coverage E-value
Homo sapiens IgG Fc receptor CAA35642 323aa 40aa
48aa
12%
14%
2.5
5.5
Homo sapiens IgM Fc receptor ACX94155.1 390aa 86aa 22% 6
Homo sapiens IgA Fc receptor P24071.1 287aa 78aa
70aa
52aa
23%
22%
18%
0.41
0.91
2
Homo sapiens IgE Fc receptor AAA52434.1 321aa 27aa
27aa
8%
8%
7.6
7.6
Mus musculus IgG Fc receptor AAA16904.1 365aa 82aa
82aa
80aa
31aa
45aa
21%
21%
19%
8%
12%
1.2
1.2
3.3
4.7
6.6
Mus musculus IgA/IgM Fc receptor EDL39730.1 310aa 91aa
91aa
38aa
63aa
63aa
28%
28%
12%
17%
17%
1.5
1.5
3.2
6.7
6.8
Table 4.1156
Protein Accession Query length Match Length Coverage E-value
Mus musculus IgE Fc receptor (II) CAA45532 330aa 76aa
76aa
147aa
70aa
147aa
21%
21%
35%
17%
35%
3.5
3.5
3.6
8.2
8.9
Schistosoma mansoni paramyosin AAA29915.1 866aa 446aa
446aa
50%
50%
3e-04
4e-04
Leishmania major Lmsp1 Not deposited† 152aa 96aa, 36aa, 28aa
96aa, 36aa, 28aa
57aa
57aa
57aa
125%
125%
40.4%
40.4%
32.3%
2e-44
9e-44
5e-04
5e-04
0.27
Trypanosoma cruzi Lmsp1 Not deposited† 154aa 91aa, 36aa
97aa, 25aa
42aa
58aa
48aa
79%
63%
27%
37%
29%
5e-40
1e-05
0.016
3.4
6.0
Trypanosoma brucei Lmsp1 Not deposited† 150aa 94aa, 36aa
43aa
65aa
46aa
85%
28%
43%
30%
1e-04
0.001
0.57
1.8
Toxoplasma gondii Beta antigen EEA98208.1 303aa 214aa, 201aa, 205aa, 175aa
203aa, 195aa, 214aa, 180aa
203aa, 195aa, 214aa, 180aa
282aa, 157aa
282aa, 157aa
76%
73%
73%
92%
92%
4e-18
8e-17
9e-17
9e-16
1e-15
Table 4.1157
Protein Accession Query length Match Length Coverage E-value
Plasmodium falciparum PfEMP1‡ AAB87407.1 178aa 41aa, 65aa
31aa, 65aa
32aa, 34aa
19aa
20%
35%
16%
16%
0.19
3.2
6.5
7.1
Streptococcus sp. Protein G CAA27638.1 480aa 45aa
45aa
9%
9%
5.2
5.3
Staphylococcus aureus Protein A AGE10364.1 367aa N/S N/S N/S
Finegoldia magna Protein L AAA67503.1 992aa N/S N/S N/S
Table 4.1 Results of BLAST searches of the A. castellanii genome using Fc-binding proteins derived from various organisms.
Peptide sequences were retrieved from the NCBI protein database and searched against the A. castellanii genome using the tBLASTn algorithm. Accession numbers, length
of aligned regions, coverage and E-values for matches are shown for each search. The top five matches are shown for each BLAST query. N/S = no significant alignment. †
Peptide sequence was not deposited in NCBI database, but retrieved in FASTA format from the original publication. ‡ PfEMP1 is encoded by a highly variable subset of
genes (var genes). To correct for this, 10 variants were selected from data in GenBank and also searched against A. castellanii (Appendix 3). No reliable matches were
returned for any PfEMP1 variants.
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Figure 4.12 Alignment of L. major Lmsp1 with matching sequence from the A. castellanii
transcriptome.
Sequences were retrieved from published data and NCBI databases and aligned using BioEdit
software (available from http://www.mbio.ncsu.edu/bioedit/bioedit.html). Black highlighting
indicates conserved residues, grey highlighting indicates similar residues. A high degree of
similarity was observed in the central region of the alignment, corresponding to the significant
E-value obtained by BLAST.
Figure 4.13 Alignment of T. gondii beta antigen with matching sequence from the A.
castellanii transcriptome.
Sequences were retrieved from published data and NCBI databases and aligned using BioEdit
software (available from http://www.mbio.ncsu.edu/bioedit/bioedit.html). Black highlighting
indicates conserved residues, grey highlighting indicates similar residues. A high degree of
similarity was observed in the central region of the alignment, corresponding to the significant
E-value obtained by BLAST.
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A.castellanii - - - - - - - - -
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Figure 4.14 Alignment of S. mansoni paramyosin with matching sequence from the A.
castellanii transcriptome.
Sequences were retrieved from published data and NCBI databases and aligned using BioEdit
software (available from http://www.mbio.ncsu.edu/bioedit/bioedit.html). Black highlighting
indicates conserved residues, grey highlighting indicates similar residues. Similarity was
observed in the C-terminal half of the alignment, interrupted by large gaps. This explains the
significant but relatively large E-value obtained by BLAST.
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. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii M A A Q R R R K G G E V E S D Y I K Y L K Y K N T G F Q V S A S D K T L A WW P T K D A D R A F C H V E V T
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
110 120 130 140 150
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii N E P A V L H N L K K R Y D A D L F H T Y S G L F L V V V N P Y K R L P V Y T P E I I D I Y R G R Q R D K V
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
210 220 230 240 250
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii A I A G R A E G G L L E Q Q L L E F N P I L E A F G N A K T T K N N N S S R F G K F I E L Q F N A G G Q I T
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
310 320 330 340 350
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii K P E D Y F F L N Q N A C Y T V D D M D D A K E F D H M L K A F D I L N I N E E E R L A I F Q T I S A I L H
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
410 420 430 440 450
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii A G N E W V T R A L N K P K A M A S R D A L C K A L F G R L F L W I V Q K I N R I L S H K D K T A L W I G V
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
510 520 530 540 550
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii I DW T F V D Y G M D S Q D C I D L I E K K P M G I L P L L D E Q T V F P D A D D T S F T K K L F Q T H E N
S.mansoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - D T E S
610 620 630 640 650
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii K K S S V R F V T G L F D E D L M P S F K A A P A E E E K A A A G G S R N R S T G R G K G G A Q F I T V A F
S.mansoni R D A R V R A E R H A - - A D - - L G F Q V D A L S E R L D E A G G S T T Q T Q E L L K R R E M E I N - - -
710 720 730 740 750
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii - - - D Q L V L D Q L K C N G V L E G I R I A R K G W P N R L K Y D E F L K R Y F L L K P G A T P T S P S T
S.mansoni K D K S H L I M E V D N V L G Q L D G A L K A K Q S A E S K L E - - - - - - - - - - - - - - - - - - - - - -
810 820 830 840 850
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii Q A I S K M V V S I Q A G A R A F L A R R M Y D K M R E Q T V S A K I L Q R N I R A W L E L K NW A W Y Q L
S.mansoni - - - - - - - - - - - - G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
910 920 930 940 950
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii L A E E D A D K L E K D L A A L K L K I L D L E G E K A D L E E D N A L L Q K K V A G L E E E L Q E E T S A
S.mansoni - - - - - - - - - - - - - - - - N F E L L H I N - - - - - - - - - - - - - - - - - Q D Y E A - - - - - - - Q
1010 1020 1030 1040 1050
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii Q D K Y E D E A A A H D S L K K K E E D L S R E L R E T K - - - - - - - - - - - - - - - - - - - - - - - - -
S.mansoni Q A K Y D E E S E E A S N L R S Q V S K F N A D I A A L K S K F E R E L M S K T E E F E E M K R K F T M R I
1110 1120 1130 1140 1150
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - D A L A D A E N I
S.mansoni R R A K A A E S L A S D L Q R R V D E L T I E V N T L T S Q N S Q L E S E N L R L K S L V N D L T D K N N L
1210 1220 1230 1240 1250
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii L A Q T R A Q L E E E K S G K E A A S - - - - S K A K Q L G Q Q L E D A R S E V D S L K S K L S - - - - - -
S.mansoni L H D A E E A L H D M D Q K Y Q A S Q A A L N H L K S E M E Q R L R E R D E E L E S L R K S T T R T I E E L
1310 1320 1330 1340 1350
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . .
A.castellanii K K A L E A K L T E L E D Q V T A L D G Q K N A A A A Q A K T L K T Q V D E T K R R L E E A E A - - - - - -
S.mansoni N K N L S Q R V K - - - - - - - - - - - - - - - - - - - - - D L E T F L D E E R R L R E A A E N N L Q I T E
1410 1420 1430 1440 1450
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Sequences obtained from protein databases exhibited considerable
dissimilarity, and it was not possible to obtain reliable phylogenetic trees. An
alternative reciprocal BLAST approach was therefore taken to make pairwise
comparisons between all sequences. As before, protein sequences were
retrieved from UNIPROT and NCBI databases based on association with Fc-
binding BLAST outputs (Appendix 4). These were restricted based on length
and then interpreted according to E-scores. Filtering parameters for sequence
length and alignment significance are given in section 4.3.11. Where
individual BLAST results from searches performed against the A. castellanii
genome produced sequences of sufficient length and significance (Table 4.2),
sequence data from the appropriate transcriptomic contig was translated in an
appropriate frame and included in the reciprocal BLAST.
Table 4.2
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.brucei_Lmsp1_contig 100 94 2.00E-54
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 91 9.00E-53
Acanthamoeba_T.brucei_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 89 1.00E-51
Leishmania_major_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 55.91 93 7.00E-34
Leishmania_major_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 55.91 93 7.00E-34
Leishmania_major_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 56.18 89 6.00E-33
Leishmania_major_Lmsp1 Trypanosoma_brucei_Lmsp1 82 150 5.00E-68
Leishmania_major_Lmsp1 Trypanosoma_cruzi_Lmsp1 84.25 127 4.00E-61
Mouse_FceR2 Streptococcus_pyogenes_FcgR 23.13 134 1.00E-05
Mouse_FceR2 Streptococcus_pyogenes_FcgR 19.64 112 1.00E-05
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 22.19 311 8.00E-10
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.81 631 2.00E-08
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 17.75 355 2.00E-07
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.13 345 1.00E-06
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.5 241 4.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 19.14 324 9.00E-07
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 21.68 309 7.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 18.36 207 7.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 20.72 613 2.00E-08
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 16.22 333 6.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 17.56 450 7.00E-06
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.07 122 5.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 35.25 122 5.00E-28
Table 4.2
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 9.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 2.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.41 156 2.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 30.14 146 2.00E-26
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 28.76 153 2.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.5 127 3.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 24.39 246 3.00E-20
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.43 173 4.00E-11
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.09 184 2.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.84 231 5.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.62 203 3.00E-09
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.92 182 5.00E-08
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 22.09 172 2.00E-06
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 24.83 149 3.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 1.00E-12
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 24.47 237 1.00E-10
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.14 242 3.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 26.28 156 6.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 2.00E-08
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 22.18 275 4.00E-08
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.71 175 1.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.43 175 7.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.58 172 3.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 21.98 182 5.00E-06
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 72.19 791 0
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.04 608 3.00E-30
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.4 308 1.00E-13
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 18.95 190 1.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 21.89 169 2.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.06 85 6.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 29.41 68 8.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.66 94 8.00E-06
Trypanosoma_brucei_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 55.06 89 3.00E-27
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 52.81 89 6.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Trypanosoma_brucei_Lmsp1 88.98 127 1.00E-52
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.brucei_Lmsp1_contig 100 94 2.00E-54
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 91 9.00E-53
Acanthamoeba_T.brucei_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 89 1.00E-51
Leishmania_major_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 55.91 93 7.00E-34
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Leishmania_major_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 55.91 93 7.00E-34
Leishmania_major_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 56.18 89 6.00E-33
Leishmania_major_Lmsp1 Trypanosoma_brucei_Lmsp1 82 150 5.00E-68
Leishmania_major_Lmsp1 Trypanosoma_cruzi_Lmsp1 84.25 127 4.00E-61
Mouse_FceR2 Streptococcus_pyogenes_FcgR 23.13 134 1.00E-05
Mouse_FceR2 Streptococcus_pyogenes_FcgR 19.64 112 1.00E-05
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 22.19 311 8.00E-10
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.81 631 2.00E-08
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 17.75 355 2.00E-07
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.13 345 1.00E-06
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.5 241 4.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 19.14 324 9.00E-07
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 21.68 309 7.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 18.36 207 7.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 20.72 613 2.00E-08
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 16.22 333 6.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 17.56 450 7.00E-06
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.07 122 5.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 35.25 122 5.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 9.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 2.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.41 156 2.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 3.00E-27
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 30.14 146 2.00E-26
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 28.76 153 2.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.5 127 3.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 24.39 246 3.00E-20
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.43 173 4.00E-11
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.09 184 2.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.84 231 5.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.62 203 3.00E-09
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.92 182 5.00E-08
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 22.09 172 2.00E-06
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 24.83 149 3.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 1.00E-12
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 24.47 237 1.00E-10
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.14 242 3.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 26.28 156 6.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 2.00E-08
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 22.18 275 4.00E-08
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.71 175 1.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.43 175 7.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.58 172 3.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 21.98 182 5.00E-06
Table 4.2
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Query I.D. Subject I.D. % Identity alignment length (aa) e-value
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 72.19 791 0
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.04 608 3.00E-30
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.4 308 1.00E-13
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 18.95 190 1.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 21.89 169 2.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.06 85 6.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 29.41 68 8.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.66 94 8.00E-06
Trypanosoma_brucei_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 55.06 89 3.00E-27
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 52.81 89 6.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Trypanosoma_brucei_Lmsp1 88.98 127 1.00E-52
Table 4.2 Reciprocal BLAST of known and predicted Fc-binding sequences.
Amino acid sequences retrieved from UNIPROT and NCBI databases were compared using automated tBLASTn queries (817 individual comparisons). Results were filtered
to exclude short alignments of less than 50aa. Alignments with E-values >0.00001 were considered non-significant and were also excluded.
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Output of reciprocal BLAST data demonstrated high levels of similarity
between mammalian Fc-receptors and FcR in less closely related species
Gallus gallus and Crassostrea gigas (see Appendix 4). The reciprocal BLAST
approach was also able to detect well conserved sequences between
Schistosoma mansoni and Taenia solius, closely related species in which
detection of conserved sequence was an expected outcome of the approach.
However significant similarity was also observed between sequences from
phylogenetically distant organisms. In particular a protein with Fc-binding
properties from Streptococcus pyogenes (Protein G) had sequence similarity to
S. mansoni and T. solius paramyosin, as well as human and mouse IgE2
receptor. Similarity between Staphylococcus aureus Protein A and mouse and
human FcR was also observed. Taken together, this indicates that our
experimental approach was sound and appropriate.
Using the initial genome BLAST significant matches to regions of the A.
castellanii genome were observed with sequences from L. major, a homologue
of the same Lmsp1 gene in T. cruzi, and sequence from T. gondii (Table 4.1,
Figures 4.12 and 4.13). These regions corresponded to hypothesised Fc
binding proteins from these organisms. Using a lower-stringency cut-off of
0.001, significant matches were also seen to a further Lmsp1 homologue in T.
brucei and also to S. mansoni paramyosin (Figure 4.14) were also observed in
this case. Similarly reciprocal BLAST confirmed matches between L. major
Lmsp1 and its Trypanosoma homologues and sequence from the aligned A.
castellanii sequence data (Table 4.2). Strong matches between A. castellanii
sequence and T. gondii Beta antigen were again also observed. Reciprocal
BLAST did not however detect significant similarity between A. castellanii
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and S. mansoni or T. solium paramyosin; although as with the primary BLAST
searches matches could be found by using a lower-stringency E-value cut-off.
4.4.10. Fc receptor in A. castellanii: Immunofluorescence
Cytospin preparations of K562, HBMEC, and A. castellanii trophozoites were
made as described in section 4.3.12. Samples were then blocked and incubated
with human IgG Fc fragment (Table 2.2, #5) followed by anti-human IgG
FITC conjugate (Table 2.2, #10), as described in sections 4.3.12. Mounted
slides were then observed and photographed under illumination at 360 and
540nm. Strong fluorescence was detected in K562, a cell type which are
known to express Fc receptors whilst no fluorescence was observed in
HBMECs (Figure 4.15). A. castellanii trophozoites demonstrated weak
fluorescence (Figure 4.15, denoted by white arrows). In contrast to K562 cells
however, this was observed in the Fc + anti-Fc-FITC treatment only.
Figure 4.15 A. castellanii trophozoites treated with human Fc fragment plus FITC
conjugated anti-human Fc demonstrate we
Fixed trophozoites were blocked and incubated with 1:300 human Fc fragment. FITC
conjugated anti-human Fc secondary antibody was then used to detect binding and nuclei were
counterstained with DAPI. Left hand panels: secondary binding cont
right hand panels: Fc fragment + anti
castellanii. Images are representative of two independent experiments. Bar = 50µm.
ak fluorescence.
rols (no Fc fragment),
-Fc secondary. Arrows denote positive staining in
169
-
-
A.
170
4.4.11. Fc receptor in A. castellanii: FACS
To further explore findings indicating that A. castellanii was weakly positive
for Fc-binding activity, populations of stained trophozoites were examined
using FACS analysis. Cells were harvested, blocked, and stained as described
in section 4.3.13 and then sorted using a FACSCantoII instrument as described
in section 4.3.13. Single cell populations (R0) were identified for both
HBMEC and A. castellanii (Figures 4.16 and 4.17, panel A), and cells from
within these populations were then gated according to unlabelled controls
(panel B). The percentage of stained cells was indicated by the proportion
appearing outside the gate in appropriate treatments (panels C and D). Some
degree of secondary antibody binding was observed for both HBMEC (36.5%)
and A. castellanii (11.5%) Treatment with both Fc fragment and detecting
antibody failed to produce a significant increase in fluorescence in either case
(-0.2% for HBMEC, +1.4% for A. castellanii).
Figure 4.16 HBMEC display low levels of fluorescence
of detecting antibody, but no significant increase in fluorescence following incubation
with human Fc fragment.
Cells were blocked and incubated with
secondary alone, or were
population of single cells. (B) Forward scatter versus FITC, unlabelled HBMEC were gated to
calculate percentage shifts. (C) Secondary antibody only, line denotes gate of unlabelled cel
(D) Fc plus anti-Fc
Weasel software v3.0.
attributable to secondary binding
1:300 Fc fragment plus anti
left unlabelled. (A) Forward scatter versus side scatter, R0 defines a
-FITC, line denotes gate of unlabelled cells. Data was analysed using
Results are representative of two independent experiments.
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-Fc-FITC secondary,
ls.
Figure 4.17 A. castellanii
binding of detecting antibody, but no significant increase in fluorescence following
incubation with human Fc fragment.
Cells were blocked and incubated with
secondary alone, or were left unlabelled. (A) Forward scatter versus side scatter, R0 defines a
population of single cells. (B) Forward scatter versus FITC, unlabelled
gated to calculate percentage shifts. (C) Secondary antibody only, line denotes gate
unlabelled cells. (D) Fc plus anti
analysed using Weasel software v3.0.
experiments.
display low levels of fluorescence attributable to secondary
1:300 Fc fragment plus anti
-Fc-FITC, line denotes gate of unlabelled cells.
Results are representative of two independent
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-Fc-FITC secondary,
A. castellanii were
of
Data was
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4.5. Discussion
A fully competent immune system is generally recognised as sufficient to
control A. castellanii infections and development of AGE. In disease states
immune control fails, however it is not clear which arms and effectors of the
immune response are primarily responsible for infection control in healthy
individuals. As a result the specific immune impairments which result in the
development of AGE also remain cryptic. As part of work presented in the
previous chapter a polyclonal antibody was used to obtain information about A.
castellanii proteins recognised by the immune system. This antibody impaired
the amoeba’s ability to bind to human endothelial cells but had no effect on
host cell survival and was unable to preserve the integrity of a host cell
monolayer. Given that the targeting of the antibody to a number of surface
epitopes was apparently ineffective in terms of cell survival outcomes, we
sought to examine whether this was due to any active process on the part of the
parasite.
Work by previous authors has demonstrated that secreted proteases are an
important contributor to the pathogenesis of AGE (Khan et al., 2000b, Alsam
et al., 2005b, Sissons et al., 2006a). Aside from any role as virulence
determinants during interactions with host cells, proteases may also play a part
in immune evasion by degrading key components of the immune response.
Mechanisms to degrade antibody have been demonstrated in the amoeba
species Entamoeba histolytica and also in A. castellanii itself (Na et al., 2001,
Na et al., 2002a, Garcia-Nieto et al., 2008). The Acanthamoeba studies in
particular made use of either purified single enzymes, or an unpurified
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excretory/secretory enzyme cocktail (ACM). Under the conditions detailed in
this study ACM profiles similar to those reported and characterised by
previous authors were obtained (Figure 4.1), with bands at molecular weights
of 33, 85 and 130-150kDa (Kim et al., 2003, Hurt et al., 2003a, Sissons et al.,
2006a)
Using ACM we were able to confirm and extend results from previous studies
which demonstrated cleavage activity against immunoglobulin. Na et al.
showed that both IgA and IgG were vulnerable to degradation by ACM and
later extended these findings to include IgM and secretory IgA (Na et al., 2001,
Na et al., 2002a). Our data support these results (Figures 4.2, 4.4 and 4.5) and
also demonstrate that IgE is similarly vulnerable to ACM-mediated
degradation (Figure 4.3). Notably cleavage was observed not just with
nonspecific control antibodies but also with polyclonal antibody raised against
A. castellanii antigens (Figure 4.6). This demonstrates that ACM proteases can
act within an environment of mixed specificities and epitopes and against Ig
derived from a physiological source. This increases the likelihood that the
antibody cleavage process occurs in vivo as well as in vitro, which although
beyond the scope of the current analysis may prove an interesting area in
which to direct future investigation.
Three major protease classes have been demonstrated in A. castellanii
secretions however evidence for roles in infection are most frequently ascribed
to serine and metallo-proteases (Hadas and Mazur, 1993, Cho et al., 2000, Kim
et al., 2006, Blaschitz et al., 2006). In this regard previous experiments have
focused mostly on cytotoxicity and blood-brain barrier breakdown (Alsam et
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al., 2005a, Sissons et al., 2006a) however our results suggest that serine
proteases in particular should also be considered as having potential immune
evasion functions.
The SDS-PAGE profiles obtained from ACM during the course of the above
experiment were observed to be highly complex, with multiple bands and
correspondingly complicated peak traces (Figures 4.2 to 4.6, lane 6).
Acanthamoeba secretions have been shown to contain multiple proteases
falling within several broad classes; serine, cysteine and metallo-proteases
(Alfieri et al., 2000, Alsam et al., 2005b). Using inhibitors specific to each
class we sought to attribute cleavage activity to one or more of these classes.
Protection from cleavage mediated by PMSF (a serine protease inhibitor) was
observed for all antibody classes including polyclonal HE2 antibody (Figures
4.2 to 4.6, lane 5). Batimastat (a metalloprotease inhibitor) also provided
partial protection although this effect was substantially less pronounced
(Figures 4.2 to 4.6, lane 3). No protection was observed in Iodoacetamide-
treated samples (cysteine protease inhibitor).
Similar results were obtained when relative peak areas of heavy and light chain
peptides were analysed (Figure 4.7). PMSF again protected both heavy and
light chain fragments most effectively whilst Batimastat also contributed to
preservation of antibody peaks for each class except IgA. Results for heavy
and light chain were broadly similar however the relative peak areas for
control and Iodoacetamide-treated samples were higher in most cases,
potentially indicating that antibody light chains were overall less sensitive to
degradation. Nevertheless although PMSF and Batimastat treatments exhibited
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elevated relative peak area compared with control samples, preservation was
on the whole lower than observed in heavy chain samples. This contradiction
is not easily interpreted but could be due to inaccuracies in measurement
induced by variable background staining of gels or strong bands of equivalent
molecular weight present in ACM.
Apparent differences between preservation of heavy or light chain under the
same inhibitor might also be attributable to the site at which antibody is
cleaved. Cleavage in the Fc region of the molecule would necessarily exclude
any effects on the light chain and would be correspondingly unaffected by
addition of protease inhibitors, as in IgE cleavage by Schistosoma mansoni
(Aslam et al., 2008). However this is not the pattern observed in our data,
which better fits a profile of multiple protease types from more than one class,
possibly also acting at a variety of sites on the molecule. Acanthamoeba serine
proteases have been shown to belong to more than one category of activity:
trypsin-like (Sissons et al., 2006a), chymotrypsin-like (Na et al., 2001), and
elastase-like (Ferreira et al., 2009). Each of these broad types demonstrate
cleavage specificities for different amino acid residues. Chymotrypsin-like
proteases for example have a deep and highly hydrophobic active site, creating
a preference for large hydrophobic amino acids such as tryptophan and
phenylalanine. By contrast elastase-like enzymes have shallower, less
hydrophobic active sites and exhibit specificity for smaller or less hydrophobic
amine acids such as valine and alanine (Hedstrom, 2002). This means there are
many possible sites for cleavage along an antibody molecule depending on
which class of protease is responsible for cleavage (an example for human IgG
is shown in Appendix 5). Careful testing with purified single-protein fractions
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will be required in order to resolve the role of individual enzyme classes and
amino acid cleavage specificity.
A second mechanism by which parasites can evade the effects of the immune
system is by sequestering antibody on the surface of the parasite. From the
point of view of the infectious organism this has a twofold advantage: 1)
sequestration of antibody prevents activation of downstream effector responses
and 2) acquiring a coat of antibody can inhibit access to the parasite’s surface
thereby preventing recognition of surface antigens by phagocytes, and
protecting against complement attack and lysis. Neither mechanism has
previously been demonstrated in A. castellanii however such processes are
known to occur in a variety of parasitic infections.
In Plasmodium falciparum for example the parasite merozoite surface protein
MSP1 induces nonspecific blocking antibody which can prevent the binding of
more active inhibitory antibodies (Holder et al., 1999). Also in malaria the
erythrocyte membrane protein PfEMP1 has been shown to bind host IgM in an
inverted orientation that prevents the Fc region from being exposed to
additional immune mediators (Ghumra et al., 2008, Czajkowsky et al., 2010).
This also has an additional benefit to the parasite of masking epitopes which
would be protective if targeted by an IgG response. This process was
demonstrated for a strain causing placental malaria where nonspecific IgM was
shown to bind competitively with monoclonal IgG specific for immunogenic
Duffy-binding-like (DBL) domains of PfEMP1. In the presence of IgM, IgG
binding was reduced to less than 20% of control levels and this interference
was shown to inhibit phagocytosis of opsonised parasites (Barfod et al., 2011).
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Examples of parasites recruiting ineffective immunoglobulin in order to evade
immunity have also been seen in Trypanosoma cruzi and Schistosoma mansoni
(Garcia et al., 1997, McIntosh et al., 2006). In the latter case immunoglobulin
binding has been ascribed to IgG Fc receptors expressed on the parasite
tegument (Torpier et al., 1979, Tarleton and Kemp, 1981) and tentatively
linked to the protein paramyosin, specific antiserum against which prevented
subsequent binding of Fc-FITC to the parasite surface (Loukas et al., 2001)
Other parasites such as Toxoplasma gondii possess immunoglobulin binding
activity that is yet to be definitively linked to a specific evasion mechanism but
is likely to play a role in host-parasite interaction (Vincendeau and Daeron,
1989, Rodriguez de Cuna et al., 1991, Villavedra et al., 2001).
Nonspecific binding of IgM had been observed in experiments forming a part
of Chapter 3, alongside a lack of protection in terms of host cell death and
monolayer disruption. These experiments were extended to investigate whether
there is a structural component to binding inhibition and how this relates to
pathogenic outcome. Initially we were able to replicate these earlier findings
which continued to indicate that both anti-Acanthamoeba and isotype control
IgM reduced binding by approximately 20% (Figure 4.8). However this effect
did not extend to monomeric isotype control IgG or purified Fc fragment.
Significantly, reduction in binding did not translate into protection of host cell
monolayers in terms of macro- or microscopic monolayer disruption (Figures
4.9 and 4.10). Neither was a protective effect observed when cytotoxicity of
host cells was measured, in fact the opposite was true with treatment groups
showing elevated levels of cell death (Figure 4.11).
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These data indicate several possible explanations. Binding is only reduced and
not ameliorated by addition of antibody so it may be hypothesised that the
usual course of infection can proceed for trophozoites that are not prevented
from binding by antibody activity. The observed lack of protection might then
be explained by the 20% reduction in amoeba binding being too small to
produce any observable reduction in monolayer pathology.
Another possibility relates to the protease activity of the organism which has
been demonstrated to degrade the Ig classes used by other groups and also
those used in this study, including HE2 (see above). Rapid activity of these
proteases could quickly counteract the effect of any binding inhibition,
especially if intact protein structure of IgM is necessary to prevent binding, as
indicated by the inability of IgG to affect adherence (Figure 4.8). Contact-
mediated pathogenesis by trophozoites has been elucidated in some depth
(Yang et al., 1997, Cao et al., 1998, Garate et al., 2005, Garate et al., 2006b)
and links between trophozoite binding and protease expression have been
made previously. For example the interaction of A. castellanii mannose-
binding protein (MBP) with exogenous mannose or host cell mannose
glycoproteins has been demonstrated to upregulate protease expression (Hurt et
al., 2003a, Leher et al., 1998c).
Alternatively binding may not be necessary for the initiation of monolayer
disruption and cell death processes at all. Pathways to endothelial pathology
have been described for several A. castellanii protease secretions (Alsam et al.,
2005b, Sissons et al., 2006a, Khan and Siddiqui, 2009, Harrison et al., 2010),
and if these are unaffected by the presence of surface-bound antibody then
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their molecular targets and processes are likely to be similarly unaffected.
Given that proteases can be upregulated in response to external cues (see
above) it is also tempting to speculate that trophozoites might mount a similar
response to antibody. This could provide an explanation for the increased
cytotoxicity observed in some treatment groups as seen in Figure 4.11 but will
require careful additional experimentation to verify.
Considering the pentameric structure and high molecular weight of IgM
(Chesebro et al., 1968) and the lack of binding inhibition exhibited by
monomeric antibody and fragments (Figure 4.8) it is possible that IgM inhibits
binding by structural interference with factors present on the amoeba cell
membrane. This is one of the major functions of immunoglobulin within the
immune response however the fact that this process occurs with both specific
and non-specific antibody in our experiments is interesting. As described
above parasites such as T. cruzi and S. mansoni have been observed to
sequester antibody and this antibody coating is linked to immune evasion. One
way in which this process is mediated is by expression of membrane proteins
which bind to the conserved (Fc) region of Ig, and hence capture antibody in
sub-optimal orientation. The ability of nonspecific IgM to impair trophozoite
binding to HBMEC monolayers suggests that this process may be occurring in
A. castellanii either specifically to IgM, or generically across all Ig classes
with only IgM capable of inhibiting binding due to its large size.
In order to test this hypothesis a bioinformatics based approach was used
alongside evidence from immunofluorescence and FACS experiments. BLAST
searches against the A. castellanii genome with proteins possessing known or
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predicted Fc-binding activity revealed little similarity to dedicated receptor
classes from human, mouse, chicken or oyster sequences (Table 4.1), and this
was confirmed by reciprocal BLAST (Table 4.2). Considering the large
evolutionary distance between the amoebazoa and these multicellular
organisms, there is only a low probability of a recognisable and intact FcR, or
equivalent sequence being present in A. castellanii. Similarities in terms of
invasion and pathogenesis strategies with other pathogens however provide a
more likely scenario in which A. castellanii might share similar Fc binding
protein activity and sequence. Searches were performed in a non-targeted
manner using only organisms with previously reported or predicted Fc-binding
activity, and where sequence of the putative binding factor was available. For
some parasites annotation was available but too limited to reliably include in
BLAST analyses. Fc-binding annotation is present in Taenia crassiceps for
example, however this refers only to a very short (~30aa) sequence which
could not be reliably incorporated into our experiments. Our approach
therefore excludes some parasites with similar infection routes or mechanisms
of pathogenesis to A. castellanii. Whilst this is a limitation at the present time
continued future improvement in genome and transcriptome annotation will
allow more far-reaching comparisons to be made between distantly related
organisms which share similarities in lifestyle and pathogenesis. We consider
this to be an important consideration for subsequent work in this field.
Our data indicates that the best matches to A. castellanii sequences were found
in other pathogenic protozoa. In particular a short ~90 aa region of sequence
matching to an Fc-binding protein (Lmsp1) in Leishmania major was
discovered in initial BLAST searches (Table 4.1). Homologues of Lmsp1 have
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been found in Trypanosoma cruzi and Trypanosoma brucei (Campos-Neto et
al., 2003) and when retrieved and compared in our dataset (Table 4.2) these
sequences were as expected highly similar to each other (>80% identity, E-
values <10-50). Matches of Lmsp1 sequences to the A. castellanii genome
showed lower levels of similarity (>50% identity, E-values <10-20), however
this still represents a significant level of matching between the sequences and
can be explained by the relatively large evolutionary distance between amoeba
and the kinetoplastids. Notably, a conserved domain search of A. castellanii
transcriptomic sequence that had aligned significantly with L. major Lmsp1
revealed conservation with group 1 from the nucleoside diphosphate kinase
protein superfamily (Appendix 6). This is also the family to which Lmsp1
belongs and as such is likely to represent genuine homology between the two
organisms.
Interestingly the binding targets for Lmsp1 as shown by Campos-Neto et al.
were IgG and IgM antibody. Both of these classes are distributed mainly in the
bloodstream and trophozoites are therefore exposed to both during systemic
infection. Capture of both or either class could facilitate evasion of subsequent
immune responses, although only IgM and not IgG binding activity was
detected in vitro in our experiments. Whilst both antibodies are present in the
blood IgM responses typically occur in the early stages of infection and as a
result an ability to evade this class might allow A. castellanii to establish itself
systemically and at the BBB before subsequent immune responses can clear
trophozoites.
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Another significant match obtained by reciprocal BLAST was between A.
castellanii and Toxoplasma gondii. Several previous studies have identified T.
gondii as possessing Fc binding activity (Budzko et al., 1989, Vercammen et
al., 1998) and the T. gondii beta antigen is located in a region predicted by
genome annotation to exhibit IgA-binding activity. It is this region which
produced significant matches to A. castellanii in our study. Interestingly the
beta antigen was also significantly similar to a protein from Streptococcus
agalactiae which possesses IgA-binding activity (Coleman et al., 1990, Heden
et al., 1991) indicating that any similar protein in A. castellanii might also
exhibit binding to this antibody class. This targeted binding to IgA is of
additional interest due to the tissue distribution of the antibody class. IgA and
especially secretory IgA play an important role in protection from infection at
mucosal surfaces. One such area of relevance to A. castellanii infections is the
eye, and IgA has been hypothesised to be the main source of immune control
in Acanthamoeba keratitis (Leher et al., 1999, Alizadeh et al., 2001, Campos-
Rodríguez et al., 2004). Ocular infections occur in patients with fully
functioning immune systems and Acanthamoeba-specific IgA is readily
isolated from AK patients (Alizadeh et al., 2001). IgA binding activity by the
parasite might therefore provide an explanation for the apparently ineffective
immune response.
Other well-characterised bacterial Fc binding proteins originating from
streptococci and staphylococci aligned with S. mansoni paramyosin sequence
in our experiments (King and Wilkinson, 1981, Bjorck and Kronvall, 1984). S.
mansoni also showed some degree of similarity to A. castellanii transcriptomic
sequence with the same protein, which has previously been reported to exhibit
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Fc-binding properties (Kalinna and McManus, 1993). This match is however
less reliable than others detected by our approach as alignments only reach
significance if a lower stringency cut-off is used. Nevertheless the fact that
some level of similarity is seen to what is one of the better characterised
parasite Fc binding proteins makes this an interesting candidate for further
inquiry.
Where the presence of Fc-binding activity in protozoa has been demonstrated,
the factor responsible for Ig binding has only been fully characterised in a
minority of cases. As such, transcriptomic and proteomic databases may not
contain the full extent of known Fc binding proteins. No entry was found for
Babesia caballi antibody binding protein for example despite previous
identification work (Ikadai et al., 2005), and trypanosome peptide sequences
could only be identified by homology to the sequence obtained from L. major
(Campos-Neto et al., 2003). Thus it is possible that sequence similarities
between Acanthamoeba and Ig-binding proteins from other taxa exist but could
not be identified using the methods outlined here.
Evidence from in vitro assays and in silico analysis suggested the presence of
Fc binding protein homologues in A. castellanii. We sought confirmatory in
vitro evidence by probing trophozoites with human Fc fragment and detecting
signal with fluorescent microscopy and FACS analysis. Fluorescent signal was
observed in labelled trophozoites and although faint by comparison to positive
controls (FcR-expressing K562 cells), levels of staining were nevertheless
higher than observed in HBMEC and unlabelled trophozoites (Figure 4.12).
FACS analysis also showed this trend (Figure 4.14) although notably binding
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of secondary antibody was observed for both HBMEC and trophozoites
(Figures 4.13 and 4.14). This in itself is indicative of Fc-binding activity and
accordingly there is evidence to suggest that other endothelial cell types
express FcR (Sedmak et al., 1991, Lyden et al., 2001, Schlachetzki et al., 2002,
Nishimura et al., 2006, Ganesan et al., 2012). With regard to A. castellanii
trophozoites addition of purified Fc fragment did not substantially increase the
observed levels of fluorescence (12.9% as opposed to 11.5%), however the
number and distribution of Fc binding residues on the amoeba cell membrane
are unknown and as such could already be saturated at the antibody
concentrations used in this experiment.
Given the outcome of our in silico analysis it seems unlikely that Fc-binding
activity demonstrated by A. castellanii is the result of proteins with significant
similarity to mammalian Fc receptors. However, homology to Fc binding
proteins from other pathogens was demonstrated by our analysis and low
levels of binding activity could be detected with in vitro assays. Sequence
matches to Fc binding proteins from other protozoa reveal several interesting
candidates for proteins with similar activity in A. castellanii which interact
with antibody classes known to be important in infection. We have also shown
that antibodies including polyclonal antibody derived from immunised mice
are cleaved by amoeba secreted proteases. Near complete loss of heavy and
light chain bands was most apparent in IgA, IgG and IgM (Figures 4.2, 4.4 and
4.6) further underlining the influence of these classes in protection. The
contextual importance of mechanisms for both degradation and capture of
antibody in A. castellanii infections remains to be fully determined. However
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the ability of trophozoites to evade antibody-mediated immunity should be
considered in future studies.
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5. Use of a novel in vitro flow system to elucidate
aspects of host cell death and monolayer disruption
Material from this chapter has previously been published as:
Acanthamoeba interactions with the blood-brain barrier under dynamic fluid
flow. Edwards-Smallbone J, Pleass RJ, Khan NA, Flynn RJ. Experimental
Parasitology 2012 Nov, 132(3).
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5.1. Abstract
The complete mechanism of pathogenesis for blood-brain barrier (BBB)
breach in Acanthamoeba granulomatous encephalitis (AGE) remains unclear.
Here we have developed a novel in vitro BBB infection model under flow
conditions which demonstrates that increases in flow rates lead to decreased
binding of A. castellanii to host cells. This is a distinct departure from
previous findings under static conditions, however similiarly to static
conditions binding of A. castellanii to host cells is host mannose dependent.
Disruption of the host cell monolayer was independent of amoeba binding, but
dependent on secreted serine proteases. Inhibition of host Protease Activated
Receptors produced no significant effect on either host necrotic or apoptotic
cell death. We report the binding dynamics of A. castellanii under
physiological conditions, showing that BBB disruption is not directly linked to
binding, instead it is reliant on secreted proteases. This disruption appears to be
independent of PAR-mediated cell death as observed in other parasitic
protozoa. Our results offer a platform on which modulation of physiological
parameters will improve the accuracy of in vitro models of A. castellanii
infection.
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5.2. Introduction
Penetration of the blood-brain barrier is a key event in the establishment of
AGE and frameworks for understanding how this occurs have been elaborated
by previous authors, revealing contributions from direct binding proteins and
protease secretions (Sissons et al., 2004, Sissons et al., 2006a, Khan and
Siddiqui, 2009). However the scope of these studies is restricted by the use of
static models of Acanthamoeba interaction with the BBB. The brain
microcirculation is a dynamic system and varies significantly in response to
metabolic demands (Ito et al., 2004, Paulson et al., 2010) so without this
context it is likely that current methods do not provide an accurate
representation of infection in vivo.
In light of this an in vitro system with improved physiological relevance was
developed using human brain microvascular endothelial cells (HBMEC)
grown in flow chamber slides and exposed to A. castellanii trophozoites or to
Acanthamoeba conditioned medium (ACM) under flow conditions. Using data
from measurements of cerebral blood flow rate made by Ito and Dörfler
(Lassen, 1985, Dorfler et al., 2000, Ito et al., 2004) flow rates in vitro were
matched to physiological parameters. Pathogenic response was then measured
using published parasite binding and host cell death assays in addition to a new
approach to quantify monolayer disruption as detailed in Chapter 2. These
results were then compared with parallel experiments conducted using standard
static techniques to examine whether the alterations made to in vitro techniques
had produced substantial differences in terms of parasite binding, disruption of
host cell monolayer integrity or host cell death.
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The contribution made by protease secretions to pathogenesis in the flow
model was of particular interest given the findings of previous chapters in
respect of immune targets and evasion through antibody degradation. Previous
experimentation has mainly focused on the degradation of tight-junction
proteins by amoeba proteases however there is evidence from studies in other
pathogenic protozoa that parasite proteases may also play a role in activating
necrotic or apoptotic cell death (Sommer et al., 2005, Nikolskaia et al., 2006a,
Lucas et al., 2008). Protease Activated Receptors (PARs) are one receptor
class which parasites can exploit to induce host cell death, and are known to be
of importance for neural infection in T. brucei (Grab et al., 2009). Although
members of this class of receptor have not been examined as mediators of cell
death in Acanthamoeba infections, the synergy of PARs with intracellular
PI3K signalling in T. b. gambiense infection (Nikolskaia et al., 2006a) could
suggest the involvement of equivalent cell death mechanisms in AGE, given
the upregulation of PI3K in response to A. castellanii infection (Sissons et al.,
2005). The importance of secreted proteases for other mechanisms of BBB
disruption thus made PARs an interesting candidate for examination.
5.3. Materials and Methods
5.3.1. Parasite and Tissue Culture
A. castellanii were grown in PYG media as described in section 2.1.1, with
cultures fed with fresh media 18 hours prior to experiments to maintain >95%
trophozoites. Amoeba were then harvested by chilling on ice and collected in
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RPMI (see section 2.3.1). Acanthamoeba conditioned medium (ACM) was
produced as described in section 2.2.2.
HBMEC were cultured and harvested under conditions as described in sections
2.1.2 and 2.4.1 and used between passages 11-20. 2.5×105 cells from fully
confluent flasks were seeded into 0.2µm chamber slides in standard growth
medium. Media was changed daily to maintain steady growth and HBMEC
reached confluence after 2-4 days.
5.3.2. Flow system
Flow chambers were set up as described in section 2.4.2, alongside 24-well
plates used for comparison with standard techniques (see section 2.4.1). Both
systems were treated with ACM or infected with a suspension of trophozoites
(sections 2.4.3 and 2.4.4) for time points up to 3 hours and monitored for
parasite binding and disruption of the host monolayer as outlined below.
5.3.3. Binding and disruption measurements
Binding was assessed by triplicate counts taken from the stock solution or
tissue culture plate supernatant at time points during, or at the termination of,
the experiment (see section 2.4.3). Counts of the number of unbound amoeba
were converted to the number of adherent amoeba by subtraction from the
initial cell concentration, and expressed as a percentage.
At time points during, or at the conclusion of the experiment, triplicate images
of monolayers were taken using a Leica DMB5000B microscope, using inbuilt
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auto-exposure and white balance settings. Open-source Image J software
(available from http://rsbweb.nih.gov/ij/) was then used to quantify disruption
using the method outlined in section 2.4.4.2.
5.3.4. Exogenous sugar treatment
To test the involvement of sugar residues in binding, amoeba suspensions were
treated with either 50mM D-mannose, 50mM D-glucose, or were left
untreated. Trophozoite suspensions were incubated for 30 minutes at 37°C
prior to initiation of the experiment and then introduced into either the flow or
static test systems.
5.3.5. Protease treatment
ACM was diluted 1 in 2 in RPMI and either treated with 5mM
phenylmethylsulphonyl fluoride (PMSF), a broad-spectrum serine protease
inhibitor or left untreated. A concentration of 5mM was selected as a midpoint
between concentrations used by Khan et al. (2000b) and Ferreira et al. (2009) .
Prior to the experiment, media was left to incubate for 90 minutes at 37°C to
minimise the effect of active PMSF on cells. ACM was then circulated through
the flow system or added to static plates in place of amoeba suspension.
PMSF-treated RPMI was used as a control.
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5.3.6. PAR inhibitor treatment
The role of PARs in Acanthamoeba-mediated host cell death was investigated
by application of specific PAR1 and PAR4 inhibitors as described in section
2.4.8.
5.3.7. Cell death assays
HBMEC were monitored for both necrotic and apoptotic cell death, by lactate
dehydrogenase (LDH) release and TdT-mediated dUTP Nick-End Labelling
(TUNEL) assays respectively. Methodology for both assays is described in
detail in sections 2.4.5 and 2.4.9.
5.3.8. Statistical analysis
Analyses were performed using GraphPad Prism software version 5.04. Data
was analysed using 1-way ANOVA for comparisons of individual treatment
groups and 2-way ANOVA where treatment groups were subdivided, for
example where there were measures from multiple time points. Significance
levels for individual groups were determined using Bonferroni post-tests for
each treatment versus a control, or individual comparisons of all treatments.
Where data appeared to follow a line or curve this was analysed using
Regression models and the R2 goodness-of-fit value given. The alpha level for
significance was set at p ≤ 0.05 for all tests (see section 2.10).
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5.4. Results
5.4.1. Seeding density optimisation
HBMEC were seeded into 0.2µm Luer microslides and allowed to grow to
confluence over a period of several days. Confluence estimates and
approximate counts per field of view were made daily up to 7 days. An
optimal seeding density of 5×106 cells/ml (2.5×105 individual cells per slide)
produced confluence after three days. Higher seeding densities proved
inhibitory to monolayer formation as cells stacked on top of one another and
failed to adhere to the slide (Figure 5.1).
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Figure 5.1 Optimisation of HBMEC seeding density with respect to confluence
2.5×105 cells produce a confluent monolayer after an optimal growth period of three days.
Excessive seeding density inhibits monolayer formation (bracketed value on graph).
5.4.2. Calibration of pump flow rate settings
The flow system was set up without the inclusion of a chamber slide, to
monitor flow rates achieved by each pump speed setting. RPMI was allowed to
pass through the pump at various speed settings and the volume of outflow
recorded. Prior measurements of cerebral blood flow rate per gram of tissue
(Lassen, 1985, Dorfler et al., 2000, Ito et al., 2004) fell within the dynamic
range of the pump and we calculated our flow rate based on these findings
(Figure 5.2). This yielded a rate of approximately 25µl per minute for 0.05g of
tissue and permitted replication of flow rates for up to 2g of neural tissue (box-
out).
5(10
(Lass0݉ /݈݉ ݅݊
CBF ≈ 50ml/min for 100g of tissueen 1985, Dorfler et al. 2000, Ito et al. 2004)
Mass of tissue in chamber = 0.05g195
0 ÷ 0.05) = 0.025݉ /݈݉ ݅݊ = 25µ /݈݉ ݅݊
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Figure 5.2 Calibration of pump flow rate settings.
The equation of the line of best fit (dashed line) was used to obtain flow rates (µl/min) for each
setting (y = 95x). Results are mean ± S.E.M. of three independent experiments.
5.4.3. HBMEC retain monolayer characteristics under flow conditions
Flow slides seeded at optimal density and grown to confluence were attached
to a peristaltic pump and incubated with warmed RPMI 1640 at a flow rate of
950µl/minute. Cells were examined microscopically every 15 minutes for 2
hours. HBMEC showed no visible alteration in morphology or monolayer
integrity over this time (Figure 5.3).
Figure 5.3 HBMEC monolayer morphology remains unaltered under flow
Images taken after (
morphology or monolayer integrity. Images were taken under ×100 magnification, scale bar =
100µm.
5.4.4. Substantial reductions in
conditions compared with static conditions
Measurements of binding were taken every 30 minutes for three hours using a
minimal flow rate of
from static plates (Figure
between static
way ANOVA).
time point and so this was set as the experimental period for subse
experiments. The effect of flow rate on binding by amoeba was then
investigated within a range of 30 to 9
in percentage binding were seen between static and flow conditi
1-way ANOVA)
and lowest flow rates (30 vs. 9
inversely correlated with flow rate. Furthermore the data conformed strongly to
A) 0 minutes, (B) 60 minutes, (C) 120 minutes. No alteration was seen in
amoeba binding are seen under flow
30µl/min, and compared with similar measurements taken
5.4 panel A). Significant differences were seen
and flow conditions at each time point measured (p<0.001, 2
Binding in static plates approached a plateau
50µl/min. Highly significant differences
. Significant differences were also seen between the highest
50µl/min) suggesting that amoeba binding is
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.
-
at the three hour
quent
ons (p<0.001,
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a fitted exponential decay model (R2 = 0.9105, one-phase decay), (Figure 5.4
panel B). Using these results and those from the flow rate calibration in section
5.4.2, a single flow rate of 95µl/min was set for use in further experiments.
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Figure 5.4 Binding of trophozoites to HBMEC is affected by flow rate.
(A) 2×105/ml Acanthamoeba trophozoites were added to HBMEC monolayers in either static
plates (white bars) or flow chamber slides (black bars) and measurements of binding taken
every thirty minutes for up to three hours. A flow rate of 95µl/min was used for flow
treatments. Significant differences between static and flow were seen at each time point (***
p<0.001, 2-way ANOVA). Results are mean + S.E.M. of triplicate counts from two
independent experiments. (B) 2×105/ml A. castellanii trophozoites were flowed over confluent
HBMEC monolayers in microslides at a range of flow rates, including a zero rate obtained
from static plates. Measurements of binding were taken after three hours. Significant
differences were observed at the two lowest flow rates (*** p<0.001, * p<0.05, 1-way
ANOVA). Data conformed closely to an exponential decay regression model (R2 = 0.91).
Results are mean + S.E.M. of triplicate counts from three independent experiments.
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5.4.5. Exogenous mannose ameliorates binding under both static and
flow conditions
A major surface mannose-binding protein (MBP) has been previously
identified in Acanthamoeba and strongly implicated in endothelial cell
attachment and BBB pathology (Garate et al., 2006b). We therefore tested the
involvement of MBP in our modified in vitro model. Amoeba suspensions
were treated with either 50mM mannose, 50mM glucose, or left untreated and
their capacity for binding measured as before (Figure 5.5). The data confirmed
that exogenous mannose significantly inhibits attachment to HBMEC in static
conditions, whilst under a low flow rate significant decreases in binding were
also observed (p<0.0001, 1-way ANOVA). However, the proportion of
binding that was inhibited by mannose was greater under flow; a reduction of
62.5% (S.D. ±13.1) as opposed to 29.4% (S.D. ±8.6) in static treatments.
Glucose treatment produced no alteration in binding capacity under either
static or flow conditions (p>0.05 by Bonferroni Multiple Comparison Test).
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Figure 5.5 Binding of trophozoites to HBMEC is MBP-dependent.
2×105/ml Acanthamoeba trophozoites in RPMI containing 50mM mannose (Man), 50mM
glucose (Glu), or left untreated (N.T.) were passed over confluent HBMEC monolayers in
microslides at a flow rate of approximately 95ul/min, or added to static culture. Measurements
of binding were taken after three hours. Overall, means differed significantly from each other
(** p<0.001, 1-way ANOVA), and the effect of flow on all samples was also highly
significant. A significant reduction in binding was observed in mannose treated samples under
both static and flow conditions (** p<0.01, * p<0.05, 1-way ANOVA). The effect of glucose
treatment was not significant. Results are mean + S.E.M of triplicate counts from three
independent experiments.
5.4.6. Monolayer disruption by trophozoites remains constant over a
range of flow rates
Given the interaction between flow rate and trophozoites’ ability to bind to
HBMEC, we were interested to investigate whether differences in monolayer
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disruption by amoeba were related to flow rate. Images of HBMEC
monolayers taken during binding experiments were analysed for monolayer
disruption by a grid counting method. Analysis found no significant difference
between percentage monolayer disruption over a range of flow rates including
static conditions (p=0.128, 1-way ANOVA) (Figure 5.6) This is surprising
given the model of binding established in earlier experiments which indicates
maximal binding at the lower end of the range.
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Figure 5.6 Monolayer disruption by trophozoites is unaffected by flow rate.
2×105/ml Acanthamoeba trophozoites were flowed over confluent HBMEC monolayers in
flow chamber slides at a range of flow rates, including a zero rate obtained from static plates.
Triplicate images were taken after three hours and percentage monolayer disruption estimated
using a grid counting method (section 2.11). There was no significant difference between flow
rates (p=0.13, 1-way ANOVA). Results are mean + S.E.M of triplicate measurements from
three independent experiments.
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5.4.7. Acanthamoeba conditioned medium causes equal disruption in both
static and flow conditions
Acanthamoeba have been previously found to secrete a variety of proteases,
which are implicated in blood-brain barrier disruption (Hadas and Mazur,
1993, Alsam et al., 2005b). Given findings which suggested there is no
relationship between binding and monolayer disruption under flow conditions
(section 5.4.6), we tested the effect of ACM alone in our model. 1 in 2
dilutions of ACM were made in RPMI and added to either static plates, or
circulated through flow chamber slides. Triplicate images were taken every
thirty minutes for three hours, and counted as before. Notably when images
were analysed there was no significant difference between monolayer
disruption under flow and static conditions, nor any significant differences
between flow rates (p=0.69, linear regression) (Figure 5.7).
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Figure 5.7 Monolayer disruption by ACM is constant over a range of flow rates.
1:2 dilutions of Acanthamoeba conditioned medium (ACM) were flowed over confluent
HBMEC monolayers in flow chamber slides at a range of flow rates, including a zero rate
obtained from static plates. Percentage monolayer disruption was estimated using a grid
counting method (section 2.11). Again there was no significant difference between flow rates
(p= 0.69, linear regression). Results are mean ± S.E.M. of triplicate measurements from three
independent experiments. Regression line is displayed.
5.4.8. Protease inhibition alters the effects of ACM under static and flow
conditions
Of the protease secretions made by Acanthamoeba, serine proteases are
thought to be the major contributor to loss of BBB integrity. We investigated
the contribution of serine protease to monolayer disruption in both static and
flow conditions using PMSF, a broad-spectrum serine protease inhibitor
(Figure 5.8). PMSF treatment produced highly significant reductions in
monolayer disruption in both static and flow conditions (p<0.0001, 1-way
ANOVA), reducing disruption to levels equivalent with control treatments,
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however no significant differences between static or flow conditions were seen
for untreated ACM. As with uninhibited ACM treatments there was no
statistically significant difference between static or flow conditions for either
PMSF-treated ACM or treatment controls (p>0.05, Bonferroni Multiple
Comparison test).
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Figure 5.8 Protease inhibition alters the effects of ACM under static and flow conditions.
1:2 dilutions of ACM treated with 5mM PMSF, left untreated, or RPMI controls were passed
over confluent HBMEC monolayers under flow conditions (95µl/min) or added to static plates.
Monolayer disruption was estimated using a grid counting method as before. Highly
significant differences were observed between PMSF-treated and untreated ACM
(****p<0.0001, 1-way ANOVA), however there was no significant difference between ACM
treatments under flow compared with static conditions. Results are mean + S.E.M. of triplicate
measurements from three independent experiments.
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5.4.9. Treatment with PAR inhibitors has no effect on the disruption of
host cell monolayer
PARs have been implicated as a protease-mediated cell death mechanism in
other parasitic infections. We selected PAR1 and PAR4 for study on the basis
of previous reports which have identified these receptors in HBMEC (Kim et
al., 2004). Selective inhibitors were used to investigate the role played by these
molecules in A. castellanii infections. HBMEC cell monolayers were prepared
in 24-well plates and treated with SCH 79797 dihydrochloride, a PAR1
inhibitor or tcY-NH2, a PAR4 inhibitor. Plates were then infected with either
ACM or trophozoites for up to 18 hours and processed for monolayer
disruption analysis.
5.4.10. Monolayer protection - staining
24-well plates were fixed after 18 hours and stained with Harris’ Haematoxylin
to assess monolayer disruption visually. PAR inhibitor treated wells displayed
qualitatively similar levels of monolayer staining to untreated ACM and
trophozoites, and substantially lower levels of staining than were seen in
negative control wells (RPMI-treated).
Figure 5.9 PAR inhibitor treatment does not protect HBMEC mono
As assessed by haematoxylin staining. Cells
trophozoites (B) and fixed/stained after 18 hours. Results are representative of two
independent experiments.
5.4.11. Monolayer protection
After 3 hours of the experimental period, micrographs of treated and infected
monolayers were taken and analysed by grid counting.
significant reduction in monolayer disruption in any of the treatment groups
when compared with positive controls of either u
trophozoites. Negative controls treated only with RPMI exhibited no
appreciable level of monolayer disruption.
were infected with ACM (
- photomicrographs
ntreated ACM or
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Figure 5.10 PAR inhibitor treatment does not significantly reduce host cell monolayer
disruption.
Cells were infected with ACM (A), or 2×105/ml trophozoites (B), photographed after 3 hours
and monolayer disruption estimated semi-quantitatively. Results are mean + S.E.M. of
triplicate measurements from two independent experiments. Treatment groups did not differ
significantly from positive controls (ACM or trophozoites) (p>0.05, 1-way ANOVA).
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5.4.12. Treatment with PAR inhibitors has no effect on LDH release as a
marker of necrotic cell death
HBMEC cultures were infected with ACM or trophozoites and treated with
PAR inhibitors at concentrations from 0.001 to 1000nM. After 24 hours
supernatants were collected and tested for release of lactate dehydrogenase and
compared with levels obtained from controls. Results indicated only low levels
of LDH release in ACM treated samples, whilst higher levels were detected in
trophozoite treatments. However, addition of PAR inhibitors produced no
significant differences in either case, with no treatment concentration differing
from positive control samples.
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Figure 5.11 PAR inhibitor treatment has no significant effect on LDH release.
Cells were infected with ACM (A), or 2×105/ml trophozoites (B), treated with a range of PAR
inhibitor concentrations for 24 hours and examined for release of LDH. Results are mean ±
S.E.M. of triplicate measurements from two independent experiments. Treatment groups did
not differ significantly from each other or positive control samples (p >0.05, 1-way ANOVA).
The dashed line denotes percentage cell death in positive control wells, treated with either
ACM or trophozoites.
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5.4.13. Treatment with PAR inhibitors has no effect on numbers of
TUNEL +ve HBMEC, used as a marker of apoptotic cell death
Cultures of HBMEC were infected with either ACM or trophozoites and
treated with PAR inhibitors. Samples were then transferred to microscope
slides by cytospin and stained for nuclear fragmentation by TUNEL.
5.4.14. Imaging
Samples were photographed using a fluorescent microscope as described in
section 2.4.9, with green fluorescence denoting cells positive for nuclear
fragmentation, a marker for apoptotic cell death. TUNEL positive cells were
observed in all samples except negative control HBMEC, however numbers of
apoptotic cells were consistent across all inhibitors, solvent controls and
untreated samples for both ACM exposure and trophozoite infections. An
increase in apoptotic cell number was only observed in cultures treated with
cisplatin, a known inducer of apoptosis.
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Figure 5.12 PAR inhibitor treatment has no effect on gross levels of host cell apoptosis.
HBMEC were treated with PAR inhibitors and infected with ACM or trophozoites, fixed,
stained by TUNEL and counterstained with DAPI. Green fluorescence indicates TUNEL +ve
nuclei, blue fluorescence indicates TUNEL –ve nuclei. (A) 50µM cisplatin, (B) untreated
HBMEC, (C) SCH 79797/ACM, (D) SCH 79797 solvent control/ACM, (E) tcY-NH2/ACM,
(F) tcY-NH2 solvent control/ACM, (G) SCH 79797/trophozoites, (H) SCH 79797 solvent
control/trophozoites, (I) tcY-NH2/trophozoites, (J) tcY-NH2 solvent control/trophozoites.
Images are representative of two independent experiments. Images are ×200 magnification, bar
= 50µm.
5.4.15. Counts
Fluorescence microscopy images from ACM-treated samples were additionally
analysed by counting the number of TUNEL positive HBMEC visible in five
fields of view under ×200 magnification, using the green (FITC) fluorescence
channel. PAR treatments produced no significant alteration in the number of
TUNEL +ve cells observed, with only cisplatin treated positive controls
showing a significant difference to any of the other treatment groups.
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Figure 5.13 PAR inhibitor treatment does not alter the number of TUNEL +ve cells.
Counts of positive cells in five fields of view were made from individual slides stained by
TUNEL. Cisplatin treatment demonstrated significantly higher levels of TUNEL +ve cells
compared to other treatments (*** p<0.001) however all other comparisons were not
statistically significant (p>0.05 1-way ANOVA). Results are mean + S.E.M. of five replicates
from two independent experiments.
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5.5. Discussion
Static culture systems for determining the adherence of Acanthamoeba to
HBMEC are well established in the literature and have been used with great
success to elucidate many important aspects of AGE pathogenesis (Sissons et
al., 2004, Sissons et al., 2006a, Khan and Siddiqui, 2009). However in many
cases in vitro findings have proved confusing when placed into a wider
context. Levels of trophozoite binding are typically high in vitro (Alsam et al.,
2003, Khan and Siddiqui, 2009); however the confinement of the disease
largely to individuals with underlying immune deficiencies suggests that
Acanthamoeba is a comparatively inefficient/low virulence pathogen. The
discrepancy between in vitro findings and the in vivo condition is in a sense
unsurprising; the brain microcirculation is a dynamic system in which any
pathogen must contend with physical forces in order both to adhere and remain
bound (Chen and Springer, 2001, Mairey et al., 2006, Zhang et al., 2009).
Therefore static culture systems are not truly representative of the dynamics of
binding, and so provide an incomplete picture of Acanthamoeba pathogenesis.
The limitations of static cultures in general as an effective model of the brain
microvasculature are increasingly recognised and as a result many groups have
added increasing levels of sophistication to their in vitro models. Two major
approaches have been taken aiming either to produce more accurate
representations of the structure of the blood-brain barrier (BBB), or more
accurate modelling of the physical forces and conditions experienced in brain
microcapillaries. The former approach incorporates not only endothelial cells
but other cell types in the BBB architecture: pericytes and astrocytes. Pericytes
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have important regulatory functions within the BBB (Armulik et al., 2010)
however in vitro methods have typically used Transwell co-cultures of
endothelium and astrocytes to induce or enhance barrier function. Astrocytes
in particular have been shown to enhance the barrier properties of the
endothelium and produce measurements of trans-endothelial electrical
resistance (TEER) which are closer to those seen in vivo when either cells or
only a cell-conditioned medium are present (Janzer and Raff, 1987, Sobue et
al., 1999, Hayashi et al., 1997). Transwell co-culture models of this sort are
advantageous in having only simple technical requirements and being
amenable for use in high-throughput screening, however for examining
parameters such as parasite binding they possess the same discrepancies with
the in vivo condition as simple static cultures.
In order to study these dynamic effects the addition of fluid flow is necessary.
Typical methodologies apply flow to endothelial cells cultured in sterile
chambers, and then monitor the properties of the cells themselves or
adhesion/other parameters relating to a second cell type in suspension
(Lawrence and Springer, 1991, Chen and Springer, 2001, Cucullo et al., 2002,
Grab et al., 2004). As a representation of the physical microenvironment this
approach has considerable advantages. There is evidence to suggest that the
effect of local physical forces can act to enhance BBB integrity by
upregulation of tight junction proteins (Santaguida et al., 2006, Siddharthan et
al., 2007) and the inclusion of flow can help to eliminate passive and
nonspecific effects caused by cells ‘settling out’ in static culture.
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The distinct advantages of both approaches have driven the development of
ever more sophisticated experimental methods incorporating co- and multi-
cultures into flow environments (Booth and Kim, 2012, Griep et al., 2012),
however expense and complex technical requirements mean these are for the
moment impractical for use in every research setting. In light of this we sought
to improve the accuracy of current in vitro models of binding and pathogenesis
in AGE by using a flow system with rates comparable to physiological
conditions. Cerebral blood flow rate (CBF) has been measured by numerous
authors employing a variety of methodologies, and typically falls in a range of
40-50ml/100g/min (Lassen, 1985, Dorfler et al., 2000, Okazawa et al., 2001,
Ito et al., 2004). We calculated our flow rate based on these findings for the
mass of cells grown in flow chambers, yielding a rate of approximately 25µl
per minute, for 0.05g of tissue or cell mass and permitting us to replicate flow
rates for up to 2g of neural tissue.
The contention that our model differs substantially from previous static
systems is supported by our findings that even low rates of flow significantly
reduce the ability of amoeba to adhere to host cells (Figure 5.4 B). This effect
increases with increasing flow rate, although seeming to approach a plateau at
the upper end of the tested range, conforming strongly to an exponential decay
curve (Figure 5.4). At low flow rates therefore relatively small alterations may
have a proportionally greater effect upon binding than they do at higher flow
rates. Capillary microvessels have long been thought to be the site of invasion
in AGE, due to their narrow width and the presence of only a single
endothelial cell layer. Blood flow rates are known to be heterogeneous across
neural tissue and capillaries in particular may only be transiently perfused,
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with flow rates intermittently trending towards zero (Hertz and Paulson, 1980,
Hudetz, 1997, Zhang et al., 2009). Such low-flow conditions produced
significantly increased binding in our model, implicating flow rate as a major
contributory factor to invasion.
Notably, several studies have indicated that cerebral blood flow rates are
lowered by up to 10ml/min in HIV+ patients and that this is the case both early
and later in the infection process (Ances et al., 2009, Ances et al., 2011). This
is significant due to the association between AGE and AIDS and our results
which indicate that low flow rates correlate with increased trophozoite binding
to endothelial cells. The clinical implications of this are that as well as AIDS
patients, pre-AIDS HIV+ patients may also be at heightened risk of developing
AGE due to increased trophozoite binding in the brain microvasculature. This
is important for monitoring and treatment of vulnerable patients and also has
relevance to other underlying conditions where lowered CBF might cause
patients to be at increased risk. The physical properties of our flow system may
also apply to other parasitic CNS infections in terms of the increased
vulnerability of patients with lowered CBF. This may be an interesting avenue
to be pursued in future studies.
Given the differences observed between static and flow conditions we were
interested to assess whether the contributions of amoeba adhesins to binding
also differed from previous reports, when under flow. The major adhesin to
have been identified is a mannose-binding protein (MBP) that is thought to be
responsible for the majority of binding (Cao et al., 1998, Hurt et al., 2003b,
Garate et al., 2004, Imbert-Bouyer et al., 2004, Garate et al., 2005, Garate et
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al., 2006b). Our findings provide further evidence for the importance of MBP,
showing that exogenous mannose significantly reduces binding in both static
and dynamic systems (Figure 5.5). Moreover mannose treatment seemingly
causes a greater proportional decrease in binding under flow conditions, up to
twofold (Figure 5.5, section 5.4.5). Once again this suggests that the in vivo
condition has not been accurately represented by standard static culture
systems and whilst the existence of a second mannose-independent adhesin has
been proposed (Kennett et al., 1999), our study showed that any mannose-
independent subset of binding may not be the primary means of active binding
in vivo.
Whilst adhesion (particularly mannose-mediated) is an important step in
initiating AGE it is not the sole factor that merits consideration. Many
Acanthamoeba genotypes secrete proteolytic enzymes which may play
important roles in pathogenesis (Khan et al., 2000b, Alsam et al., 2005b)
however the response of endothelial cells to these protease secretions has not
been studied under flow conditions. We used a method based on counting grid
squares superimposed over photomicrographs to estimate the degree of
monolayer disruption, as a marker for loss of blood-brain barrier integrity.
Using this method we initially analysed images of adherent trophozoites to
assess the degree to which binding affects monolayer disruption. Interestingly,
given the wide variation seen in binding over a range of flow rates there was
no significant difference in the extent of monolayer disruption (Figure 5.6).
This null relationship was particularly evident at low flow rates and under
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static conditions, where high levels of adherence had been observed but levels
of monolayer disruption did not show any significant differences.
This raises the possibility of a decoupling of binding and BBB pathology and
to investigate this further we made use of a cell free conditioned supernatant
(ACM). This contains a number of secreted proteases which have been shown
to break down tight junctions in vitro, leading to a loss of integrity in the
blood-brain barrier (Alsam et al., 2005b, Kim et al., 2006, Sissons et al.,
2006a, Khan and Siddiqui, 2009). Testing ACM in our flow model revealed
that monolayer integrity is affected by the presence of secreted proteases under
both static and flow conditions (Figure 5.7) however we once more found that
flow is not a significant contributory factor, as disruption occurs at a constant
level irrespective of rate. The main driving forces behind BBB disruption are
thought to be serine proteases, with other secreted molecules playing a
complementary role (Alsam et al., 2005b, Sissons et al., 2006a, Alizadeh et al.,
2008). Our experiments suggest that this holds true for flow as well as for
static conditions, with PMSF treatment able to reduce the degree of disruption
to levels indistinguishable from untreated controls (figure 5.8). Given these
significant reductions and the apparently minimal contribution of trophozoite
adherence it is tempting to infer that the greater part of the mechanism of BBB
disruption occurring under flow conditions is serine protease dependent.
One mechanism by which proteases are known to have effects on the integrity
of the BBB is through the action of a class of G-protein coupled receptors
known as Protease Activated Receptors (PARs). These are expressed on
endothelial cells where they act in consort with thrombin to promote
221
haemostasis and inflammation (Kataoka et al., 2003, Gudmundsdottir et al.,
2008, Gudmundsdottir et al., 2006). PARs have also been implicated in
parasitic disease (Yang et al., 2009, Park et al., 2011) and notably blood-brain
barrier traversal (Grab et al., 2009). Nikolskaia et al. demonstrated that
Trypanosoma brucei proteases were responsible for activation by cleavage of
these molecules, leading to intracellular signalling and host cell death by
apoptosis.
General induction of apoptotic cell death has been reported in a wide range of
parasitic protozoa including Plasmodium falciparum, Toxoplasma gondii,
Cryptosporidium parvum, Trypanosoma cruzi and Trypanosoma brucei (Lopes
et al., 1995, Toure-Balde et al., 1996, McCole et al., 2000, Nishikawa et al.,
2002, Wei et al., 2002, Stiles et al., 2004, Wilson et al., 2008). In a number of
cases this process has been linked to protein secretions and more specifically to
cysteine proteases, especially in groups of large extracellular protozoa such as
trypanosomatids and trichomonads (Lucas et al., 2008, Sommer et al., 2005,
Grab et al., 2009). Extensive cysteine protease secretions have also been
observed in Entamoeba histolytica although they have not yet been definitively
linked with host apoptotic cell death (Hirata et al., 2007, Becker et al., 2010).
Indeed for the majority of protozoan pathogens the host mechanisms inducing
cell death have not been fully determined although evidence from E.
histolytica and Giardia intestinalis suggests that pro-apoptotic enzymes
caspases 8, 9 and 3 play a substantial role (Huston et al., 2000, Kim et al.,
2007, Panaro et al., 2007). As with A. castellanii however the relative
importance of secreted versus nonsecreted virulence factors and the
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necrotic/apoptotic balance is debated (Berninghausen and Leippe, 1997,
Seydel and Stanley, 1998, Huston et al., 2000).
Given the widespread expression of proteases as virulence factors and the role
played by PARs in linking secreted proteases to apoptotic cell death in T.
brucei (Nikolskaia et al., 2006a, Grab et al., 2009), we sought to determine
whether a similar mechanism might contribute to BBB penetration in AGE.
PAR1 and PAR4 were selected for study from receptors previously identified
in HBMEC (Kim et al., 2004). Our intention was to conduct a brief initial
investigation of PARs in A. castellanii pathogenesis and to examine whether
global PAR activation contributes to monolayer disruption and cell death. As
such our experiments did not include other receptors which may also
contribute to endothelial injury by similar mechanisms, such as PAR2.
We treated cells with specific PAR antagonists during in vitro infections with
trophozoites or ACM. Outcomes of infection (i.e. cell death) were studied in
terms of apoptotic (Figures 5.12 and 5.13) and necrotic (Figure 5.11)
mechanisms, as well as measures of gross pathology such as monolayer
disruption (Figure 5.9 and 5.10). However the presence of PAR inhibitors did
not make any significant difference to the outcome of infection in either case.
It is reasonable to conclude therefore that HBMEC cell death in AGE does not
proceed by PAR1 and/or PAR4 activation. Nevertheless this is not sufficient
evidence to rule out a possible contribution by other PAR classes, in particular
PAR2 which is known to be expressed on endothelial cells and has been
implicated in BBB traversal by T. brucei (Grab et al., 2009). Future
examination of this, and other PAR classes will be required in order to rule out
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or confirm direct PAR activation as a contributory factor to AGE. Our data
suggests however that any such activation is not global and must either be
specific to individual PAR classes or result from the action of endogenous host
PAR activators.
Discounting a contribution from PARs, tight junction (TJ) proteins appear to
be one candidate for the molecular target of secreted proteases as elucidated
from experiments with the standard static model (Khan and Siddiqui, 2009).
These proteins are of critical importance in maintaining the integrity of the
BBB and interestingly there is evidence to suggest that loss of TJs may result
in cells entering apoptosis (Beeman et al., 2012). A. castellanii proteases have
also been demonstrated to degrade components of the extracellular matrix
(ECM) (Sissons et al., 2006a, Rocha-Azevedo et al., 2009a, Rocha-Azevedo et
al., 2009b). These, via integrins, are important in rescuing cells from otherwise
entering apoptosis (Frisch and Francis, 1994, Bates et al., 1994). It is therefore
possible that cell death processes caused by the degradation of TJs, ECM and
potentially integrin may contribute to pathology in AGE. Kumar et al. have
suggested a similar mechanism contributes to E. histolytica gut pathology
where the process is mediated by secreted cysteine proteases (Kumar et al.,
2012). Direct evidence to support this conjecture is not provided by our work
however, and substantial additional experiments are required if this hypothesis
is to be upheld.
In consideration of the contribution of blood flow rate to pathogenesis, if the
paradigm of TJs and/or ECM/integrins as the major molecular target for
proteases holds true under flow conditions then the process of tight junction
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degradation may be ruled solely by enzyme-substrate kinetics, independently
from trophozoite binding. In this scenario flow rate may not make a substantial
contribution until cells are detached from each other or their substrate. It is at
this point that cells are then swept away by the action of flow. This may
explain why levels of disruption appear relatively constant in our model,
especially if physical forces or timeframes in excess of those we have used are
required to fully detach cells.
Taking our findings as they stand binding appears to have little connection to
monolayer disruption, however there is ample evidence that trophozoites are
able to induce BBB perturbations and that binding may induce Acanthamoeba
to upregulate protease production (Cao et al., 1998, Alsam et al., 2003, Hurt et
al., 2003a, Khan and Siddiqui, 2009). Adherence is also thought to induce
apoptosis in HBMEC and this could prove to be an additional contributory
factor to pathogenesis (Alizadeh et al., 1994, Mattana et al., 2001, Mattana et
al., 2002, Zheng et al., 2004, Sissons et al., 2005). A further factor to consider
is that over longer timeframes adherent trophozoites may begin to replicate,
increasing the disruptive effect upon the BBB. If this is the case then a
colonisation phase may precede invasion and thus pathology may correlate
with amoeba population growth. Apoptotic processes are likely to occur at a
slower rate than protease-dependent perturbations however and thus they may
not be relevant during the initial stages of infection which our model
represents. The significance of host cell death during the later stages of host-
parasite interactions remains an important issue to be addressed in future
studies.
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6. General Discussion
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Throughout this study we have examined the immunology and pathogenesis of
the haematogenous stage of AGE. Our experiments focus in particular on
events occurring in the brain microvasculature, within the context of host
antibody and the local environment of endothelial cells. Data previously
collected concerning this aspect of AGE pathogenesis is sparse and has not
considered the role that humoral immunity may play in preventing initiation of
disease in healthy individuals.
Our data shows the isolation and functional analysis of a polyclonal antibody
(HE2) derived in vivo, including elucidation of the antigenic targets of this
antibody. Analysis of HE2 function in vitro revealed an ability to limit
trophozoite adhesion to HBMEC alongside a similar effect observed with an
isotype control. Binding inhibition did not however translate into a protective
phenotype by measures of cell death and monolayer disruption. This suggests
two major findings: 1) that binding plays a less crucial role in pathogenesis
than had previously been thought; and 2) that trophozoites may possess
multiple means to interfere with normal antibody function. This first
conclusion is supported by results from a novel in vitro flow model of disease,
whilst our second conclusion is supported by our in vitro and in silico analysis
and comparisons across other parasite models.
Both protozoa and helminths have been shown to evade the action of the
humoral immune response by both sequestration and degradation of antibody.
Our evaluation of these two mechanisms confirmed previous reports of
antibody cleavage by A. castellanii and additionally suggested that amoebae,
like some other protozoa, exhibit a low level of Fc-binding activity. We
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investigated the dynamics of amoeba/host interaction in brain microcapillaries
by adapting the standard in vitro model to incorporate the effect of blood flow,
resulting in substantial reductions in the ability of trophozoites to bind to
endothelial cells. Two important mediators of pathogenesis, mannose-binding
protein and serine proteases behaved as previously described in this system.
However results reveal a disconnection between the number of trophozoites
binding to endothelial cells and the extent of both host cell death and the
disruption observed in the cell monolayer. In light of these findings we have
proposed several modifications to the current concept of AGE pathogenesis
and suggest that adoption of more refined in vitro techniques may produce a
more thorough understanding of this life-threatening infection.
In examining AGE it is important to consider the context in which the disease
occurs, predominantly where the host immune system is compromised. The
underlying cause of immune deficiency may be due to a number of factors.
Deliberate suppression of the immune response, for example during organ
transplant or as a result of chemotherapy can leave patients at increased risk of
infection (Duarte et al., 2006, Mutreja et al., 2007). Underlying states affecting
immunity such as alcoholism, malnutrition, primary immune deficiency, or
infection also heighten risk. The severe immune deficiencies resulting from
HIV infection in particular are thought to be a strong predisposing factor in the
development of AGE (Rosenberg and Morgan, 2001, MacLean et al., 2007).
HIV infection causes a progressive loss in lymphocyte function leading to
severe immune deficiencies, with the individual typically succumbing to
opportunistic infections. Loss of B-cell and CD4+ T-cell function is debilitating
to humoral immunity as these cell types have critical roles in antibody
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production. Plasma cells differentiated from B-cells synthesise antibody
specific to invading microbes and are the source for antibodies of a given class
and with affinity-matured antigen specificity. CD4+ T-cells play a crucial role
in initiating and regulating this process by co-stimulation of B-cells in the
context of APC and secretion of the stimulatory cytokines IL-2, IL-4, IL-5,
IFNγ, and TGFβ. In AIDS the humoral response, its associated effector
functions, and acquired immunological memory are seriously impaired and so
even commonly encountered microbes can re-emerge as a threat to the
individual.
The ubiquity of A. castellanii is demonstrated by the large proportion of
healthy individuals who display seroconversion (Chappell et al., 2001);
however the role antibody plays in controlling infection and the antigens that
initiate immunity in healthy individuals are not known. We addressed these
areas by generating antibody experimentally.
Our panel of antibodies yielded a number of colonies positive for IgG and IgM
classes (Figure 3.2), in support of observations from previous studies (Kennett
et al., 1999, Leher et al., 1999, Turner et al., 2005). Whilst a number of the
antibodies produced during these earlier studies were reactive only against the
amoeba’s encysted form, antibody screened during our experiments reacted
strongly with trophozoites (Figure 3.4). This is of greater benefit in assisting
our understanding of factors expressed by the active, proliferating cell and
therefore those which are likely to be of importance during BBB penetration.
Nevertheless when translated into an in vitro model system the ultimate
protective effect of antibody on host endothelial cells was minimal. This raises
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interesting questions regarding the role being filled by antibody during
infection and parasite evasion strategies specific to host antibody.
Studies of the intestinal amoeba E. histolytica have revealed that secretory IgA
at the gut mucosa acts to inhibit trophozoite binding by targeting surface
adhesion factors (Haque et al., 2001, Abd-Alla et al., 2006). One of these
(Gal/GalNAc) is a lectin, a class of sugar-binding proteins of which a member
has also been identified in Acanthamoeba - MBP (Garate et al., 2006b). A
small reduction in binding of trophozoites to endothelial cells was prompted by
antibody treatment in our experiments and this could indicate a role for
antibody in limiting adhesion by targeting amoeba binding proteins (Figures
3.10 and 4.8). This hypothesis seems especially attractive given the
localisation of HE2 immunofluorescent staining to the cell membrane (Figure
3.8). However the loss in binding capacity as a result of antibody treatment
was low in our experiments when compared with similar studies and when
compared with the reduction seen when trophozoites are treated solely with
mannose. Furthermore, MBP was not identified as a target antigen of HE2,
although polyclonal supernatant showed diffuse staining in the molecular
weight range of single MBP subunits. HE2 represents only a single hybridoma
from a range of those generated and so it is possible that protective anti-MBP
activity may lie with other hybridoma clones. Nevertheless of the hybridoma
lines generated and tested, HE2 demonstrated the greatest ability to inhibit
trophozoite binding (Figure 3.6). Therefore if in vivo protective immunity to A.
castellanii is mediated by an adhesin-specific antibody it is unlikely to be one
which was detected in our study.
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One point that is worthy of consideration is that fact that all previous attempts
to classify the effect of antibody on adhesion of A. castellanii trophozoites
have used static (standard tissue culture or Transwell) model systems (Leher et
al., 1998a, Kennett et al., 1999). We have presented evidence which
demonstrates that using an in vitro flow system substantially reduces the
ability of trophozoites to adhere to microvascular endothelial cells (Figure 5.4).
Separately we have also shown that binding is reduced in the presence of
antibody in a static culture system (Figure 4.8). Due to time and resource
constraints we did not explore these two effects in combination; however we
predict that a synergistic interaction would reduce binding to minimal levels.
Testing this hypothesis is suggested as a priority for subsequent research.
As a more accurate representation of in vivo conditions, flow systems have
been used to great effect to investigate the dynamics of endothelial binding, for
example in P. falciparum (Adams et al., 2000, Gray et al., 2003, Phiri et al.,
2009). In the context of work by these groups, and other similar studies in
different organisms the flow system we have presented has wider applications
than solely in Acanthamoeba research. In particular the physical and fluidic
properties of in vitro flow systems can be applied to many disease states, and
provide a platform on which the interaction of microbes with the brain
endothelium can be studied. As such, the improved knowledge of AGE
resulting from incorporation of the effect of flow will also contribute to
understanding of other cerebral infections.
Static systems for investigating pathogenesis of Acanthamoeba have yielded
valuable discoveries however our preliminary data has shown that effects seen
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in these in vitro systems are unrepresentative of what may occur in vivo. This
is especially true of trophozoite binding which our data suggests is
considerably overestimated in static culture. This has relevance to immune
control of binding in that if levels of binding in vivo are lower than current
static in vitro models suggest the small antibody-mediated reductions seen in
our data could prove proportionally highly influential in determining whether
trophozoites can invade the BBB.
These reductions need not necessarily result from specific recognition of
binding proteins. MS/MS analysis of antigens recognised by HE2 produced
matches to proteins involved in metabolism and protein synthesis (Tables 4.1
and 4.2). Some of these proteins have been ascribed roles in virulence in other
organisms, for example the Trichomonas vaginalis AP65 adhesin exhibits
sequence homology with malic enzyme (O'Brien et al., 1996). Furthermore
even where antigens have no reported involvement in virulence, recognition
may prompt reductions in adhesion due to localisation on the cell membrane.
Especially in the case of IgM which has a polymeric structure and high
molecular weight, binding to non-adhesive antigens proximal to binding
factors could physically inhibit the interaction between binding receptors and
their relevant ligands.
Impairment of pathogen motility is another means by which antibody protects
the host. One target revealed by our experiments is the cytoskeletal component
actin. Formation of amoebastomes and other rearrangements of the
cytoskeleton are known virulence mechanisms both in A. castellanii (Khan,
2001, Mattana et al., 1997) and in other pathogenic amoebae (Bailey et al.,
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1987, Sohn et al., 2010). Therefore targeting this pathway is one means by
which host antibody could prevent invasion. This possibility is given further
credence by our observation of the capacity of HE2 to aggregate trophozoites
(Figure 3.9), providing an additional means by which trophozoite motility
might be limited.
Despite the reductions in trophozoite binding observed in antibody and
antibody fragment treated cultures no reduction was observed in monolayer
disruption or cell death. The interpretation that immune targeting of
trophozoite binding (whether mediated by membrane antigens, the
cytoskeleton or both) is the primary means of humoral immunity against A.
castellanii is therefore not a reliable one. In this case other possibilities must
be considered.
One possibility specific to the IgM isotype antibody seen in our experiments
relates to activation of the complement cascade. A. culbertsoni is known to fix
complement by the alternative pathway (Ferrante and Rowan-Kelly, 1983,
Pumidonming et al., 2011) although this process may not lead to trophozoite
lysis (Toney and Marciano-Cabral, 1998). However the role played by
classical activation has not been determined. IgM is a particularly effective
complement activator because of its multiple valency which means that only a
single molecule is required to initiate the cascade (Plaut et al., 1972). Cleavage
or sequestration of IgM in particular as well as other classes may therefore
represent an important mechanism for evasion of complement. We did not
investigate the interaction between complement and IgM in AGE however this
may be an important topic to be addressed by future studies.
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Another possibility is that antibody might act to neutralise secreted proteases
which have been shown to be an important factor in BBB disruption
Acanthamoeba trophozoites (Alsam et al., 2005b). Soluble virulence factors
such as proteases may be inactivated by specific antibody in a number of ways.
The most straightforward is direct neutralisation where antibody binding is
sufficient to interfere with the normal function of the target molecule. For
proteases this may include binding at or near to the active site inhibiting the
interaction between enzyme and substrate. The most thoroughly characterised
examples of this are seen in responses to bacterial toxins for example the
Clostridium botulinum neurotoxins (Babcock et al., 2006, Hussack et al.,
2011). Antibody binding also acts as a signal for phagocytosis of the target
antigen by phagocytes, where it is degraded internally. Additionally,
complexes can form consisting of multiple antibody and antigen molecules.
Activation of the complement cascade causes deposition of complement
subunits onto the immune complex, prompting recognition and binding by cell
types expressing complement receptor such as erythrocytes which facilitate
transport of complexes to the liver and spleen. Macrophages resident in these
organs then recognise and internalise the complex via their own Fc and
complement receptors. Due to its multiple valency IgM is a particularly
efficient complement activator and can also bind multiple antigens per single
molecule. It may therefore play an especially important role in inactivating
secreted amoeba proteases.
Serine proteases in particular play a major role in degrading tight junction
proteins as demonstrated in work by Alsam et al. (2005) and Sissons et al.
(2006). As tight junctions are responsible for the enhanced barrier properties of
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the brain microvasculature compared with other endothelial types their
targeting by A. castellanii is a major risk factor in the development of AGE.
The importance of secreted proteases in tight junction disruption has been
reported for infections caused by other protozoan parasites. For example, E.
histolytica secretes proteases which act on epithelial tight junctions in a similar
way to A. castellanii secretions (Leroy et al., 2000, Lauwaet et al., 2004,
Kumar et al., 2012). In more general terms proteases are virulence factors for a
wide variety of other parasites for example T. brucei, where they participate in
signalling mechanisms which lead to host cell death (Nikolskaia et al., 2006a,
Grab et al., 2009). As a result proteases have been explored as targets for
therapeutic intervention across a range of species (Doyle et al., 2007,
Mahmoudzadeh-Niknam and McKerrow, 2004, Vermeire et al., 2012).
Our experiments further underline the importance of proteases to pathogenesis.
In vitro treatment with the serine protease inhibitor PMSF reduced the extent
of monolayer disruption to a level equivalent to that seen in uninfected
HBMEC, demonstrating that protease inhibition can be effective in limiting
BBB perturbations (Figure 5.8). Monolayer disruption also occurred to the
same extent regardless of the flow rate applied to cells, not just for cell-free
ACM treatment but also with trophozoite infections (Figure 5.7). The
implication of this finding is that the number of trophozoites binding (which
we found to increase with decreasing flow rate) has less effect upon
endothelial monolayers than the presence of trophozoite secretions. Therefore
proteases may be more important to BBB invasion than has previously been
considered. This effect is paralleled in the BBB perturbations caused by T.
brucei which have also been found to depend on parasite proteases. In the
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specific instance of sleeping sickness endothelial cells become apoptotic as the
result of induction by the cysteine protease brucipain and this process has been
elucidated by Grab and colleagues (2009) to occur via Protease Activated
Receptors (PARs). We investigated whether PAR transduction might also have
a role in A. castellanii-induced cell death but discovered no evidence to
suggest that antagonists of PAR1 or PAR4 prevent BBB disruption by either
trophozoites or ACM. It therefore seems more likely that induction of cell
death occurs via alternative pathways such as tight junction loss-mediated
apoptosis as seen in E. histolytica (Kumar et al., 2012).
Regardless of the mechanisms by which proteases induce cell death, as a result
of their secretion into the extracellular environment or association with the cell
surface it might be assumed that A. castellanii proteases would be likely target
antigens for humoral immunity. This assertion is supported by studies in other
parasites demonstrating targeting of proteases during infection. For example
cruzipain, the major pathogenic protease of T. cruzi initiates B and CD4+ T-
cell responses (Schnapp et al., 2002), with specific antibody detectable in sera
of human patients (Martinez et al., 1991). Studies of S. mansoni proteases have
also shown the importance of protease targets to immunity. IgE responses are
rapidly induced by parasite cysteine protease with a vital contribution from
CD4+ T-cells (de Oliveira Fraga et al., 2010). Acquired immunity to a different
protease (calpain) has also been demonstrated to enhance macrophage
activation and ultimately killing of the parasite (Jankovic et al., 1996).
However our MS/MS sequencing of a range of protein bands recognised by
polyclonal antibody failed to demonstrate the presence of any proteases. This
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was the case both for proteases integral to cell survival and the parasite
lifecycle e.g. cysteine (Leitsch et al., 2010), and also those previously
implicated as virulence factors e.g. serine (Cho et al., 2000). It is possible that
these may reside in unsequenced or low abundance bands, however given the
apparent inability of HE2 to prevent monolayer disruption by ACM it seems
more likely that our isolation procedure did not produce antibody specific to
proteases. One proviso to this assertion is that although proteases themselves
may not be specifically targeted by antibody some of the antigens which were
detected are potentially involved in protease synthesis and export. Strong
matches were obtained for peptides from elongation factors (eukaryotic
translation elongation factor 2 and elongation factor 1γ) which play a role in 
protease synthesis and also for actin, which as a component of the cytoskeleton
is crucial for exocytosis. These are however intracellular antigens and so
unless they are present in complexes associated with the plasma membrane or
there is a process of active uptake by the parasite, the way in which antibody
specific to these antigens reaches its target is not clear.
The interaction between antibody and secreted/non-secreted virulence factors
in AGE is a complex one. Our data does not fully support an assertion that one
aspect of pathogenesis is of superior importance. HE2 appears to target
amoeba surface or surface-associated antigens and reduces host cell binding
however this is not protective in terms of host cell death or monolayer
protection. Conversely inhibition of proteases protects host monolayers from
disruption but proteases appear not to be a major antibody target.
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In order to reconcile this apparently conflicting evidence we considered
whether the inability of antibody to protect host cells in vitro resulted from
parasite immune evasion mechanisms. Amongst the most well characterised
evasion mechanisms in other pathogenic protozoa are the antigenic variation
type, where surface factors that might be recognised and targeted by the
immune system are altered or exchanged for unrecognised ones. Prominent
examples include the Variant Surface Glycoprotein (VSG) molecules of T.
brucei which are responsible for the waves of parasitaemia characteristic in
African sleeping sickness, and P. falciparum var genes, which create
polymorphic versions of PfEMP-1, a protein of key importance in malarial
pathogenesis. No evidence for antigenic variation in A. castellanii has ever
been described although the large number of genotypes (sixteen known to date
(Kong, 2009, Corsaro and Venditti, 2010)) of which only a few have been
described as pathogenic suggests that strain-specific variations could be
responsible for enhancing virulence. Protease expression has been suggested as
a candidate for correlation with differential virulence (Hadaś and Mazur,
1993), however this connection has not yet been conclusively made, and it is
unknown whether any A. castellanii virulence factors vary in response to the
host immune environment.
The most likely role for proteases in immune evasion lies in their ability to
cleave and/or degrade antibody. By degrading antibody parasites can protect
themselves from immune effector mechanisms such as complement fixation
(which is enhanced by antibody via the classical activation pathway) and
phagocytosis (phagocytes recognise opsonised pathogens via the antibody Fc
domain). The ability to cleave antibody has been observed in both other
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protozoa and also in multicellular parasites. For example E. histolytica
degrades host IgA via surface-associated cysteine protease activity (Garcia-
Nieto et al., 2008) and serine proteases from two life stages of S. mansoni
cleave IgE (Pleass et al., 2000). Evidence for similar cleavage by
Acanthamoeba proteases has been detailed by Na et al. for IgA, IgG and IgM
classes. Our data supports these conclusions and also extends findings to
include cleavage of IgE and a physiologically derived IgM antibody (Figures
4.2 to 4.6). The protease classes responsible for this cleavage activity were
primarily serine proteases with an additional contribution from
metalloproteases. This is a similar finding to the trypsin-like proteases of
importance in S. mansoni infections (Pleass et al., 2000, Aslam et al., 2008),
however stands in contrast with findings from the parasites T. cruzi and F.
hepatica where cleavage activity has been instead ascribed to cysteine protease
activity (Berasain et al., 2000, Berasain et al., 2003).
It should be considered that the data presented both by our study and by the
work of other researchers was obtained from in vitro experiments that may not
reflect cleavage processes as they occur in vivo. Contributions from blood
serum components such as endogenous protease inhibitors or antimicrobial
peptides could stabilise antibody or inhibit protease activity and so it would be
an interesting strategy to examine the status and structure of antibody from
infected patients. However if cleavage activity is maintained in vivo this will
have interesting implications for the outcome of immune recognition. The
precise molecular mechanisms of evasion depend on the location of any
cleavage site within the molecule. Trophozoites could inhibit activation of
phagocytes by removing the Fc region as in S. mansoni for example (Aslam et
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al., 2008). Alternatively degradation might occur at the hinge region as has
been seen in F. hepatica (Berasain et al., 2000) or proteases could act at
multiple sites in the protein depending on local conditions as with T. cruzi
(Berasain et al., 2003). Semi-quantitation of band intensity in our experiments
suggested that if any such preferential cleavage occurs it is most likely to be
found in the heavy chain subunit (Figure 4.7). However cleavage is not
necessarily so specific. Overall our data suggests that proteases of different
classes may act in consort, possibly at a variety of sites along the antibody
leading to a more generalised degradation of structure than the single specific
cleavage events seen in, for example, S. mansoni. Further experiments will be
required in order to address this point in detail.
Aside from the ability of trophozoites to render antibody ineffective via
cleavage, other data from our experiments suggested the presence of an
evasion mechanism mediated by antibody binding. Isotype control antibody
proved equally as effective at reducing trophozoite adherence to HBMEC
monolayers as polyclonal HE2; however this did not translate into a protective
phenotype in either case. Sequestration of antibody by parasites is a general
phenomenon that has been observed on a number of occasions in a variety of
species with examples reported in P. falciparum, T. cruzi, S. mansoni, T.
gondii and L. major (Budzko et al., 1989, Garcia et al., 1997, Loukas et al.,
2001, Campos-Neto et al., 2003, Czajkowsky et al., 2010). Our analysis
identified regions of similarity between proteins previously implicated in
antibody-binding activity and homologous regions in the A. castellanii genome
(Tables 4.1 and 4.2). In some cases these results conformed to protein families
conserved across a number of species for example the nucleoside diphosphate
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kinase superfamily, to which L. major Lmsp1 and its Trypanosome
homologues belong. A. castellanii also showed similarity to regions from other
genes involved in antibody binding from T. gondii, and S. mansoni. This in
silico evidence is further supported by immunofluorescence and FACS assays
which demonstrate nonspecific binding of secondary antibody, and also a
small enhancement of the effect when Fc fragment was used as a probe
(Figures 4.12 and 4.14).
Taken together this data suggests that - if not necessarily a dedicated Fc-
binding protein - trophozoites do exhibit some level of antibody-binding
activity and that this should be investigated in subsequent experimental work.
To use an example from our studies, this effect could be responsible for
overestimation of signal or false-positive membrane specificity for hybridoma
or serum antibody. This point has been raised in papers describing antibody-
binding properties of T. gondii for example (Budzko et al., 1989) and a similar
awareness amongst researchers investigating immunoglobulin interactions with
A. castellanii is advised. Nevertheless it should be considered that the
concentrations of antibody required to observe an effect under our
experimental conditions were high. Thus this may not represent a specific
blocking effect but rather a passive outcome of high protein concentrations in
experimental media. We did not perform a titration of antibody in order to
determine whether this was the case, and as such this is suggested as an
important next stage in the analysis of the Fc-binding activity exhibited by A.
castelanii. An experiment of this kind would also have the additional benefit of
determining the minimum concentration at which antibody produces a
measurable effect on trophozoite binding. This will prove informative for
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determining the specificity of binding inhibition and the likelihood of an
equivalent process occurring in vivo.
Overall, the data we have presented increases our understanding of how A.
castellanii interacts with antibody at the endothelial interface. That infected
and exposed individuals produce antibody has been demonstrated in a number
of studies (Alizadeh et al., 2001, Kiderlen et al., 2009) but the role of
immunoglobulin in controlling infection has not been fully determined. The
prominence of IgM in our experiments is especially interesting due to the
prominence of this class in serum surveys and its role in complement fixation.
This relationship also provides an insight into the potential purpose of
antibody-binding activity on the parasite’s surface. Recruitment of IgM in an
inverted orientation (i.e. mediated through binding to the Fc region) could
prevent interaction with complement subunits and phagocytes, thereby
protecting trophozoites from phagocytosis and/or lysis. In addition protease
activity may play a role in antibody inactivation via cleavage events. These
processes may be of particular interest in Acanthamoeba keratitis which occurs
in individuals with functional immune systems.
From our experiments it appears that both specific and nonspecific antibody
reduce trophozoite binding, however antibody alone has little bearing on cell
survival or monolayer preservation. Indeed the synergy between the cellular
and humoral components of the immune system means that control solely by
antibody is in any case an unlikely scenario. Future advances in the field may
therefore depend on identifying important control mechanisms by systematic
elimination of individual immune components. The most efficient
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methodology for this approach may be to make use of knockout mouse strains.
Mice with total immune deficiency (e.g. SCID) have already been used to
simulate free-living amoeba infections (Janitschke et al., 1996). However use
of strains with more specific deficiencies will allow protective immune control
mechanisms to be traced more precisely. For example µMT mice are deficient
in B-cells and thus useful for investigating immune function in the absence of
antibody. Similarly RAG-/- T-cell deficient animals may be used to examine
the effects of a loss of T-cell mediated immunity.
In AGE depletion of normal immune processes allows trophozoite growth to
continue unchecked. Knowledge of the ways in which trophozoites interact
with the immune system therefore has the potential to enhance therapeutic
strategies aimed at restoring essential disease prevention processes. Whilst
having minimal preservation ability on the BBB, antibody may still combat
haematogenous spread by aggregation and immobilisation of trophozoites or
limiting adhesion. This is especially the case if as indicated by results from our
in vitro flow system the ability of trophozoites to bind to HBMEC is lower
than that estimated using static models.
Our work also has applications in therapeutic strategies targeting essential
processes of the parasite itself. We have identified a number of amoeba
antigens that are targets for the immune system and which therefore may be
exploited through vaccination or immunotherapy. These may prove to be
valuable targets for drug development and widen the limited array of
pharmaceutical compounds available to clinicians. We hope that this will
improve the prognosis for patients suffering Acanthamoeba infections.
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Appendices
Appendix 1
Buffer preparations used in the study are given below.
1) Phosphate-Buffered Saline (PBS)
1× PBS tablet
To 500ml with dH2O
2) PBS-Tween 20 (PBST)
2× PBS tablets
0.5ml Tween-20
To 1L with dH2O
3) Acetone / ethanol fixative
100ml Acetone
100ml 100% Ethanol
4) 4% Formaldehyde
55ml 36.5% w/v Formaldehyde solution
To 500ml with ddH2O
5) 1M Tris Base pH 8.8
18g NH2C(CH2OH)3
To 150ml with dH2O
Adjust to pH 8.8
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6) 1M Glycine elution buffer
37.5g C2H5NO2
To 500ml with dH2O
Adjust to pH 3
7) Carbonate/bicarbonate coating buffer
3g Na2CO3
6g NaHCO3
To 1L with dH2O
Adjust to pH 9.6
8) 5% Bovine Serum Albumin
2.5g BSA
To 50ml with PBS
9) 2M Sulphuric Acid
55ml conc. H2SO4 (18M)
To 500ml with dH2O
10) TGS blotting buffer
50ml 10× TGS blot buffer
200ml Methanol
To 1L with ddH2O
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11) SDS running buffer
50ml 20× SDS run buffer
To 1L with ddH2O
12) Coomassie staining buffer
200ml Methanol
50ml Glacial Acetic acid
0.125g Coomassie Brilliant Blue
To 500ml with ddH2O
13) Destaining buffer
200ml Methanol
50ml Glacial Acetic acid
To 500ml with ddH2O
14) Silver staining fixing solution
100ml Ethanol
25ml Glacial Acetic acid
To 250ml with dH2O
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15) Silver staining sensitising solution
75ml Ethanol
10ml 5% w/v Sodium thiosulphate
17g Sodium acetate
1.25ml 25% w/v Glutardialdehyde
To 250ml with dH2O
16) Silver staining silver solution
25ml 2.5% w/v Silver nitrate solution
To 250ml with dH2O
17) Silver staining developing solution
6.25g Sodium carbonate
0.2ml 37% w/v Formaldehyde
To 250ml with dH2O
18) Silver staining stop solution
3.65g EDTA-Na2•2H2O
To 250ml with dH2O
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19) Zymogram wash buffer
7.88g NH2C(CH2OH)3 •HCl [Trizma HCl]
25g Triton X-100
To 1L with dH2O
Adjust pH to 7.5
20) Zymogram developing buffer
7.88g NH2C(CH2OH)3 •HCl [Trizma HCl]
1.1g CaCl2
To 1L with dH2O
Adjust pH to
21) Zymogram nonreducing sample buffer
2ml Glycerol
1ml 0.5M NH2C(CH2OH)3 •HCl [Trizma HCl]
0.4ml 2-β-Mercaptoethanol
0.2ml 0.05% w/v Bromophenol blue
To 8ml with dH2O
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Appendix 2
Peptide identities from tandem MS sequencing obtained from searches against
the NCBI n “ESTs others” dataset. Limited additional hits were seen within the
amoebazoa and in other organisms. The best matches were found for the
mitochondrial F1 complex ATP synthase in Polysphondylium pallidum (a
slime mould), Selaginella moellendorffii (a vascular plant) and Dictyostelium
fasciculatum (a social amoeba).
Band Identity (Best matches) BLAST
identity
BLAST E-
value
1 N/S N/S N/S
2/3 N/S N/S N/S
4 Hypothetical protein
(Monosiga brevicollis) 30% 0.063
5 Mitochondrial F1 complex ATP synthase
(Polysphondylium pallidum)
(Dictyostelium fasciculatum
Hypothetical protein
(Selaginella moellendorffii)
17%
20%
33%
34%
1e-11
8e-10
3e-17
9e-17
Appendix 3
10 PfEMP1 variant sequences were retrieved from NCBI GenBank and aligned
using SeaView version 4.4.1. As expected, and in accordance with reports of
antigenic variation in PfEMP1, sequence variability was observed. The
PfEMP1 variants were therefore used a
the A. castellanii
s individual tBLASTn queries against
genome.
276
277
Accession Query length Match length Coverage E-value
AAB87407 178aa 41aa, 65aa 20% 0.19
AAB87405 178aa 41aa, 65aa 20% 0.19
AAB87403 174aa 46aa, 48aa 26% 0.004†
AAB87401 174aa 51aa 26% 0.90
AAB87399 174aa 114aa, 35aa 58% 0.17
AAB87397 129aa 16aa 12% 6.9
AAB87395 147aa 29aa, 39aa 18% 1.9
AAB87393 141aa 26aa, 39aa 18% 5.8
AAB87391 151aa 41aa 27% 1.7
AAB87389 142aa 59aa 37% 4.0
BLAST output for 10 PfEMP1 variants against A. castellanii. No significant
alignments were seen for any variant examined. Peptide sequences were
retrieved from the NCBI protein database and searched against the A.
castellanii genome using the tBLASTn algorithm. Accession numbers, length
of aligned regions, coverage and E-values for matches are shown for each
search and the best match only is displayed. †The E-value for this match was
significant but similarity was fragmented across several transcriptomic regions.
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Appendix 4
Unfiltered reciprocal BLAST output for Fc binding protein sequences.
Query I.D. Subject I.D. %
Ident.
alignment
length
e-
value
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.brucei_Lmsp1_contig 100 94 2.00E-54
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 91 9.00E-53
Acanthamoeba_Leishmania_Lmsp1_contig Acanthamoeba_Toxoplasma_beta_contig 31.58 19 0.51
Acanthamoeba_T.brucei_Lmsp1_contig Acanthamoeba_T.cruzi_Lmsp1_contig 100 89 1.00E-51
Acanthamoeba_T.brucei_Lmsp1_contig Acanthamoeba_Toxoplasma_beta_contig 31.58 19 0.5
Acanthamoeba_T.cruzi_Lmsp1_contig Acanthamoeba_Toxoplasma_beta_contig 31.58 19 0.48
Acanthamoeba_Toxoplasma_beta_contig Acanthamoeba_Schistosoma_paramyosin_contig 38.46 26 2.7
Chicken_FcR Acanthamoeba_Schistosoma_paramyosin_contig 26.67 30 4
Chicken_FcR Acanthamoeba_Toxoplasma_beta_contig 34.78 23 0.28
Chicken_FcR Acanthamoeba_Toxoplasma_beta_contig 36.84 19 0.82
Chicken_FcR Acanthamoeba_Toxoplasma_beta_contig 50 12 2.4
Chicken_FcR Leishmania_major_Lmsp1 30.43 23 2.6
Chicken_FcR Leishmania_major_Lmsp1 27.08 48 3.4
Chicken_FcR Streptococcus_pyogenes_FcgR 25.64 39 0.64
Chicken_FcR Streptococcus_pyogenes_FcgR 33.33 30 1.1
Chicken_FcR Streptococcus_pyogenes_FcgR 33.33 18 4.2
Chicken_FcR Toxoplasma_gondii_Beta 80 10 0.22
Chicken_FcR Trypanosoma_brucei_Lmsp1 50 8 1.5
Chicken_FcR Trypanosoma_cruzi_Lmsp1 50 8 3.5
Human_Fca_mR Acanthamoeba_Leishmania_Lmsp1_contig 47.62 21 0.013
Human_Fca_mR Acanthamoeba_Leishmania_Lmsp1_contig 29.17 24 0.25
Human_Fca_mR Acanthamoeba_Schistosoma_paramyosin_contig 38.89 18 3.2
Human_Fca_mR Acanthamoeba_Schistosoma_paramyosin_contig 33.33 27 4.1
Human_Fca_mR Acanthamoeba_Schistosoma_paramyosin_contig 30.77 13 7
Human_Fca_mR Acanthamoeba_Schistosoma_paramyosin_contig 33.33 18 9.2
Human_Fca_mR Acanthamoeba_T.brucei_Lmsp1_contig 47.62 21 0.013
Human_Fca_mR Acanthamoeba_T.brucei_Lmsp1_contig 29.17 24 0.24
Human_Fca_mR Acanthamoeba_T.cruzi_Lmsp1_contig 47.62 21 0.012
Human_Fca_mR Acanthamoeba_T.cruzi_Lmsp1_contig 29.17 24 0.23
Human_Fca_mR Acanthamoeba_Toxoplasma_beta_contig 46.15 13 3.2
Human_Fca_mR Acanthamoeba_Toxoplasma_beta_contig 38.46 13 4.2
Human_Fca_mR Chicken_FcR 33.33 36 7.00E-04
Human_Fca_mR Chicken_FcR 100 6 3.6
Human_Fca_mR Human_FceR1 38.46 13 0.86
Human_Fca_mR Human_FceR1 37.5 16 2.5
Human_Fca_mR Human_FceR1 60 5 4.3
Human_Fca_mR Human_FceR2 30.77 39 1
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Query I.D. Subject I.D. %
Ident.
alignment
length
e-
value
Human_Fca_mR Human_FceR2 60 5 8.8
Human_Fca_mR Human_FcgR1b 33.33 18 3.3
Human_Fca_mR Human_FcgR1b 33.33 18 4.3
Human_Fca_mR Human_FcgR2a 33.33 18 1.5
Human_Fca_mR Human_FcgR2a 38.46 13 7.4
Human_Fca_mR Human_FcgR2a 31.25 16 7.4
Human_Fca_mR Human_FcgR2B 38.46 13 7.1
Human_Fca_mR Human_FcgR3a 22.35 85 0.11
Human_Fca_mR Human_FcgR3a 31.25 16 0.54
Human_Fca_mR Human_FcgR3B 20.48 83 0.18
Human_Fca_mR Human_FcgR3B 26.32 19 3.3
Human_Fca_mR Leishmania_major_Lmsp1 58.82 17 0.24
Human_Fca_mR Leishmania_major_Lmsp1 23.81 21 2.1
Human_Fca_mR Leishmania_major_Lmsp1 26.32 19 3.5
Human_Fca_mR Mouse_FcamR 48.62 436 5.00E-97
Human_Fca_mR Mouse_FceR1 38.89 18 0.3
Human_Fca_mR Mouse_FceR1 25.93 27 2.5
Human_Fca_mR Mouse_FceR1 40 10 5.6
Human_Fca_mR Mouse_FceR2 25 16 0.82
Human_Fca_mR Mouse_FceR2 33.33 9 3.1
Human_Fca_mR Mouse_FceR2 55.56 9 3.1
Human_Fca_mR Mouse_FceR2 33.33 18 4.1
Human_Fca_mR Mouse_FceR2 60 5 6.9
Human_Fca_mR Mouse_FceR2 83.33 6 9
Human_Fca_mR Mouse_FcgR1 23.81 21 0.35
Human_Fca_mR Mouse_FcgR1 44.44 18 0.46
Human_Fca_mR Mouse_FcgR1 25 16 8.7
Human_Fca_mR Mouse_FcgR2b 45.45 11 1.5
Human_Fca_mR Mouse_FcgR2b 40 25 2.5
Human_Fca_mR Mouse_FcgR2b 57.14 7 4.3
Human_Fca_mR Mouse_FcgR3 45.45 11 2.6
Human_Fca_mR Mouse_FcgR3 46.15 13 3.4
Human_Fca_mR Mouse_FcgR3 57.14 7 4.4
Human_Fca_mR Mouse_FcgR4 21.74 161 0.42
Human_Fca_mR Mouse_FcgR4 55.56 9 4.6
Human_Fca_mR Mouse_FcgR4 26.32 19 6
Human_Fca_mR Mouse_FcgR4 42.86 14 7.9
Human_Fca_mR Oyster_FceR 37.5 16 6.9
Human_Fca_mR Plasmodium_falciparum_PfEMP1 25 16 2.5
Human_Fca_mR Plasmodium_falciparum_PfEMP1 23.53 17 9.4
Human_Fca_mR Staphylococcus_aureus_ProteinA 36.84 19 4.1
Human_Fca_mR Streptococcus_agalactiae_FcaR 22.09 86 0.043
Human_Fca_mR Streptococcus_agalactiae_FcaR 34.48 29 1.1
Human_Fca_mR Streptococcus_agalactiae_FcaR 21.88 32 3.1
Human_Fca_mR Streptococcus_agalactiae_FcaR 27.27 22 4
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Query I.D. Subject I.D. %
Ident.
alignment
length
e-
value
Human_Fca_mR Streptococcus_pyogenes_FcgR 22.97 74 3.3
Human_Fca_mR Streptococcus_pyogenes_FcgR 35.29 17 9.6
Human_Fca_mR Toxoplasma_gondii_Beta 28.57 28 1.2
Human_Fca_mR Trypanosoma_brucei_Lmsp1 58.82 17 0.24
Human_Fca_mR Trypanosoma_brucei_Lmsp1 62.5 8 2
Human_Fca_mR Trypanosoma_cruzi_Lmsp1 58.82 17 0.25
Human_Fca_mR Trypanosoma_cruzi_Lmsp1 24.24 33 2.1
Human_FcaR1 Acanthamoeba_Leishmania_Lmsp1_contig 31.25 16 3
Human_FcaR1 Acanthamoeba_Leishmania_Lmsp1_contig 26.67 15 8.8
Human_FcaR1 Acanthamoeba_Schistosoma_paramyosin_contig 31.58 19 4.1
Human_FcaR1 Acanthamoeba_T.brucei_Lmsp1_contig 31.25 16 3
Human_FcaR1 Acanthamoeba_T.brucei_Lmsp1_contig 26.67 15 8.6
Human_FcaR1 Acanthamoeba_T.cruzi_Lmsp1_contig 31.25 16 2.8
Human_FcaR1 Acanthamoeba_T.cruzi_Lmsp1_contig 26.67 15 8.3
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 46.67 15 0.51
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 54.55 11 0.67
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 26.92 26 2.5
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 36.36 22 2.5
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 29.41 17 3.3
Human_FcaR1 Acanthamoeba_Toxoplasma_beta_contig 57.14 7 5.6
Human_FcaR1 Chicken_FcR 30.27 185 5.00E-10
Human_FcaR1 Chicken_FcR 23.15 203 6.00E-05
Human_FcaR1 Chicken_FcR 24.66 219 5.00E-04
Human_FcaR1 Human_Fca_mR 36.67 30 1.3
Human_FcaR1 Human_FceR1 19.59 148 0.013
Human_FcaR1 Human_FceR1 27.03 37 0.016
Human_FcaR1 Human_FceR1 50 12 0.021
Human_FcaR1 Human_FceR2 45.45 11 4
Human_FcaR1 Human_FcgR1b 26.98 63 0.006
Human_FcaR1 Human_FcgR1b 22.22 54 0.049
Human_FcaR1 Human_FcgR1b 36.36 11 0.31
Human_FcaR1 Human_FcgR2a 24.24 66 1.00E-04
Human_FcaR1 Human_FcgR2a 24.27 103 0.029
Human_FcaR1 Human_FcgR2a 37.5 8 0.7
Human_FcaR1 Human_FcgR2a 12.9 31 7.8
Human_FcaR1 Human_FcgR2B 23.81 63 1.00E-04
Human_FcaR1 Human_FcgR2B 24.27 103 0.012
Human_FcaR1 Human_FcgR2B 27.27 55 0.035
Human_FcaR1 Human_FcgR2B 30 10 0.39
Human_FcaR1 Human_FcgR2B 12.9 31 7.4
Human_FcaR1 Human_FcgR3a 24.78 113 0.004
Human_FcaR1 Human_FcgR3a 19.28 83 0.19
Human_FcaR1 Human_FcgR3a 27.78 18 0.25
Human_FcaR1 Human_FcgR3B 25.23 111 7.00E-04
Human_FcaR1 Human_FcgR3B 20.48 83 0.049
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Query I.D. Subject I.D. %
Ident.
alignment
length
e-
value
Human_FcaR1 Human_FcgR3B 27.78 18 0.24
Human_FcaR1 Leishmania_major_Lmsp1 28.57 14 8.2
Human_FcaR1 Mouse_FcamR 53.33 15 0.96
Human_FcaR1 Mouse_FcamR 28.57 21 4.8
Human_FcaR1 Mouse_FcamR 57.14 7 6.2
Human_FcaR1 Mouse_FcamR 54.55 11 8.1
Human_FcaR1 Mouse_FceR1 37.5 24 0.01
Human_FcaR1 Mouse_FceR1 71.43 7 0.063
Human_FcaR1 Mouse_FceR1 36.36 11 0.41
Human_FcaR1 Mouse_FcgR1 27.59 58 0.002
Human_FcaR1 Mouse_FcgR1 23.77 122 0.043
Human_FcaR1 Mouse_FcgR2b 30.56 108 1.00E-06
Human_FcaR1 Mouse_FcgR2b 38.46 13 0.082
Human_FcaR1 Mouse_FcgR3 30.1 103 1.00E-05
Human_FcaR1 Mouse_FcgR3 50 8 0.19
Human_FcaR1 Mouse_FcgR3 36.36 11 0.71
Human_FcaR1 Mouse_FcgR4 31.82 44 1.00E-04
Human_FcaR1 Mouse_FcgR4 24.56 114 0.003
Human_FcaR1 Mouse_FcgR4 22.89 83 0.03
Human_FcaR1 Mouse_FcgR4 25 40 0.051
Human_FcaR1 Oyster_FceR 87.5 8 0.097
Human_FcaR1 Plasmodium_falciparum_PfEMP1 44.44 9 2
Human_FcaR1 Plasmodium_falciparum_PfEMP1 37.5 8 4.4
Human_FcaR1 Streptococcus_agalactiae_FcaR 26.67 90 1
Human_FcaR1 Toxoplasma_gondii_Beta 32 25 0.021
Human_FceR1 Acanthamoeba_Schistosoma_paramyosin_contig 41.67 12 1.2
Human_FceR1 Acanthamoeba_Schistosoma_paramyosin_contig 22.73 22 6.1
Human_FceR1 Chicken_FcR 24.81 133 7.00E-06
Human_FceR1 Chicken_FcR 37.5 48 4.00E-04
Human_FceR1 Chicken_FcR 26.03 73 0.003
Human_FceR1 Chicken_FcR 32.26 31 0.075
Human_FceR1 Chicken_FcR 24.43 131 0.64
Human_FceR1 Human_FceR2 27.78 18 2.7
Human_FceR1 Human_FcgR1b 43.33 150 1.00E-40
Human_FceR1 Human_FcgR1b 16.28 43 6.8
Human_FceR1 Human_FcgR2a 38.1 168 3.00E-36
Human_FceR1 Human_FcgR2a 30.61 49 0.004
Human_FceR1 Human_FcgR2B 38.69 168 1.00E-36
Human_FceR1 Human_FcgR2B 30.61 49 0.004
Human_FceR1 Human_FcgR3a 43.98 166 2.00E-39
Human_FceR1 Human_FcgR3B 43.98 166 4.00E-39
Human_FceR1 Leishmania_major_Lmsp1 37.5 8 4.2
Human_FceR1 Mouse_FcamR 60 5 4.1
Human_FceR1 Mouse_FceR1 52.22 180 1.00E-53
Human_FceR1 Mouse_FceR2 27.27 22 0.33
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Human_FceR1 Mouse_FcgR1 43.37 166 6.00E-40
Human_FceR1 Mouse_FcgR1 23.61 144 9.00E-07
Human_FceR1 Mouse_FcgR1 32.76 58 9.00E-04
Human_FceR1 Mouse_FcgR2b 41.92 167 2.00E-38
Human_FceR1 Mouse_FcgR3 41.32 167 4.00E-38
Human_FceR1 Mouse_FcgR3 30 20 1.4
Human_FceR1 Mouse_FcgR4 41.32 167 7.00E-38
Human_FceR1 Mouse_FcgR4 66.67 6 0.38
Human_FceR1 Oyster_FceR 75 8 0.19
Human_FceR1 Oyster_FceR 39.29 28 2.1
Human_FceR1 Plasmodium_falciparum_PfEMP1 25.93 27 2.3
Human_FceR1 Schistosoma_mansoni_paramyosin 38.46 13 1.6
Human_FceR1 Schistosoma_mansoni_paramyosin 20.59 34 2.7
Human_FceR1 Schistosoma_mansoni_paramyosin 41.67 24 2.7
Human_FceR1 Streptococcus_agalactiae_FcaR 83.33 6 2.6
Human_FceR1 Streptococcus_agalactiae_FcaR 45.45 11 5.8
Human_FceR1 Streptococcus_agalactiae_FcaR 45.45 11 5.8
Human_FceR1 Streptococcus_agalactiae_FcaR 45.45 11 5.8
Human_FceR1 Streptococcus_agalactiae_FcaR 45.45 11 5.8
Human_FceR1 Streptococcus_agalactiae_FcaR 45.45 11 5.8
Human_FceR1 Streptococcus_agalactiae_FcaR 27.27 11 7.5
Human_FceR1 Taenia_solium_paramyosin 28.57 35 0.55
Human_FceR1 Taenia_solium_paramyosin 28.95 76 0.72
Human_FceR1 Taenia_solium_paramyosin 38.46 13 1.6
Human_FceR1 Toxoplasma_gondii_Beta 42.86 7 6.6
Human_FceR1 Trypanosoma_brucei_Lmsp1 28.13 32 1.1
Human_FceR1 Trypanosoma_cruzi_Lmsp1 30.43 23 0.51
Human_FceR1 Trypanosoma_cruzi_Lmsp1 71.43 7 1.9
Human_FceR2 Acanthamoeba_Leishmania_Lmsp1_contig 50 12 0.36
Human_FceR2 Acanthamoeba_T.brucei_Lmsp1_contig 50 12 0.35
Human_FceR2 Acanthamoeba_T.cruzi_Lmsp1_contig 50 12 0.34
Human_FceR2 Chicken_FcR 41.67 12 5
Human_FceR2 Chicken_FcR 30 20 8.5
Human_FceR2 Human_FcgR1b 26.79 56 0.94
Human_FceR2 Human_FcgR2a 80 5 3.6
Human_FceR2 Human_FcgR2B 41.67 12 2
Human_FceR2 Human_FcgR2B 80 5 3.4
Human_FceR2 Human_FcgR3a 31.82 22 2.9
Human_FceR2 Human_FcgR3B 31.82 22 2.8
Human_FceR2 Mouse_FcamR 40.54 37 0.12
Human_FceR2 Mouse_FcamR 30.43 46 0.16
Human_FceR2 Mouse_FcamR 36.84 19 0.77
Human_FceR2 Mouse_FcamR 25 20 5
Human_FceR2 Mouse_FceR1 20 40 3.5
Human_FceR2 Mouse_FceR2 52.13 282 2.00E-82
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Human_FceR2 Mouse_FcgR1 23.73 59 0.84
Human_FceR2 Mouse_FcgR1 37.5 8 1.4
Human_FceR2 Mouse_FcgR2b 35.29 17 1.6
Human_FceR2 Mouse_FcgR3 35.29 17 1.6
Human_FceR2 Mouse_FcgR3 40 10 2.8
Human_FceR2 Mouse_FcgR3 38.46 13 8.1
Human_FceR2 Oyster_FceR 32.3 161 1.00E-25
Human_FceR2 Oyster_FceR 33.33 27 0.66
Human_FceR2 Schistosoma_mansoni_paramyosin 24.24 99 0.061
Human_FceR2 Schistosoma_mansoni_paramyosin 21.55 116 0.061
Human_FceR2 Schistosoma_mansoni_paramyosin 17.78 90 0.14
Human_FceR2 Schistosoma_mansoni_paramyosin 27.03 37 0.52
Human_FceR2 Schistosoma_mansoni_paramyosin 23.76 101 1.2
Human_FceR2 Schistosoma_mansoni_paramyosin 37.5 16 9.8
Human_FceR2 Streptococcus_agalactiae_FcaR 60 15 0.29
Human_FceR2 Streptococcus_agalactiae_FcaR 27.03 37 1.9
Human_FceR2 Streptococcus_agalactiae_FcaR 55.56 9 9.2
Human_FceR2 Streptococcus_pyogenes_FcgR 24.76 105 0.017
Human_FceR2 Streptococcus_pyogenes_FcgR 33.33 42 0.11
Human_FceR2 Streptococcus_pyogenes_FcgR 19.3 114 0.18
Human_FceR2 Streptococcus_pyogenes_FcgR 25.93 54 0.91
Human_FceR2 Taenia_solium_paramyosin 22.64 53 0.52
Human_FceR2 Taenia_solium_paramyosin 24.32 37 1.2
Human_FceR2 Taenia_solium_paramyosin 22.81 57 1.5
Human_FceR2 Taenia_solium_paramyosin 24.24 33 2
Human_FceR2 Taenia_solium_paramyosin 16.95 118 2.6
Human_FceR2 Trypanosoma_brucei_Lmsp1 50 8 1.7
Human_FcgR1b Acanthamoeba_Schistosoma_paramyosin_contig 38.89 18 4.8
Human_FcgR1b Chicken_FcR 25.84 178 6.00E-05
Human_FcgR1b Chicken_FcR 24.34 152 0.009
Human_FcgR1b Chicken_FcR 25 76 0.5
Human_FcgR1b Chicken_FcR 33.33 12 9.4
Human_FcgR1b Human_FcgR2a 49.01 151 1.00E-42
Human_FcgR1b Human_FcgR2a 17.24 29 3.1
Human_FcgR1b Human_FcgR2B 46.95 164 2.00E-42
Human_FcgR1b Human_FcgR3a 44.07 177 3.00E-45
Human_FcgR1b Human_FcgR3B 45.2 177 3.00E-46
Human_FcgR1b Leishmania_major_Lmsp1 38.46 13 3.3
Human_FcgR1b Leishmania_major_Lmsp1 50 8 3.3
Human_FcgR1b Leishmania_major_Lmsp1 50 6 7.4
Human_FcgR1b Mouse_FcamR 23.4 94 0.17
Human_FcgR1b Mouse_FcamR 34.62 26 1.1
Human_FcgR1b Mouse_FcamR 83.33 6 1.4
Human_FcgR1b Mouse_FcamR 42.86 14 4.2
Human_FcgR1b Mouse_FcamR 36.84 19 4.2
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Human_FcgR1b Mouse_FceR1 40.52 153 7.00E-34
Human_FcgR1b Mouse_FceR1 20.41 49 1.4
Human_FcgR1b Mouse_FceR2 38.89 18 0.74
Human_FcgR1b Mouse_FcgR1 69.83 179 5.00E-72
Human_FcgR1b Mouse_FcgR1 22.76 123 0.003
Human_FcgR1b Mouse_FcgR1 31.48 54 0.003
Human_FcgR1b Mouse_FcgR2b 45.35 172 2.00E-46
Human_FcgR1b Mouse_FcgR3 42.93 184 5.00E-46
Human_FcgR1b Mouse_FcgR4 45.73 164 5.00E-43
Human_FcgR1b Oyster_FceR 37.5 16 1.2
Human_FcgR1b Oyster_FceR 40 10 2.8
Human_FcgR1b Staphylococcus_aureus_ProteinA 36.36 22 0.067
Human_FcgR1b Staphylococcus_aureus_ProteinA 36.36 22 0.067
Human_FcgR1b Streptococcus_agalactiae_FcaR 37.5 16 3.4
Human_FcgR1b Streptococcus_pyogenes_FcgR 23.53 34 2.2
Human_FcgR1b Taenia_solium_paramyosin 62.5 8 2.8
Human_FcgR2a Acanthamoeba_Leishmania_Lmsp1_contig 60 10 0.71
Human_FcgR2a Acanthamoeba_Leishmania_Lmsp1_contig 41.67 12 2.1
Human_FcgR2a Acanthamoeba_T.brucei_Lmsp1_contig 60 10 0.7
Human_FcgR2a Acanthamoeba_T.brucei_Lmsp1_contig 41.67 12 2
Human_FcgR2a Acanthamoeba_T.cruzi_Lmsp1_contig 60 10 0.68
Human_FcgR2a Acanthamoeba_T.cruzi_Lmsp1_contig 41.67 12 2
Human_FcgR2a Chicken_FcR 24.44 90 8.00E-04
Human_FcgR2a Chicken_FcR 29.63 108 0.003
Human_FcgR2a Chicken_FcR 31.58 38 0.22
Human_FcgR2a Chicken_FcR 31.25 16 0.29
Human_FcgR2a Chicken_FcR 50 8 1.5
Human_FcgR2a Chicken_FcR 23.81 21 2.5
Human_FcgR2a Chicken_FcR 42.86 14 4.2
Human_FcgR2a Human_FcgR2B 93.64 173 7.00E-101
Human_FcgR2a Human_FcgR3a 51.5 167 2.00E-47
Human_FcgR2a Human_FcgR3B 52.1 167 1.00E-48
Human_FcgR2a Leishmania_major_Lmsp1 50 6 5.7
Human_FcgR2a Mouse_FcamR 34.38 32 0.23
Human_FcgR2a Mouse_FcamR 30.77 39 0.38
Human_FcgR2a Mouse_FcamR 57.14 7 7.2
Human_FcgR2a Mouse_FceR1 34.12 170 1.00E-27
Human_FcgR2a Mouse_FceR2 35.71 14 0.75
Human_FcgR2a Mouse_FceR2 26.47 34 2.8
Human_FcgR2a Mouse_FcgR1 45.83 168 4.00E-41
Human_FcgR2a Mouse_FcgR1 21.39 173 6.00E-05
Human_FcgR2a Mouse_FcgR2b 62.71 177 1.00E-67
Human_FcgR2a Mouse_FcgR3 61.02 177 8.00E-65
Human_FcgR2a Mouse_FcgR3 37.5 24 0.004
Human_FcgR2a Mouse_FcgR4 49.72 177 4.00E-48
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Human_FcgR2a Mouse_FcgR4 35.71 14 4.2
Human_FcgR2a Oyster_FceR 50 8 8.1
Human_FcgR2a Plasmodium_falciparum_PfEMP1 30 10 3
Human_FcgR2B Acanthamoeba_Leishmania_Lmsp1_contig 50 10 1.5
Human_FcgR2B Acanthamoeba_Leishmania_Lmsp1_contig 41.67 12 2
Human_FcgR2B Acanthamoeba_Schistosoma_paramyosin_contig 22.95 61 2
Human_FcgR2B Acanthamoeba_T.brucei_Lmsp1_contig 50 10 1.5
Human_FcgR2B Acanthamoeba_T.brucei_Lmsp1_contig 41.67 12 1.9
Human_FcgR2B Acanthamoeba_T.cruzi_Lmsp1_contig 50 10 1.4
Human_FcgR2B Acanthamoeba_T.cruzi_Lmsp1_contig 41.67 12 1.9
Human_FcgR2B Chicken_FcR 23.33 90 6.00E-04
Human_FcgR2B Chicken_FcR 28.04 107 0.004
Human_FcgR2B Chicken_FcR 23.33 60 0.16
Human_FcgR2B Chicken_FcR 31.25 16 0.28
Human_FcgR2B Chicken_FcR 45 20 0.62
Human_FcgR2B Chicken_FcR 50 8 1.4
Human_FcgR2B Chicken_FcR 23.81 21 1.8
Human_FcgR2B Human_FcgR3a 50.3 167 3.00E-47
Human_FcgR2B Human_FcgR3B 50.9 167 2.00E-48
Human_FcgR2B Leishmania_major_Lmsp1 50 6 5.4
Human_FcgR2B Mouse_FcamR 34.38 32 0.21
Human_FcgR2B Mouse_FcamR 30.77 39 0.36
Human_FcgR2B Mouse_FceR1 34.12 170 2.00E-27
Human_FcgR2B Mouse_FceR2 35.71 14 0.71
Human_FcgR2B Mouse_FceR2 26.47 34 2.7
Human_FcgR2B Mouse_FcgR1 47.02 168 4.00E-42
Human_FcgR2B Mouse_FcgR1 22.42 165 6.00E-05
Human_FcgR2B Mouse_FcgR1 22.89 83 0.081
Human_FcgR2B Mouse_FcgR2b 64.71 170 1.00E-67
Human_FcgR2B Mouse_FcgR3 62.21 172 1.00E-64
Human_FcgR2B Mouse_FcgR3 33.33 24 0.014
Human_FcgR2B Mouse_FcgR4 50.59 170 4.00E-48
Human_FcgR2B Mouse_FcgR4 50 10 4
Human_FcgR2B Plasmodium_falciparum_PfEMP1 30 10 2.9
Human_FcgR2B Trypanosoma_cruzi_Lmsp1 50 12 1.4
Human_FcgR3a Acanthamoeba_Schistosoma_paramyosin_contig 30.43 23 1.7
Human_FcgR3a Chicken_FcR 40 25 0.012
Human_FcgR3a Chicken_FcR 41.18 17 0.062
Human_FcgR3a Chicken_FcR 30 20 0.1
Human_FcgR3a Chicken_FcR 29.03 31 0.18
Human_FcgR3a Human_FcgR3B 97.28 184 1.00E-108
Human_FcgR3a Leishmania_major_Lmsp1 31.58 19 0.7
Human_FcgR3a Mouse_FcamR 24.42 86 0.31
Human_FcgR3a Mouse_FceR1 36.69 169 7.00E-29
Human_FcgR3a Mouse_FceR2 41.67 12 5
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Human_FcgR3a Mouse_FcgR1 44.09 186 2.00E-42
Human_FcgR3a Mouse_FcgR1 23.18 151 0.002
Human_FcgR3a Mouse_FcgR1 30.77 39 0.023
Human_FcgR3a Mouse_FcgR2b 50.88 171 3.00E-51
Human_FcgR3a Mouse_FcgR3 49.44 178 4.00E-51
Human_FcgR3a Mouse_FcgR3 30 20 0.39
Human_FcgR3a Mouse_FcgR4 67.86 168 1.00E-70
Human_FcgR3a Mouse_FcgR4 50 10 9.9
Human_FcgR3a Plasmodium_falciparum_PfEMP1 30 20 7.1
Human_FcgR3a Streptococcus_agalactiae_FcaR 29.17 24 8.1
Human_FcgR3a Streptococcus_agalactiae_FcaR 36.84 19 8.1
Human_FcgR3a Toxoplasma_gondii_Beta 50 8 4.2
Human_FcgR3B Chicken_FcR 40 25 0.009
Human_FcgR3B Chicken_FcR 41.18 17 0.1
Human_FcgR3B Chicken_FcR 25 44 0.22
Human_FcgR3B Chicken_FcR 29.03 31 0.29
Human_FcgR3B Chicken_FcR 25 20 0.38
Human_FcgR3B Mouse_FcamR 62.5 8 2.5
Human_FcgR3B Mouse_FceR1 36.09 169 3.00E-28
Human_FcgR3B Mouse_FceR2 41.67 12 8.3
Human_FcgR3B Mouse_FcgR1 45.83 168 5.00E-42
Human_FcgR3B Mouse_FcgR1 22.45 147 2.00E-04
Human_FcgR3B Mouse_FcgR1 30.77 39 0.038
Human_FcgR3B Mouse_FcgR2b 51.46 171 6.00E-52
Human_FcgR3B Mouse_FcgR3 50 178 8.00E-52
Human_FcgR3B Mouse_FcgR3 30 20 0.37
Human_FcgR3B Mouse_FcgR4 66.67 168 2.00E-69
Human_FcgR3B Mouse_FcgR4 50 10 9.4
Human_FcgR3B Plasmodium_falciparum_PfEMP1 30 20 6.7
Human_FcgR3B Schistosoma_mansoni_paramyosin 27.03 37 2.2
Human_FcgR3B Schistosoma_mansoni_paramyosin 35.29 17 2.8
Human_FcgR3B Schistosoma_mansoni_paramyosin 21.43 28 8.2
Human_FcgR3B Streptococcus_agalactiae_FcaR 24.24 33 4.5
Human_FcgR3B Toxoplasma_gondii_Beta 50 8 4
Leishmania_major_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 55.91 93 7.00E-34
Leishmania_major_Lmsp1 Acanthamoeba_Schistosoma_paramyosin_contig 40 15 0.77
Leishmania_major_Lmsp1 Acanthamoeba_Schistosoma_paramyosin_contig 26.47 34 2.9
Leishmania_major_Lmsp1 Acanthamoeba_Schistosoma_paramyosin_contig 28.57 14 6.5
Leishmania_major_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 55.91 93 7.00E-34
Leishmania_major_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 56.18 89 6.00E-33
Leishmania_major_Lmsp1 Acanthamoeba_Toxoplasma_beta_contig 26.32 19 5.4
Leishmania_major_Lmsp1 Plasmodium_falciparum_PfEMP1 33.33 12 4.2
Leishmania_major_Lmsp1 Trypanosoma_brucei_Lmsp1 82 150 5.00E-68
Leishmania_major_Lmsp1 Trypanosoma_cruzi_Lmsp1 84.25 127 4.00E-61
Mouse_FcamR Acanthamoeba_T.brucei_Lmsp1_contig 25 24 7.6
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Mouse_FcamR Acanthamoeba_T.cruzi_Lmsp1_contig 21.43 14 9.5
Mouse_FcamR Acanthamoeba_Toxoplasma_beta_contig 34.78 23 0.82
Mouse_FcamR Chicken_FcR 40 30 0.7
Mouse_FcamR Chicken_FcR 43.48 23 2
Mouse_FcamR Chicken_FcR 25 16 7.8
Mouse_FcamR Oyster_FceR 60 5 3.9
Mouse_FcamR Schistosoma_mansoni_paramyosin 33.33 21 1.4
Mouse_FcamR Schistosoma_mansoni_paramyosin 19.61 51 5.3
Mouse_FcamR Staphylococcus_aureus_ProteinA 26.67 45 3
Mouse_FcamR Streptococcus_agalactiae_FcaR 30.56 36 0.6
Mouse_FcamR Streptococcus_agalactiae_FcaR 30.61 49 0.6
Mouse_FcamR Streptococcus_agalactiae_FcaR 24.39 41 1.3
Mouse_FcamR Streptococcus_agalactiae_FcaR 29.03 31 1.7
Mouse_FcamR Streptococcus_agalactiae_FcaR 27.78 36 2.3
Mouse_FcamR Streptococcus_agalactiae_FcaR 27.78 36 3.9
Mouse_FcamR Streptococcus_agalactiae_FcaR 54.55 11 5
Mouse_FcamR Streptococcus_agalactiae_FcaR 31.25 16 6.6
Mouse_FcamR Streptococcus_agalactiae_FcaR 25.56 90 6.6
Mouse_FcamR Streptococcus_agalactiae_FcaR 26.09 23 8.6
Mouse_FcamR Streptococcus_pyogenes_FcgR 24.56 57 0.099
Mouse_FcamR Streptococcus_pyogenes_FcgR 31.82 22 0.64
Mouse_FcamR Streptococcus_pyogenes_FcgR 100 6 2.4
Mouse_FcamR Streptococcus_pyogenes_FcgR 60 10 3.2
Mouse_FcamR Streptococcus_pyogenes_FcgR 23.91 46 9.3
Mouse_FcamR Taenia_solium_paramyosin 25.45 55 0.48
Mouse_FcamR Taenia_solium_paramyosin 35 20 1.4
Mouse_FcamR Toxoplasma_gondii_Beta 24.07 54 1.9
Mouse_FcamR Toxoplasma_gondii_Beta 44.44 18 2.5
Mouse_FcamR Toxoplasma_gondii_Beta 62.5 8 9.5
Mouse_FcamR Toxoplasma_gondii_Beta 66.67 6 9.5
Mouse_FcamR Toxoplasma_gondii_Beta 66.67 6 9.5
Mouse_FcamR Toxoplasma_gondii_Beta 66.67 6 9.5
Mouse_FcamR Trypanosoma_cruzi_Lmsp1 44.44 9 1.6
Mouse_FcamR Trypanosoma_cruzi_Lmsp1 100 5 2
Mouse_FceR1 Acanthamoeba_Leishmania_Lmsp1_contig 50 8 2.7
Mouse_FceR1 Acanthamoeba_T.brucei_Lmsp1_contig 50 8 2.6
Mouse_FceR1 Acanthamoeba_T.cruzi_Lmsp1_contig 50 8 2.5
Mouse_FceR1 Chicken_FcR 27.08 48 0.026
Mouse_FceR1 Chicken_FcR 60 10 0.076
Mouse_FceR1 Chicken_FcR 40 20 0.099
Mouse_FceR1 Chicken_FcR 33.33 15 0.64
Mouse_FceR1 Chicken_FcR 66.67 6 1.9
Mouse_FceR1 Chicken_FcR 44.44 9 7.1
Mouse_FceR1 Mouse_FceR2 20.45 44 3.6
Mouse_FceR1 Oyster_FceR 55.56 9 0.72
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Mouse_FceR1 Plasmodium_falciparum_PfEMP1 26.67 15 5.1
Mouse_FceR1 Schistosoma_mansoni_paramyosin 45.45 11 2.8
Mouse_FceR1 Schistosoma_mansoni_paramyosin 26.47 34 3.6
Mouse_FceR1 Schistosoma_mansoni_paramyosin 33.33 18 8
Mouse_FceR1 Streptococcus_agalactiae_FcaR 33.33 21 1.2
Mouse_FceR1 Taenia_solium_paramyosin 37.5 16 0.95
Mouse_FceR1 Taenia_solium_paramyosin 23.53 34 1.6
Mouse_FceR1 Taenia_solium_paramyosin 50 10 4.7
Mouse_FceR1 Trypanosoma_cruzi_Lmsp1 30.43 23 9.7
Mouse_FceR2 Leishmania_major_Lmsp1 50 12 0.21
Mouse_FceR2 Mouse_FcamR 50 18 0.46
Mouse_FceR2 Mouse_FcamR 25 16 1.3
Mouse_FceR2 Mouse_FcamR 33.33 9 6.7
Mouse_FceR2 Mouse_FcamR 41.67 12 6.7
Mouse_FceR2 Mouse_FcamR 42.86 7 8.7
Mouse_FceR2 Oyster_FceR 31.68 161 9.00E-19
Mouse_FceR2 Oyster_FceR 33.33 6 9.8
Mouse_FceR2 Plasmodium_falciparum_PfEMP1 66.67 6 0.42
Mouse_FceR2 Plasmodium_falciparum_PfEMP1 38.89 18 2.7
Mouse_FceR2 Schistosoma_mansoni_paramyosin 23.13 134 5.00E-05
Mouse_FceR2 Schistosoma_mansoni_paramyosin 20.45 132 3.00E-04
Mouse_FceR2 Schistosoma_mansoni_paramyosin 23.64 110 4.00E-04
Mouse_FceR2 Schistosoma_mansoni_paramyosin 21.84 87 0.048
Mouse_FceR2 Staphylococcus_aureus_ProteinA 25.81 124 0.006
Mouse_FceR2 Staphylococcus_aureus_ProteinA 18.52 108 0.69
Mouse_FceR2 Streptococcus_agalactiae_FcaR 21.77 124 0.001
Mouse_FceR2 Streptococcus_agalactiae_FcaR 21.6 125 0.016
Mouse_FceR2 Streptococcus_agalactiae_FcaR 27.69 65 0.17
Mouse_FceR2 Streptococcus_agalactiae_FcaR 38.1 21 0.66
Mouse_FceR2 Streptococcus_agalactiae_FcaR 30 20 1.1
Mouse_FceR2 Streptococcus_agalactiae_FcaR 25 24 9.5
Mouse_FceR2 Streptococcus_pyogenes_FcgR 23.13 134 1.00E-05
Mouse_FceR2 Streptococcus_pyogenes_FcgR 19.64 112 1.00E-05
Mouse_FceR2 Streptococcus_pyogenes_FcgR 26.05 119 0.029
Mouse_FceR2 Streptococcus_pyogenes_FcgR 80 5 4.7
Mouse_FceR2 Taenia_solium_paramyosin 22.33 103 3.00E-04
Mouse_FceR2 Taenia_solium_paramyosin 17.45 149 9.00E-04
Mouse_FceR2 Taenia_solium_paramyosin 20 105 0.01
Mouse_FceR2 Taenia_solium_paramyosin 17.43 109 0.028
Mouse_FceR2 Taenia_solium_paramyosin 20.16 124 0.028
Mouse_FceR2 Taenia_solium_paramyosin 19.53 128 0.18
Mouse_FceR2 Taenia_solium_paramyosin 13.33 60 0.7
Mouse_FceR2 Toxoplasma_gondii_Beta 46.15 13 0.43
Mouse_FceR2 Trypanosoma_brucei_Lmsp1 50 12 0.27
Mouse_FcgR1 Acanthamoeba_Leishmania_Lmsp1_contig 50 8 6.8
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Mouse_FcgR1 Acanthamoeba_Leishmania_Lmsp1_contig 42.86 7 8.9
Mouse_FcgR1 Acanthamoeba_Schistosoma_paramyosin_contig 46.15 13 9.6
Mouse_FcgR1 Acanthamoeba_T.brucei_Lmsp1_contig 50 8 6.6
Mouse_FcgR1 Acanthamoeba_T.brucei_Lmsp1_contig 42.86 7 8.6
Mouse_FcgR1 Acanthamoeba_T.cruzi_Lmsp1_contig 50 8 6.4
Mouse_FcgR1 Acanthamoeba_T.cruzi_Lmsp1_contig 42.86 7 8.3
Mouse_FcgR1 Chicken_FcR 27.38 84 1.00E-04
Mouse_FcgR1 Chicken_FcR 21.85 238 0.001
Mouse_FcgR1 Chicken_FcR 29.87 77 0.004
Mouse_FcgR1 Chicken_FcR 24.84 161 0.069
Mouse_FcgR1 Chicken_FcR 28.57 28 1.3
Mouse_FcgR1 Leishmania_major_Lmsp1 71.43 7 3.8
Mouse_FcgR1 Leishmania_major_Lmsp1 50 8 8.4
Mouse_FcgR1 Mouse_FcamR 30.3 33 0.041
Mouse_FcgR1 Mouse_FcamR 26.32 19 1.7
Mouse_FcgR1 Mouse_FcamR 31.25 16 2.9
Mouse_FcgR1 Mouse_FcamR 66.67 6 2.9
Mouse_FcgR1 Mouse_FceR1 42.35 170 5.00E-37
Mouse_FcgR1 Mouse_FceR1 24.05 158 7.00E-04
Mouse_FcgR1 Mouse_FceR1 26.76 71 0.004
Mouse_FcgR1 Mouse_FceR2 50 10 2.5
Mouse_FcgR1 Mouse_FcgR2b 46.71 167 2.00E-44
Mouse_FcgR1 Mouse_FcgR2b 28.65 178 4.00E-11
Mouse_FcgR1 Mouse_FcgR2b 33.33 15 0.71
Mouse_FcgR1 Mouse_FcgR2b 41.67 12 0.93
Mouse_FcgR1 Mouse_FcgR3 46.51 172 4.00E-45
Mouse_FcgR1 Mouse_FcgR3 24.5 151 1.00E-08
Mouse_FcgR1 Mouse_FcgR3 28.57 56 0.066
Mouse_FcgR1 Mouse_FcgR3 26.09 23 0.73
Mouse_FcgR1 Mouse_FcgR4 41.57 166 2.00E-37
Mouse_FcgR1 Mouse_FcgR4 25.5 149 4.00E-06
Mouse_FcgR1 Mouse_FcgR4 38.1 21 0.04
Mouse_FcgR1 Oyster_FceR 29.17 24 1.9
Mouse_FcgR1 Schistosoma_mansoni_paramyosin 38.1 21 4.4
Mouse_FcgR1 Staphylococcus_aureus_ProteinA 36.36 22 1.1
Mouse_FcgR1 Staphylococcus_aureus_ProteinA 36.36 22 1.1
Mouse_FcgR1 Streptococcus_agalactiae_FcaR 30 30 3.2
Mouse_FcgR1 Streptococcus_agalactiae_FcaR 45.45 11 3.2
Mouse_FcgR1 Streptococcus_agalactiae_FcaR 66.67 6 5.4
Mouse_FcgR1 Streptococcus_agalactiae_FcaR 29.41 17 7
Mouse_FcgR1 Streptococcus_pyogenes_FcgR 30.43 23 2.6
Mouse_FcgR1 Streptococcus_pyogenes_FcgR 35.71 14 5.9
Mouse_FcgR1 Taenia_solium_paramyosin 35 20 3.4
Mouse_FcgR1 Taenia_solium_paramyosin 40 15 5.7
Mouse_FcgR1 Taenia_solium_paramyosin 46.15 13 7.5
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Mouse_FcgR1 Toxoplasma_gondii_Beta 66.67 6 7.9
Mouse_FcgR1 Trypanosoma_cruzi_Lmsp1 30 20 6.6
Mouse_FcgR2b Acanthamoeba_Schistosoma_paramyosin_contig 26.15 65 0.19
Mouse_FcgR2b Chicken_FcR 27.59 87 8.00E-04
Mouse_FcgR2b Chicken_FcR 20.61 165 0.02
Mouse_FcgR2b Chicken_FcR 26.42 106 0.026
Mouse_FcgR2b Chicken_FcR 33.33 27 7.1
Mouse_FcgR2b Leishmania_major_Lmsp1 44.44 9 4.3
Mouse_FcgR2b Mouse_FcamR 25 80 0.058
Mouse_FcgR2b Mouse_FcamR 43.48 23 0.13
Mouse_FcgR2b Mouse_FceR1 39.64 169 2.00E-32
Mouse_FcgR2b Mouse_FceR2 22.5 40 0.56
Mouse_FcgR2b Mouse_FceR2 40 15 8.1
Mouse_FcgR2b Mouse_FcgR3 92.66 177 1.00E-100
Mouse_FcgR2b Mouse_FcgR3 30 20 0.13
Mouse_FcgR2b Mouse_FcgR4 45.81 179 4.00E-45
Mouse_FcgR2b Mouse_FcgR4 66.67 6 0.49
Mouse_FcgR2b Mouse_FcgR4 35.71 14 3.2
Mouse_FcgR2b Oyster_FceR 42.86 21 0.94
Mouse_FcgR2b Oyster_FceR 50 8 4.7
Mouse_FcgR2b Plasmodium_falciparum_PfEMP1 45.45 11 0.27
Mouse_FcgR2b Staphylococcus_aureus_ProteinA 36.84 19 1.3
Mouse_FcgR2b Staphylococcus_aureus_ProteinA 28.57 21 8.1
Mouse_FcgR2b Staphylococcus_aureus_ProteinA 28.57 21 8.1
Mouse_FcgR2b Streptococcus_pyogenes_FcgR 25 28 2.9
Mouse_FcgR2b Streptococcus_pyogenes_FcgR 46.15 13 4.9
Mouse_FcgR3 Chicken_FcR 29.23 65 0.007
Mouse_FcgR3 Chicken_FcR 25.71 140 0.009
Mouse_FcgR3 Chicken_FcR 20.75 106 0.012
Mouse_FcgR3 Chicken_FcR 23.08 65 0.5
Mouse_FcgR3 Mouse_FcamR 36.67 30 0.17
Mouse_FcgR3 Mouse_FcamR 28.24 85 0.23
Mouse_FcgR3 Mouse_FceR1 40.12 172 2.00E-33
Mouse_FcgR3 Mouse_FceR2 22.5 40 0.75
Mouse_FcgR3 Mouse_FceR2 40 15 8.3
Mouse_FcgR3 Mouse_FcgR4 46.59 176 3.00E-46
Mouse_FcgR3 Mouse_FcgR4 30 20 0.23
Mouse_FcgR3 Mouse_FcgR4 66.67 6 0.5
Mouse_FcgR3 Mouse_FcgR4 35.71 14 3.3
Mouse_FcgR3 Oyster_FceR 50 8 4.8
Mouse_FcgR3 Plasmodium_falciparum_PfEMP1 45.45 11 0.12
Mouse_FcgR3 Staphylococcus_aureus_ProteinA 36.84 19 2.2
Mouse_FcgR3 Streptococcus_agalactiae_FcaR 50 8 5.9
Mouse_FcgR3 Streptococcus_pyogenes_FcgR 30 30 2.3
Mouse_FcgR3 Streptococcus_pyogenes_FcgR 46.15 13 3.9
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Mouse_FcgR4 Chicken_FcR 44 25 0.013
Mouse_FcgR4 Chicken_FcR 20.54 112 0.028
Mouse_FcgR4 Chicken_FcR 32.26 31 0.081
Mouse_FcgR4 Chicken_FcR 32.14 28 0.11
Mouse_FcgR4 Mouse_FcamR 36.36 22 0.24
Mouse_FcgR4 Mouse_FcamR 75 8 0.9
Mouse_FcgR4 Mouse_FcamR 62.5 8 3.4
Mouse_FcgR4 Mouse_FceR1 40.48 168 4.00E-32
Mouse_FcgR4 Mouse_FceR2 37.5 16 3.9
Mouse_FcgR4 Oyster_FceR 33.33 15 5
Mouse_FcgR4 Plasmodium_falciparum_PfEMP1 38.46 13 3.1
Mouse_FcgR4 Plasmodium_falciparum_PfEMP1 40 15 3.1
Mouse_FcgR4 Schistosoma_mansoni_paramyosin 45.45 11 6.7
Mouse_FcgR4 Schistosoma_mansoni_paramyosin 83.33 6 6.7
Mouse_FcgR4 Schistosoma_mansoni_paramyosin 50 10 8.8
Mouse_FcgR4 Streptococcus_agalactiae_FcaR 54.55 11 6.3
Mouse_FcgR4 Toxoplasma_gondii_Beta 25.53 47 1.1
Mouse_FcgR4 Toxoplasma_gondii_Beta 31.58 19 9.3
Oyster_FceR Acanthamoeba_Leishmania_Lmsp1_contig 55.56 9 0.8
Oyster_FceR Acanthamoeba_Schistosoma_paramyosin_contig 56.25 16 0.062
Oyster_FceR Acanthamoeba_Schistosoma_paramyosin_contig 26.92 26 2.6
Oyster_FceR Acanthamoeba_Schistosoma_paramyosin_contig 38.89 18 5.8
Oyster_FceR Acanthamoeba_Schistosoma_paramyosin_contig 71.43 7 5.8
Oyster_FceR Acanthamoeba_T.brucei_Lmsp1_contig 55.56 9 0.78
Oyster_FceR Acanthamoeba_Toxoplasma_beta_contig 45.45 11 7.8
Oyster_FceR Chicken_FcR 29.41 17 1.3
Oyster_FceR Chicken_FcR 19.64 56 2.3
Oyster_FceR Leishmania_major_Lmsp1 50 10 3.8
Oyster_FceR Plasmodium_falciparum_PfEMP1 40 25 0.017
Oyster_FceR Plasmodium_falciparum_PfEMP1 40 15 0.022
Oyster_FceR Plasmodium_falciparum_PfEMP1 66.67 6 3.5
Oyster_FceR Staphylococcus_aureus_ProteinA 20.51 39 1.5
Oyster_FceR Staphylococcus_aureus_ProteinA 35.71 14 1.5
Oyster_FceR Staphylococcus_aureus_ProteinA 17.95 39 7.6
Oyster_FceR Staphylococcus_aureus_ProteinA 17.95 39 9.9
Oyster_FceR Streptococcus_agalactiae_FcaR 33.33 33 0.66
Oyster_FceR Streptococcus_agalactiae_FcaR 34.15 41 1.9
Oyster_FceR Streptococcus_agalactiae_FcaR 71.43 7 3.3
Oyster_FceR Streptococcus_agalactiae_FcaR 33.33 15 9.5
Oyster_FceR Streptococcus_pyogenes_FcgR 29.17 24 0.55
Oyster_FceR Streptococcus_pyogenes_FcgR 75 8 2.7
Oyster_FceR Trypanosoma_brucei_Lmsp1 50 8 3.8
Oyster_FceR Trypanosoma_brucei_Lmsp1 50 10 6.5
Oyster_FceR Trypanosoma_cruzi_Lmsp1 50 10 6.7
Oyster_FceR Trypanosoma_cruzi_Lmsp1 29.41 17 8.7
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Schistosoma_mansoni_paramyosin Acanthamoeba_Leishmania_Lmsp1_contig 71.43 7 2.2
Schistosoma_mansoni_paramyosin Acanthamoeba_Leishmania_Lmsp1_contig 38.46 13 6.5
Schistosoma_mansoni_paramyosin Acanthamoeba_T.brucei_Lmsp1_contig 71.43 7 2.2
Schistosoma_mansoni_paramyosin Acanthamoeba_T.brucei_Lmsp1_contig 38.46 13 6.4
Schistosoma_mansoni_paramyosin Acanthamoeba_T.cruzi_Lmsp1_contig 71.43 7 2.1
Schistosoma_mansoni_paramyosin Acanthamoeba_T.cruzi_Lmsp1_contig 38.46 13 6.1
Schistosoma_mansoni_paramyosin Acanthamoeba_Toxoplasma_beta_contig 27.27 33 2.1
Schistosoma_mansoni_paramyosin Leishmania_major_Lmsp1 71.43 7 2.3
Schistosoma_mansoni_paramyosin Plasmodium_falciparum_PfEMP1 30.77 26 3.5
Schistosoma_mansoni_paramyosin Plasmodium_falciparum_PfEMP1 50 12 3.5
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 26.14 153 4.00E-05
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 19.32 88 0.19
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 21.3 108 0.93
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 28.57 35 4.6
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 30.43 23 6
Schistosoma_mansoni_paramyosin Staphylococcus_aureus_ProteinA 50 10 6
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 32.5 40 0.065
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 22.38 143 0.084
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 30 40 0.32
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 29.17 24 1.6
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 23.08 26 2.7
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 66.67 6 4.6
Staphylococcus_aureus_ProteinA Acanthamoeba_Toxoplasma_beta_contig 23.08 26 6
Streptococcus_agalactiae_FcaR Acanthamoeba_Leishmania_Lmsp1_contig 44.44 9 2.7
Streptococcus_agalactiae_FcaR Acanthamoeba_Leishmania_Lmsp1_contig 22.5 80 2.7
Streptococcus_agalactiae_FcaR Acanthamoeba_Leishmania_Lmsp1_contig 26.92 26 4.6
Streptococcus_agalactiae_FcaR Acanthamoeba_Leishmania_Lmsp1_contig 42.11 19 6.1
Streptococcus_agalactiae_FcaR Acanthamoeba_Schistosoma_paramyosin_contig 33.33 24 5.8
Streptococcus_agalactiae_FcaR Acanthamoeba_T.brucei_Lmsp1_contig 44.44 9 2.6
Streptococcus_agalactiae_FcaR Acanthamoeba_T.brucei_Lmsp1_contig 22.5 80 2.6
Streptococcus_agalactiae_FcaR Acanthamoeba_T.brucei_Lmsp1_contig 26.92 26 4.5
Streptococcus_agalactiae_FcaR Acanthamoeba_T.brucei_Lmsp1_contig 42.11 19 5.9
Streptococcus_agalactiae_FcaR Acanthamoeba_T.cruzi_Lmsp1_contig 44.44 9 2.5
Streptococcus_agalactiae_FcaR Acanthamoeba_T.cruzi_Lmsp1_contig 22.86 70 3.3
Streptococcus_agalactiae_FcaR Acanthamoeba_T.cruzi_Lmsp1_contig 26.92 26 4.3
Streptococcus_agalactiae_FcaR Acanthamoeba_T.cruzi_Lmsp1_contig 42.11 19 5.6
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 42.86 28 0.012
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 40.54 37 0.047
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 39.13 23 0.4
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 24.53 53 0.52
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 32.26 31 0.68
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 53.85 13 0.68
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 29.63 27 1.2
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 25.93 27 2
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 26.92 26 2
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Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 20 45 2
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 46.15 13 2
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 32 25 2.6
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 20 65 3.4
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 29.63 27 4.4
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 42.11 19 4.4
Streptococcus_agalactiae_FcaR Acanthamoeba_Toxoplasma_beta_contig 25 24 9.8
Streptococcus_agalactiae_FcaR Leishmania_major_Lmsp1 27.27 33 2.7
Streptococcus_agalactiae_FcaR Plasmodium_falciparum_PfEMP1 27.16 81 0.047
Streptococcus_agalactiae_FcaR Plasmodium_falciparum_PfEMP1 37.5 16 0.3
Streptococcus_agalactiae_FcaR Plasmodium_falciparum_PfEMP1 25.93 27 5.7
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 22.19 311 8.00E-10
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.81 631 2.00E-08
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 17.75 355 2.00E-07
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.13 345 1.00E-06
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.5 241 4.00E-06
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 19.57 138 0.01
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 25 48 0.14
Streptococcus_agalactiae_FcaR Schistosoma_mansoni_paramyosin 22.58 31 7.8
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 17.68 198 8.00E-04
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 17.71 192 0.1
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 30.77 52 0.39
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 23.08 65 0.67
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 28.85 52 0.88
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 28.85 52 1.1
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 25.58 43 3.3
Streptococcus_agalactiae_FcaR Staphylococcus_aureus_ProteinA 24.53 53 3.3
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 19.14 324 9.00E-07
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 21.68 309 7.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 18.36 207 7.00E-06
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 20.19 322 1.00E-04
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 23.58 229 0.038
Streptococcus_agalactiae_FcaR Streptococcus_pyogenes_FcgR 23.08 26 7.8
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 20.72 613 2.00E-08
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 16.22 333 6.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 17.56 450 7.00E-06
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 18.91 497 1.00E-04
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 16.38 574 9.00E-04
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 28.57 63 0.006
Streptococcus_agalactiae_FcaR Taenia_solium_paramyosin 25 76 0.19
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.07 122 5.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 35.25 122 5.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 9.00E-28
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 2.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.41 156 2.00E-27
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Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 36.13 119 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 33.61 122 3.00E-27
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 30.14 146 2.00E-26
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 28.76 153 2.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 31.5 127 3.00E-25
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 24.39 246 3.00E-20
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 22.5 80 0.003
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 28.57 35 0.19
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 24.32 37 1.2
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 19.3 57 1.6
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 26.47 34 1.6
Streptococcus_agalactiae_FcaR Toxoplasma_gondii_Beta 22.22 36 3.6
Streptococcus_agalactiae_FcaR Trypanosoma_brucei_Lmsp1 34.62 26 0.25
Streptococcus_agalactiae_FcaR Trypanosoma_brucei_Lmsp1 28.95 38 3.6
Streptococcus_agalactiae_FcaR Trypanosoma_cruzi_Lmsp1 26.83 41 2.2
Streptococcus_pyogenes_FcgR Acanthamoeba_Schistosoma_paramyosin_contig 41.67 12 3.6
Streptococcus_pyogenes_FcgR Acanthamoeba_Schistosoma_paramyosin_contig 29.73 37 4.7
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.43 173 4.00E-11
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.09 184 2.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.84 231 5.00E-10
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 25.62 203 3.00E-09
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 26.92 182 5.00E-08
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 22.09 172 2.00E-06
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 24.83 149 3.00E-06
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 21.89 169 6.00E-04
Streptococcus_pyogenes_FcgR Schistosoma_mansoni_paramyosin 21.23 146 0.005
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 23.5 183 0.003
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 22.86 140 0.066
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 31.25 32 1.2
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 40 15 2.8
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 62.5 8 3.6
Streptococcus_pyogenes_FcgR Staphylococcus_aureus_ProteinA 62.5 8 3.6
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 1.00E-12
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 24.47 237 1.00E-10
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.14 242 3.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 26.28 156 6.00E-09
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.15 167 2.00E-08
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 22.18 275 4.00E-08
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.71 175 1.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 23.43 175 7.00E-07
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 25.58 172 3.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 21.98 182 5.00E-06
Streptococcus_pyogenes_FcgR Taenia_solium_paramyosin 21.13 194 0.052
Streptococcus_pyogenes_FcgR Toxoplasma_gondii_Beta 50 8 2.3
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Streptococcus_pyogenes_FcgR Trypanosoma_brucei_Lmsp1 47.06 17 0.019
Streptococcus_pyogenes_FcgR Trypanosoma_brucei_Lmsp1 83.33 6 2.4
Streptococcus_pyogenes_FcgR Trypanosoma_brucei_Lmsp1 40 15 6.9
Streptococcus_pyogenes_FcgR Trypanosoma_brucei_Lmsp1 40 15 9
Taenia_solium_paramyosin Acanthamoeba_Schistosoma_paramyosin_contig 25.93 54 2.7
Taenia_solium_paramyosin Acanthamoeba_Toxoplasma_beta_contig 28.57 35 0.55
Taenia_solium_paramyosin Acanthamoeba_Toxoplasma_beta_contig 26.47 34 3.6
Taenia_solium_paramyosin Acanthamoeba_Toxoplasma_beta_contig 25 16 6.1
Taenia_solium_paramyosin Plasmodium_falciparum_PfEMP1 22.5 40 2.1
Taenia_solium_paramyosin Plasmodium_falciparum_PfEMP1 50 12 3.5
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 72.19 791 0
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.04 608 3.00E-30
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 22.4 308 1.00E-13
Taenia_solium_paramyosin Schistosoma_mansoni_paramyosin 20.69 174 2.00E-05
Taenia_solium_paramyosin Staphylococcus_aureus_ProteinA 31.82 22 6
Toxoplasma_gondii_Beta Acanthamoeba_Leishmania_Lmsp1_contig 32 25 1.5
Toxoplasma_gondii_Beta Acanthamoeba_Leishmania_Lmsp1_contig 35.71 14 2
Toxoplasma_gondii_Beta Acanthamoeba_Leishmania_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_Leishmania_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_Leishmania_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_Schistosoma_paramyosin_contig 24 25 2.2
Toxoplasma_gondii_Beta Acanthamoeba_T.brucei_Lmsp1_contig 32 25 1.5
Toxoplasma_gondii_Beta Acanthamoeba_T.brucei_Lmsp1_contig 35.71 14 1.9
Toxoplasma_gondii_Beta Acanthamoeba_T.brucei_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_T.brucei_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_T.brucei_Lmsp1_contig 28.57 14 3.3
Toxoplasma_gondii_Beta Acanthamoeba_T.cruzi_Lmsp1_contig 32 25 1.4
Toxoplasma_gondii_Beta Acanthamoeba_T.cruzi_Lmsp1_contig 35.71 14 1.8
Toxoplasma_gondii_Beta Acanthamoeba_T.cruzi_Lmsp1_contig 28.57 14 3.1
Toxoplasma_gondii_Beta Acanthamoeba_T.cruzi_Lmsp1_contig 28.57 14 3.1
Toxoplasma_gondii_Beta Acanthamoeba_T.cruzi_Lmsp1_contig 28.57 14 3.1
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 18.95 190 1.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 21.89 169 2.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.06 85 6.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 29.41 68 8.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 27.66 94 8.00E-06
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 35 40 2.00E-04
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 20 135 3.00E-04
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 33.33 30 0.008
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 29.63 27 0.024
Toxoplasma_gondii_Beta Acanthamoeba_Toxoplasma_beta_contig 20.47 127 0.053
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 27.85 79 0.067
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 33.33 48 0.088
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 34.78 23 0.088
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 21.98 91 0.11
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Query I.D. Subject I.D. %
Ident.
alignment
length
e-
value
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 21.18 85 0.2
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 22.64 106 0.2
Toxoplasma_gondii_Beta Staphylococcus_aureus_ProteinA 20.41 147 1.3
Trypanosoma_brucei_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 54.84 93 4.00E-28
Trypanosoma_brucei_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 55.06 89 3.00E-27
Trypanosoma_brucei_Lmsp1 Staphylococcus_aureus_ProteinA 29.41 17 8.6
Trypanosoma_brucei_Lmsp1 Toxoplasma_gondii_Beta 28 25 9.3
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_Leishmania_Lmsp1_contig 52.81 89 6.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.brucei_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Acanthamoeba_T.cruzi_Lmsp1_contig 52.81 89 5.00E-23
Trypanosoma_cruzi_Lmsp1 Plasmodium_falciparum_PfEMP1 40 10 4.3
Trypanosoma_cruzi_Lmsp1 Staphylococcus_aureus_ProteinA 27.27 22 1
Trypanosoma_cruzi_Lmsp1 Trypanosoma_brucei_Lmsp1 88.98 127 1.00E-52
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Appendix 5
Human IgG Heavy chain (BAA37168.1)
QVQLQESGGGLVQPGGSLRLSCAASGFTVSGNYMTWVRQAPGKGLE
WVSVVYSGGSTFYADSVKGRFTISRDISKNTLYLQMNSLRPEDTALYY
CATSYERWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKTVERK
Human IgG Light chain (CAA42227.1)
MASFPLLLTLLTHCAGSWAQSVLTQPPSASGTPGQRVTISCSGSNSNIG
GNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGL
QSEDEAAYYCAAWDDSLNGHVLFGGGTKLTVLGQPKAAPSVTLFPPS
SEEL
Predicted cleavage residues present in human IgG heavy and light chain for
chymotrypsin-like (green) and elastase-like (red) serine proteases.
Immunoglobulin peptide sequence was retrieved from NCBI GenBank and
manually analysed using a standard text editor.
298
Appendix 6
An A. castellanii transcriptomic sequence showed significant alignment with
protein superfamily. A conserved domain search of this matc
L. major Lmsp1, a gene from the nucleoside diphosphate kinase
hing sequence revealed conservation with NDPk group 1.
